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ABSTRACT 
The age-related decline in the immune system, known as immunosenescence, 
predisposes old individuals to increased mortality and morbidity from infectious 
diseases (such as shingles, caused by reactivation of varicella zoster virus, VZV) 
and is associated with impaired vaccine responses. While multiple age-related 
changes have been identified in circulating memory T cells, little is known about 
the effects of ageing on memory T cells within peripheral tissues.    
T cells within human skin were characterised, and surprisingly neither their 
numbers, differentiation markers or effector functions were altered during ageing. 
VZV-specific CD4+ T cells were more frequent in the skin than in the blood, and 
their frequency in the skin did not decline with age. Increased PD-1 expression 
on T cells and an increased frequency of regulatory T cells in ageing skin 
consolidated evidence that old skin represents an inhibitory microenvironment.  
Vaccination of old individuals with the shingles vaccine Zostavax® did not alter 
the total number of T cells, or frequency of VZV-specific T cells, in the skin but 
did boost the frequency of circulating VZV-specific T cells. This was associated 
with a heightened delayed type hypersensitivity (DTH) response to VZV antigen, 
and with an upregulation of genes involved in T cell migration and activation. It is 
proposed here that Zostavax® prevents shingles by enhancing the recruitment of 
circulating VZV-specific memory T cells to sensory nerves during episodes of 
silent VZV reactivation.  
Increased early expression of p38 MAPK-associated pro-inflammatory genes has 
been observed in VZV- or saline-challenged old skin and was associated with 
poor DTH responses to VZV antigen. In an experimental medicine study, pre-
treatment of ageing individuals with the p38 MAPK inhibitor losmapimod 
effectively restored robust VZV-specific DTH responses. Ageing of the population 
necessitates improved vaccination strategies, and p38 MAPK inhibition prior to 
vaccine administration presents a potential therapeutic opportunity to achieve 
this.  
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IMPACT STATEMENT 
The human population is rapidly ageing, with the United Nations predicting the 
number of people aged over 60 will more than double to 2.1 billion in 2050 and 
more than triple to 3.1 billion in 2100. A multi-faceted decline in the ageing 
immune system, known as immunosenescence, renders old people more 
susceptible to cancer and infectious diseases, such as shingles, influenza and 
pneumonia. The weakened immune system in the old is compounded by the fact 
that ageing people respond poorly to vaccination. Concurrently, old people are 
more prone to developing increased inflammation in the body, which can 
contribute to the onset of arthritis, heart disease and dementia. This excessive 
inflammation in old age, known as inflammaging, has also been associated with 
poor vaccine responses. 
Shingles is a painful and debilitating skin disease caused by reactivation of 
varicella zoster virus (VZV), the same virus that causes chickenpox. In the UK 
there are over 50,000 cases of shingles in the over 70s each year, and the lifetime 
risk of developing shingles is 1 in 4. Shingles is more frequent, more severe, and 
more likely to lead to chronic pain (post-herpetic neuralgia) in the old – yet it 
remains unknown why VZV reactivates in certain individuals. In work funded by 
the skin disease charities Dermatrust and the British Skin Foundation, we used a 
novel research strategy to investigate how the shingles vaccine Zostavax® 
boosts skin immunity. We induced immune responses to VZV in the skin of 
ageing volunteers before and after vaccination, and by taking skin biopsies over 
the course of 7 days we were able to delineate the kinetics of the skin immune 
response at the cellular level. This is a research technique that could be adopted 
by vaccinologists researching the mechanism of action of other vaccines.     
Increased inflammation was observed in ageing skin and this was associated with 
impaired skin immunity to VZV. In an experimental medicine project funded by an 
MRC Grand Challenge grant in collaboration with GlaxoSmithKline, we pre-
treated ageing volunteers with an anti-inflammatory drug (the p38 MAP kinase 
inhibitor, losmapimod) for 4 days, and this led to an enhancement in their skin 
immunity to VZV. This suggests that blocking inflammation may be a strategy for 
boosting cutaneous immunity during ageing. We plan to extend this concept to a 
forthcoming trial investigating whether losmapimod enhances immune responses 
to the influenza vaccine in ageing individuals. The implications of this work are 
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potentially far-reaching with regards to optimising vaccination strategy and 
enhancing the health of older people.  
During this work we engaged the public by regularly hosting “Ageing Immunity” 
Open Days at UCL, where we showcased our immunology research, educated 
the public with talks and interactive sessions, and offered ageing individuals the 
opportunity to volunteer for immunology research studies.   
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1 INTRODUCTION 
Ageing is accompanied by a multi-faceted decline in virtually all components of 
the immune system, a process known as immunosenescence1,2. As a 
consequence, aged humans are more susceptible to morbidity and mortality from 
infectious diseases and cancer1–4, and lose the ability to respond effectively to 
vaccination5,6. Old individuals are more susceptible to infections that are novel7, 
previously encountered8, or reactivated from a latent state – such as shingles, 
due to reactivated varicella zoster virus (VZV)9,10. Meanwhile, 
hyperresponsiveness of the innate immune system leads to increased 
inflammation in tissues, predisposing the ageing individual to osteoarthritis, 
atherosclerotic disease and neurodegenerative disease11. The human population 
is ageing rapidly, such that the United Nations predicts the number of people 
aged over 60 will more than double from 962 million in 2017 to 2.1 billion in 2050 
and more than triple to 3.1 billion in 2100 12. The projected increase in morbidity 
and mortality from age-related infectious diseases, coupled with the lack of 
effective measures to prevent them, raises an interest in investigating the 
mechanisms underlying immunosenescence – ultimately in order to inform 
strategies to boost immunity during old age. 
1.1 T Cell Biology 
1.1.1 T cell development  
Haematopoietic stem cells in the bone marrow give rise to lymphoid progenitors, 
some of which migrate via the blood to the thymus, where they differentiate and 
proliferate intensely, producing large numbers of thymocytes. Thymocytes 
undergo gene rearrangement of their T cell receptors (TCR), generating a 
colossal breadth of antigen specificity across the naïve T cell population. 
Rigorous positive and negative selection occur, ensuring the 2% of surviving 
thymocytes can recognise self-peptide:self-major histocompatibility complex 
(MHC) complexes and are self-tolerant. Mature T cells, single positive for either 
CD4 or CD8, are exported from the thymus into the peripheral circulation as naïve 
T cells, specific for a given epitope. CD4+ T cells recognise peptide bound to MHC 
class II molecules, expressed by antigen presenting cells (APCs), while CD8+ T 
cells recognise peptide bound to MHC class I molecules, expressed by all 
nucleated cells in the body. The thymus also generates a smaller population of 
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CD4+ T cells termed natural regulatory T cells (nTregs) that express the 
transcription factor Forkhead Box p3 (Foxp3). These cells have high expression 
of CD25 and CTLA-4, and serve to maintain self-tolerance13. 
1.1.2 T cell activation 
Dendritic cell activation 
Dendritic cells (DCs) are specialised APCs. They take up antigen in peripheral 
tissues and migrate to secondary lymphoid organs (SLOs), where they present 
peptide:MHC class II complexes to naïve CD4+ T cells. DCs sense and are 
activated by pathogen-associated molecular patterns (PAMPs), which they 
recognise using pathogen recognition receptors (PRRs), including multiple Toll-
like receptors (TLRs). Activated DCs intensify their antigen-processing and 
upregulate the lymph node homing marker CCR7, facilitating their egress from 
the periphery and entry into the draining lymph node (LN). By the time it arrives 
in the LN, the mature DC has increased its expression of MHC molecules, 
adhesion molecules, the co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2), 
and secretes the chemokine CCL18 which attracts naïve T cells14.    
Naïve T cell entry into lymph nodes 
Naïve T cells, expressing the lymph node homing markers CCR7 and CD62L, 
access the SLOs from the blood, and pass through the T cell zones of lymph 
nodes or the white pulp of the spleen. There, they scan the peptide:MHC 
complexes on the surface of thousands of DCs every day, to enhance the 
probability of encountering their cognate antigen. If their specific antigen is not 
encountered, the naïve T cells re-enter the circulation via efferent lymphatics (or 
blood vessels in the case of the spleen). Egress from the SLO is controlled by the 
concentration gradient of the lipid molecule sphingosine 1-phosphate (S1P), 
recognised by the S1P receptor (S1P1) on the surface of the T cell. The 
concentration of S1P is higher in the blood and lymph than in the SLO, 
encouraging the T cell to leave the SLO15.  
T cell activation 
During their migration through the cortical region of the lymph node, naïve T cells 
bind transiently to each APC they encounter, aided by the interactions between 
cell-adhesion molecules on both cell surfaces, including LFA-1 on the T cell. In 
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the rare event of the naïve T cell recognising cognate antigen presented by the 
APC, the affinity between the two cells increases and the association may persist 
for several days, during which the T cell becomes activated, proliferates and 
differentiates into effector T cells.  
Activation of naïve T cells requires the delivery of 3 signals to the cell. Signal 1 
involves the interaction of the TCR with its specific peptide:MHC complex on the 
surface of an APC. This interaction is stabilised by co-receptors, including the 
CD3 complex, which contains immunoreceptor tyrosine-based activation motifs 
(ITAMs) that participate in signal transduction, and also the co-receptors CD4 or 
CD8, which bind MHC as previously mentioned. CD4 and CD8 recruit 
lymphocyte-specific protein tyrosine kinase (Lck) on their cytoplasmic tails to the 
TCR-CD3 complex, leading to phosphorylation of the ITAMs associated with this 
complex. This allows recruitment and phosphorylation of zeta-chain-associated 
protein kinase 70 (ZAP-70) and further downstream signalling events, eventually 
leading to induction of transcription factors, including nuclear factor of activated 
T-cells (NFAT), activator protein 1 (AP-1) and nuclear factor κB (NFκB), that 
promote IL-2 gene expression16. 
Signal 2 comprises co-stimulatory signals delivered by the APC, characteristically 
involving the binding of B7 molecules on the APC surface with CD28 on the T 
cell. This signal is essential for the optimal clonal expansion of naïve T cells. 
CD28 co-stimulation contributes to the production of IL-2 by the T cell, which acts 
in an autocrine manner to promote T cell survival, proliferation and differentiation. 
Additional co-stimulation may be provided by the following pairs of co-stimulatory 
receptors on T cells and ligands on APCs respectively: ICOS and ICOS ligand 
(ICOSL); CD27 and CD70; OX40 and OX40L; 4-1BB and 4-1BBL. CTLA-4 on T 
cells also binds B7 molecules, but this leads to an inhibitory signal as opposed to 
a co-stimulatory one. Antigen recognition in the absence of co-stimulation leads 
to T cell deletion or anergy17. 
Signal 3 relies on cytokine production by the APC, which directs the polarisation 
of the T cell into various subsets, including Th1, Th2, Th17, Th9, Th22, T follicular 
helper cells (Tfh) and induced regulatory T cells (iTregs)18,19. These subsets are 
defined based on the cytokines they secrete, and contribute different roles to the 
immune response, as shown in Table 1-1. 
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T cell subset Characteristic 
cytokines 
Cell type assisted / 
recruited 
Physiological role 
Th1 IFN-γ Macrophages Protect against 
intracellular bacteria 
Th2 IL4, IL-5 Eosinophils, mast 
cells, plasma cells 
(producing IgE) 
Protect against 
parasites 
Th17 IL-17 Neutrophils Protect against 
extracellular bacteria, 
fungi 
Th9 IL-9  Protect against 
parasites 
Th22 IL-22  Skin immunity 
Tfh IL-21 B cells Antibody production 
Induced Treg TGF-β, IL-10  Self-tolerance 
Table 1-1  Characteristics and functions of CD4+ T cell subsets 
Activation of CD8+ T cells leads to their differentiation into cytotoxic lymphocytes 
(CTLs), which play a key role in killing host cells infected by intracellular 
pathogens, particularly viruses. Infected cells display viral antigens on their 
surface MHC class I molecules, which are recognised by CTLs and destroyed. 
CD8+ T cell activation is generally assisted by CD4+ effector T cells.  
Effector T cell expansion and function 
After intensely proliferating for several days, expanding up to 105-fold 20, activated 
T cells differentiate into effector T cells that can produce the molecules needed 
to perform their helper or cytotoxic functions. They increase their expression of 
the adhesion molecules LFA-1 and VLA-4 but lose expression of CD62L, 
facilitating their entry into peripheral sites of infection via inflamed endothelium. 
On encountering cognate antigen, effector T cells are able to perform their 
effector functions without requiring co-stimulation. Effector T cells bind to target 
cells via LFA-1 and CD2. If the TCRs recognise their specific antigen:MHC 
complexes, the interaction between the two cells is strengthened, and an 
immunological synapse is formed, through which the effector T cell releases its 
effector molecules. T cells secrete cytokines, which have a broad range of effects, 
and cytotoxic T cells also secrete cytotoxins (including perforin, granzymes, 
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granulysin and Fas ligand) which assist in the killing of infected cells. Once the 
infection has cleared, >95% of effector T cells die by apoptosis during the 
contraction phase, and the remaining T cells develop into long-lived memory T 
cells21. As an example of their longevity, virus-specific T cells have been detected 
at least 25 years after vaccination22.  
1.1.3 T cell memory 
Memory subsets 
Memory T cells are heterogeneous and have been divided into various subsets 
based on their phenotype, migration properties, effector functions and 
proliferative capacity. These subsets include central memory T cells (TCM), stem 
cell memory T cells (TSCM), effector memory T cells (TEM), effector memory T cells 
re-expressing CD45RA (TEMRA), and tissue resident memory T cells (TRM) 23–25.  
The characteristic phenotypic markers used to differentiate between these 
subsets include CCR7, CD62L, CD27 and CD45RA25. CCR7 and CD62L are both 
lymph node homing markers, facilitating the entry of the memory T cell into the 
lymph nodes to scan for cognate antigen. CD27 belongs to the TNF receptor 
family and acts as a co-stimulatory molecule to enhance T cell activation when it 
binds to its ligand CD70 on APCs. CD27 signalling promotes T cell survival and 
proliferation, and is required for the generation of memory T cells. CD45RA is the 
longest isoform of the leukocyte common antigen CD45, which is a tyrosine 
phosphatase that regulates the activation threshold of T cells.  
TCM have a CCR7+ CD62L+ CD27+ CD45RA- phenotype and circulate between 
the lymph nodes and blood. They have high proliferative potential, and on 
stimulation produce high amounts of IL-2, but have low effector function.  
TSCM are a relatively rare subset with a CCR7+ CD62L+ CD27+ CD45RA+ 
phenotype that is typically associated with the naïve T cell compartment, as well 
as expressing CD95. They have high proliferative and self-renewal capabilities, 
with a multipotent ability to generate TCM, TEM and effector T cells, but have no 
effector function26.  
TEM are CCR7- CD62L- CD27- CD45RA- and traffic between the blood and 
peripheral tissues. They display various adhesion molecules and chemokine 
receptors to facilitate access to inflamed tissues. They are less proliferative than 
TCM but are potent immediate producers of effector cytokines such as IFN-γ.  
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TEMRA are CCR7- CD62L- CD27- CD45RA+ as well as CD28- and are present in 
the circulation. They are mostly present within the CD8+ T cell compartment, and 
their frequency in blood is correlated with persistent cytomegalovirus (CMV) 
infection27. They are considered to be terminally differentiated and exhibit various 
features of senescence28. They exhibit a low capacity to proliferate or produce IL-
2, but a high capacity for IFN-γ production.   
TRM remain confined to tissues and do not recirculate. They are CCR7- CD62L- 
but are harder to categorise using the above system, as they express their own 
set of unique phenotypic markers. This will be discussed below in the context of 
skin residency.  
Factors determining effector and memory T cell differentiation 
In view of the heterogeneous production of effector and memory T cells during 
an immune response, a number of different models have been proposed to 
explain the fate decisions made by activated naïve T cells15,29,30. The effector-first 
model proposes that the activated T cell proliferates and differentiates into 
effector T cells. These then subsequently die, or differentiate into memory T cells.  
The linear progression or decreasing potential model suggests that repeated 
antigenic stimulation of activated T cells drives greater proliferation and passage 
through a stepwise differentiation programme. The consensus on the 
differentiation sequence appears to be TN – TSCM – TCM – TEM – TEMRA and the 
endpoint is a terminal effector T cell that will eventually die. 
The asymmetric division model suggests that a single activated precursor T cell 
divides unequally, such that the daughter cell closer to the APC becomes an 
effector T cell due to increased TCR signals through the immunological synapse, 
and the distal daughter cell becomes a memory T cell.  
Similar to this is the signal strength model, whereby the strength of stimulatory 
signals early on during T cell activation determines the differentiation fate of the 
cell. Stronger signals drive clonal expansion and a more differentiated memory 
phenotype, but excessive signals lead to the formation of terminal effector cells 
(and eventual cell death). Thus, divergent cell fates are possible from a single 
precursor T cell. In reality there may be overlap between all of these models, and 
the same outcome is reached – the generation of a heterogeneous population of 
effector and memory T cells.  
25 
 
The factors that influence the differentiation of T cells into the various memory 
subsets remain a subject of debate. These factors include TCR signal strength, 
APC co-stimulation, proximity to APC at the time of T cell division, inflammatory 
cytokines, transcription factors and metabolic regulators23. The following are 
associated with differentiation of activated T cells into memory T cells as opposed 
to effector T cells: 
• Reduced duration of antigen exposure and reduced inflammatory stimuli 
during T cell activation29,31 
• Increased expression of IL-7Rα, CXCR3, CD27, CD62L, BCL-2 and reduced 
expression of KLRG1 and IL-2Rα 23,29 
• Increased expression of the transcription factors Id3, BCL-6, TCF-1, STAT3, 
Foxo1, Eomes and reduced expression of T-bet, Id2, Blimp1, Zeb2, STAT4  
15,23,29,31 
• Increased availability of the cytokines IL-10, IL-21, TGF-β and reduced 
availability of IL-2, IL-12, IFN-γ, IL-27 23,31 
• Energy requirements derived from fatty acid oxidation and mitochondrial 
oxidative phosphorylation, and signalling through AMPK (with effector cells 
favouring glycolysis and mTOR signalling) 15,23,29 
Maintenance of T cell memory 
Memory T cells persist long-term independently of antigen, and this is a dynamic 
process involving cell proliferation and death. The doubling time of a naïve T cell 
was estimated to be 1 year, a TCM cell every 60 days, and a TEM cell every 20 
days32. The maintenance of memory T cells is dependent on the homeostatic 
cytokines IL-7 and IL-15 33, with the former appearing more important for survival 
and the latter for proliferation15.  
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1.2 Immunosenescence 
1.2.1 The Innate Immune System 
Immunosenescence affects both the innate and adaptive arms of the immune 
system. Alterations in the numbers, phenotype and function of various innate 
immune cell types – haematopoietic stem cells, neutrophils, monocytes, 
macrophages, dendritic cells, natural killer cells – and changes in TLR expression 
and signalling have been demonstrated in ageing humans34–36. Furthermore, the 
decline in innate immunity has been associated with poor clinical outcomes from 
infectious diseases37,38.  
1.2.2 The Adaptive Immune System 
Ageing has been shown to have multiple profound effects on the adaptive 
immune system. A significant change is the reduced thymic output of naïve T 
cells39 accompanied by decreased numbers of naïve T cells in blood and SLOs40. 
Age-related naïve T cell decline predominantly affects CD8+ T cells, with CD4+ T 
cells relatively preserved41,42. There is also a reduction in the diversity of the naïve 
T cell repertoire by a factor of 2 to 5 between the ages of 30 and 70, as well as a 
major inequality in naïve T cell clonal sizes, suggesting a disturbance in 
homeostatic proliferation43.  
Memory T cells first generated in youth are considered to be strongly protective 
long-term, but memory T cell responses first derived in old age are profoundly 
impaired – suggesting the critical factor in memory persistence is the age of the 
naïve cell at the time of activation, and not the duration of time since memory 
induction44,45. With increasing age, naïve T cells develop shortened telomeres, 
altered TCR signalling, and incomplete differentiation towards memory T cells on 
activation46,47. The age-related decline in the naïve T cell compartment is 
considered to be a factor in the increased susceptibility to novel, previously 
unencountered pathogens in the old.  
The loss of naïve T cells is accompanied by the accumulation of highly-
differentiated antigen-experienced effector memory T cells in ageing individuals 
infected with CMV, who undergo a massive clonal expansion in CMV-specific 
CD8+ T cells48,49. Late-differentiated TEMRA cells demonstrate reduced expression 
of the co-stimulatory molecules CD28 and CD27; they take on characteristics of 
senescence with shortened telomeres, reduced telomerase activity, increased 
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DNA damage as visualised by γH2AX, and increased expression of KLRG1 and 
CD57; and they manifest reduced IL-2 production and impaired proliferation28,50. 
The effector functions of these cells are nevertheless preserved, with high 
production of cytokines and high cytotoxic activity28,50,51. CD8+ TEMRA senescent 
cells take on innate-like features of natural killer (NK) cells, pointing to a 
convergence of innate and adaptive immunity with increasing age52. Shortened 
telomere length in aged individuals has been associated with a higher mortality 
rate from infectious disease53, providing evidence for a link between cellular 
senescence and clinical outcomes from age-related disease.  
Intracellular signalling downstream of the TCR has been shown to be disrupted 
in late-differentiated T cells in ageing humans54. The early phases of the TCR 
signalling cascade are prominently affected; an alteration in Lck activation is 
particularly notable with increasing age54. The classical and alternative p38 
mitogen-activated protein kinase (p38 MAPK) pathways were recently shown to 
be lacking, and increased p38 MAPK activation occurred due to a novel 
intrasensory pathway driven by low-nutrient and DNA damage response 
signalling55. Inhibition of p38 MAPK in CD4+ TEMRA cells restored telomerase 
activity and survival after TCR activation56,57. Senescent CD8+ T cells undergo 
several metabolic changes, including reliance on glycolysis for energy, 
mitochondrial dysfunction, reduced mitochondrial biogenesis, increased 
production of reactive oxygen species (ROS), impaired autophagy, and failure to 
activate mammalian target of rapamycin (mTOR)51. Blocking p38 MAPK reversed 
many of these metabolic derangements58, demonstrating the close relationship 
between metabolic and senescence pathways.  
Persistent antigenic challenge in the form of chronic viral infection can lead to 
exhaustion of T cells in aged individuals – such viral infections include HIV, 
Epstein-Barr virus, hepatitis B and C. Exhaustion involves the progressive loss of 
T cell function, leading to deletion of the cell. Functions that are lost include the 
production of IL-2 and other cytokines, proliferative capacity and cytotoxicity. 
Exhausted cells are characterised by the accumulation of inhibitory receptors 
including PD-1, CTLA-4, TIM3, LAG3, BIM and Blimp1 28,44.  
PD-1 is a surface immune checkpoint receptor found on T cells and other immune 
cells (including B cells, monocytes and DCs). Its expression is transient on 
activated T cells and sustained on exhausted T cells. Engagement of PD-1 with 
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its ligands PDL-1 and PDL-2 leads to the transduction of an inhibitory signal, 
giving rise to diminished T cell proliferation and cytokine production. These result 
in the promotion of tolerance and inhibition of immune responses59. 
Thus, in summary, with ageing numerous changes to the adaptive immune 
system may occur including decline of naïve T cells, accumulation of terminally-
differentiated senescent T cells, cell signalling and metabolic disturbances, and 
functional exhaustion – all of which may contribute to immune impairment in the 
old.  
1.2.3 Inflammaging 
Ageing is associated with a persistent low-grade inflammatory state, termed 
inflammaging, and this is characterised by increased levels of IL-6, TNF-α and 
CRP60. The cause of this heightened inflammation is unconfirmed but multiple 
putative sources have been proposed. One potential source is the accumulation 
of senescent immune and stromal cells that take on a senescence-associated 
secretory phenotype (SASP)61, producing increased cytokines, chemokines, 
growth factors and proteases62. Other contributory sources during ageing include 
increased intestinal permeability and changes in the gut microbiota, persistent 
viral antigens stimulating the innate immune system, accumulating self-debris 
(including damaged cellular and organelle components, free radicals, fatty acids), 
circulating mitochondrial products serving as DAMPS, increased adiposity, 
increased activation of the coagulation system, and defects in the complement 
pathway62,63. Chronic inflammation is proposed to induce tissue damage either 
by the actions of infiltrating immune cells that release reactive molecules, or by 
the action of inflammatory cytokines inducing phenotypic changes in nearby 
cells63,64. Inflammaging is a significant risk factor for mortality and morbidity in the 
elderly, and is implicated in the pathogenesis of various chronic diseases 
including diabetes mellitus type II, ischaemic heart disease, osteoporosis and 
Alzheimer’s disease62,64. Evidence for the detrimental effect of inflammaging on 
immune function includes the down-regulation of CD28 expression on CD4+ T 
cells by TNF-α 65, telomerase inhibition and telomere erosion in CD8+ T cells by 
IFN-α 66, and observations that chronic inflammatory diseases are associated 
with shortening of telomeres in peripheral blood leukocytes51.  
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1.3 The Skin Immune System 
The majority of immunosenescence studies have focused on changes occurring 
in the circulation. However, pathogens are typically encountered and engaged by 
the immune system at the body’s various interfaces with the external environment 
i.e. the skin and the mucosal surfaces of the respiratory tract, gut or urogenital 
tract. In recent years, attention has shifted to characterising the local immune 
system in these peripheral tissues, as it is recognised that these peripheral sites 
play a critical and active role in immune surveillance and defence.  
The skin, as the outermost layer of the body with an extensive surface area of 
approximately 1.7 m2, is the first line of defence against a multitude of external 
pathogens. It consists of two layers: above is the epidermis, a thin layer 
(approximately 0.1mm thick) of stratified squamous epithelium, composed of four 
strata of keratinocytes in progressive stages of differentiation. The surface of the 
epidermis is densely populated by diverse commensal microbiota, which have 
been recognised to contribute to host immunity through competition with 
pathogenic microorganisms, enhancement of host innate immune responses, 
and priming of host adaptive immunity67,68.  
Below the epidermis is the dermis, a thicker layer (up to 3-4 mm depending on 
body site) consisting of a matrix of connective tissue produced by fibroblasts, and 
structures such as blood vessels, lymphatics, nerves, sweat glands and 
pilosebaceous units. Aside from presenting a mechanical barrier to physical and 
microbial insults, the skin contains a complex network of innate and adaptive 
immune cells with surveillance and effector functions (Figure 1-1), which in 
healthy adults provides a robust defence against pathogenic invasion69. The 
functions of these cells are discussed in turn below. Importantly, the skin is a 
tissue whose immune system is highly amenable to scientific investigation, in 
view of its accessibility and relative ease of sampling.   
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Figure 1-1 Immune cells within the skin 
Diagram demonstrating the anatomical relationship between the epidermis and dermis, and the 
array of immune cells contained within these layers (adapted from Nestle et al70) 
 
1.3.1 Epithelial cell defence 
Keratinocytes contribute to the innate immune response in the skin. They 
recognise PAMPS through their PRRs, and in response to pathogenic stimuli they 
produce pro-inflammatory cytokines, chemokines, and anti-microbial 
peptides70,71. Keratinocytes may also contribute to the adaptive immune 
response. They were shown to have the ability to process and present antigen to 
antigen-specific CD4+ and CD8+ memory T cells in vitro, leading to cytokine 
secretion and target cell lysis respectively72. Thus, keratinocytes are 
multifunctional cells that are crucial for host defence, with important roles in 
maintenance of the epidermal barrier, early sensing of pathogens and release of 
innate immune mediators, as well as priming of the adaptive immune response.  
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1.3.2 Innate immune cells 
The Epidermis 
Langerhans cells are immature, dendritic, antigen-presenting cells that reside in 
the epidermis. As the outermost immune sentinels in the skin, they extend 
dendrites to the stratum corneum to probe for foreign antigens73. During a skin 
infection, they become activated through PRRs, take up antigen, undergo 
maturation and migrate to the skin-draining lymph nodes to present antigen to 
naïve T cells. Migration is dependent on signals from TNF-α and IL-1β 74. Studies 
have shown that Langerhans cells maintain immune tolerance in normal skin, but 
in the presence of infection stimulate effector T cell responses75,76.  
The Dermis 
The key innate immune cells in the dermis are dermal dendritic cells (DDCs) and 
monocytes/macrophages. Other cell types include mast cells and innate 
lymphoid cells, which are understood to contribute to skin inflammatory 
responses but which have been poorly characterised to date77. DDCs take up 
and process antigen, and after migration to the skin-draining lymph nodes, 
present antigen to naïve or memory CD4+ or CD8+ T cells78. Activated DDCs also 
contribute to immune responses by producing pro-inflammatory cytokines70. Skin 
resident macrophages within the dermis remain in situ and scan the dermis for 
antigen. Additionally, circulating monocytes pass through the skin, assisting with 
antigen recognition and transport to the draining lymph node. The various subsets 
of monocytes and macrophages in the skin may be pro-inflammatory, anti-
inflammatory, or assist with wound healing77.  
1.3.3 T cells 
Besides central memory and effector memory T cells, it is now recognised that 
there is a third major population of memory T cells in the body, termed tissue 
resident memory T cells (TRM)79. These have been identified in the skin, mucosal 
surfaces (including gut, lungs, genital tract), non-barrier internal organs (including 
brain, liver and kidney), exocrine glands (pancreas, salivary glands) and 
secondary lymphoid organs24,80–82. These cells do not recirculate and are 
therefore absent from blood. TRM have been shown to be phenotypically and 
transcriptionally distinct from TCM and TEM and therefore represent an altogether 
separate population of cells83–85.  
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It has been estimated that there are 2 x 1010 T cells in human skin86, more than 
double those present in the blood, and the majority of these (80-90%) are TRM 87. 
Skin TRM express CD69, are negative for CCR7, and approximately 50% are 
positive for CCR8 87–89. CD69 is a surface receptor which is considered to block 
the egress of TRM from peripheral tissue by inhibiting S1P1 90,91. The minority of T 
cells in the skin that recirculate between skin and blood are CD69-, and have 
been divided into a population termed skin tropic central memory T cells, which 
are CCR7+ CD62L+ and have access to the lymph nodes, and another population 
called migratory memory T cells (TMM), which are CCR7+ CD62L- and may have 
access to skin draining lymph nodes but not other lymph nodes87.  
As well as CD69, another surface marker, CD103, has been found to be 
expressed by TRM. CD103 is an integrin that binds to E-cadherin which is 
expressed on keratinocytes92, and this interaction may be relevant for the 
retention of TRM in the skin93. Of the CD69+ TRM in human epidermis, 70% were 
CD103+, while only 40% of dermal TRM were positive for this marker87. The ratio 
of CD4+ to CD8+ T cells was found to be approximately 3:1 in human epidermis 
and 6:1 in dermis87, compared to 1.8:1 in the blood94. Thus, the predominant T 
cell type in the skin is a dermal CD4+CD69+CD103- TRM. Dermal CD4+ T cells 
tend to be arranged in clusters around blood vessels in the upper dermis86.  
Transcriptional analysis of TRM in various tissues showed downregulation of the 
transcription factors KLF2, T-bet and Eomes, and of the homing receptors S1P1, 
CD62L and CX3CR1, and upregulation of the transcription factors Hobit and 
Blimp1, the chemokine receptor CXCR6 and the collagen-binding integrin CD49a 
– all of which may be relevant for the retention of TRM in peripheral tissue 
sites83,84,95,96. Additionally, CD49a positivity was shown to denote a subpopulation 
of CD8+ skin TRM that produced IFN-γ, perforin and granzyme on stimulation97. 
TRM express IL-2, IFN-γ, TNF-α, IL-17 more highly than circulating TEM, and this 
was also true for the inhibitory cytokine IL-10 24,95. Furthermore, TRM express the 
inhibitory receptors PD-1, CTLA-4 and LAG3 24,95. These transcriptional data 
suggest TRM have both protective and regulatory roles.  
Cutaneous TRM are generated after skin infections and are antigen-specific to the 
causative pathogen98. Accordingly, skin TRM were found to exhibit a diverse TCR 
repertoire86. Neonatal skin was shown to have very few TRM, reflecting minimal 
previous cutaneous exposure to pathogens87. During a primary skin infection, 
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DCs from the skin take up antigen, migrate to the draining lymph node and 
present antigen to naïve T cells, upon which these T cells become activated, 
differentiate into effector cells and undergo clonal expansion. DCs originating 
from the skin, expressing skin-derived vitamin D3 and prostaglandin E2 (PGE2), 
imprint these effector T cells to express CLA, CCR4, CCR8 and CCR10 99,100, 
and the effector T cells migrate via the circulation to the inflamed tissue. Here, 
activated endothelium expressing E-selectin, CCL17, CCL1, CCL27 and ICAM-1 
– the respective ligands for CLA, CCR4, CCR8, CCR10 and LFA-1 expressed on 
the surface of skin-homing T cells – assists effector T cells in entering the skin 
where they can perform their various effector functions101.  
Once the skin infection has cleared, a proportion of KLRG1- effector T cells 
differentiate into TRM 83, with upregulation of CD69 and CD103 occurring within 
weeks87. Local signalling by cytokines including IL-15, TGF-β, Il-33 and TNF-α 
have been implicated in the formation of TRM 83,102,103. Concurrently, clonal 
populations of TCM are generated in LNs with identical antigen-specificity to the 
clonal populations of TRM generated in the skin, indicating that TCM and TRM are 
derived from a common naïve T cell precursor104. Following a localised skin 
infection, long-lasting TRM are generated throughout the entire skin surface, but 
with the highest concentration at the initial site of infection105.  
These TRM now sustain a stable, long-lived population within the skin and are 
protective against future encounters with the same pathogen79,105–107. Long-term 
maintenance of TRM appears to be antigen-independent103. Transcriptional 
analysis of skin TRM suggested these cells were poised to respond to danger 
signals and were in a more activated state than their recirculating counterparts85. 
Human patients with alemtuzumab-treated cutaneous T cell lymphoma (CTCL), 
whose circulating T cells are depleted but have intact skin TRM, have a low 
incidence of skin infections, highlighting the protective role of this latter T cell 
population108. The specificity of TRM located at each tissue location relates to the 
pathogens previously encountered at that site. For example, skin contains VZV-, 
HSV- and Candida-specific T cells, lung has influenza-specific T cells, hepatitis 
B-specific T cells may be found in the liver, and EBV-specific T cells are located 
in the spleen and tonsils24.  
Following secondary skin infection, DCs can directly present antigen to skin TRM, 
which proliferate in situ, ultimately resulting in the generation of increased 
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numbers of TRM 105,109,110. Local inflammation facilitates the recruitment of 
bystander T cells and other immune cells from the circulation in a non-specific 
manner71,111. Antigen-specific TCM are also recruited from the draining LN, which 
then home to the site of infection to contribute to the immune response, and a 
proportion of these cells will subsequently differentiate into long-lived TRM, adding 
to the existing TRM population71,105,109–111. Secondary antigen encounter in the 
skin massively increased the formation of vaccinia-specific CD8+ skin TRM in mice 
by 50-100 fold112, although another study in mice found that inflammation alone 
in the absence of antigen was sufficient to generate HSV-specific CD8+ skin TRM 
113. Although both TRM and TCM contribute to the secondary immune response, 
TRM have been shown to dominate the local T cell response and are more 
protective against re-infection than TCM87,109,110.  
More work is needed to investigate the mechanisms through which TRM perform 
their protective functions. While 95% of skin TRM were shown to be Th1 
polarised86, as a whole the skin TRM population is heterogeneous, and production 
of IFN-γ, TNF-α, IL-9, Il-13, IL-17 among others has been demonstrated alone or 
in combination81. There is some evidence that cytotoxic TRM can migrate towards 
virally-infected cells114,115 and perform cell lysis116. In animal models, reactivated 
CD8 TRM rapidly conditioned the local environment by inducing broadly active 
antiviral and antibacterial genes117, and secreting cytokines that triggered brisk 
adaptive and innate immune responses, including local humoral responses, 
maturation of local dendritic cells, and activation of natural killer cells118,119. This 
rapid response induced an antiviral state that was inhospitable to an antigenically 
unrelated virus118.   
CD8+ skin TRM expressed high fatty-acid-binding proteins 4 and 5 (FABP4 and 
FABP5), which are cytoplasmic proteins that mediate cellular uptake and 
intracellular transport of free fatty acids (FFA), and demonstrated increased 
uptake of extracellular FFA120. TRM relied on FABP4/FABP5 for survival and 
protection against viral infection120. The maintenance and protective capability of 
skin TRM may be dependent on oxidative metabolism of exogenous FFAs120, and 
this might be a crucial metabolic adaptation for survival in the epidermis, a lipid-
rich but nutrient-poor environment121.     
Overall, therefore, it appears that TRM are well-poised as immune sentinels at the 
interface between the skin and the environment, and on pathogen detection their 
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actions are broad - they rapidly proliferate, activate and recruit other immune cells 
to the site of infection, and release cytokines and perform cytotoxic activity 
against infected cells.  
Regulatory T cells 
CD4+Foxp3+CD25hi Tregs constitute approximately 10% of the T cell population 
in the skin122,123. The predominant expression of CD25, CTLA-4 and ICOS, as 
well as CD45RO, indicated an activated memory Treg phenotype, and the lack 
of CCR7 expression suggested that these cells were resident in the skin124. Tregs 
in circulation express high levels of the skin homing markers CLA, CCR4 and 
CCR6, indicating that the skin is a major trafficking site for these cells125. As a 
major interface with the environment, the skin is constantly exposed to a high 
antigenic load, and it is speculated that the role of the cutaneous Treg population 
is to dampen excessive immune responses, including to innocuous non-self 
antigens, auto-antigens, and non-pathogenic commensal microbiota125,126. Mice 
in which Tregs were unable to migrate to the skin developed severe cutaneous 
inflammation, demonstrating the importance of maintaining immune tolerance at 
this site127. 
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1.4 The Delayed Type Hypersensitivity Response 
The delayed type hypersensitivity (DTH) response is a useful model for studying 
in vivo immune responses in the skin. This involves intradermal injection of a 
recall antigen into the forearm skin, allowing for direct visualisation and 
assessment of the clinical response. The clinical response is a visible indicator of 
the degree of inflammation at the antigen-challenged site and takes into account 
erythema, palpability and diameter of the swelling. The presence of erythema 
reflects localised dilatation of skin capillaries and attendant increased blood flow, 
while the palpable swelling is due to fluid (containing cells and protein) escaping 
from these leaky capillaries causing local oedema. The clinical response evolves 
over days – first becoming apparent by 24 hours, then peaking at 48-72 hours 
before tailing off over the next several days. The skin at the DTH site can be 
sampled at a chosen time-point, with analysis of the various immune cells 
present.  
The DTH response is a memory CD4+ T cell-mediated immune response128–130. 
A robust DTH response requires successful integration of the innate and adaptive 
arms of the immune system. Following intradermal injection of antigen, the 
presence of tissue damage and pathogen-derived antigen stimulates a variety of 
skin-residing cells with innate immune functions to produce pro-inflammatory 
cytokines to initiate the inflammatory process70. These cells include epidermal 
keratinocytes and Langerhans cells as well as dermal macrophages and DCs70. 
The production of TNF-α, IL-1 and IL-6 by macrophages activates local 
endothelium, triggering endothelial cell expression of the adhesion molecules E-
selectin, ICAM-1 and VCAM-1 that allows further recruitment of leukocytes from 
the circulation131–135. IFN-γ production by T cells also contributes to endothelial 
activation via upregulation of ICAM-1136–139. Modelling of the kinetics of the DTH 
to tuberculin purified protein derivative (PPD) revealed a brisk cellular influx at 
the site of injection, with the majority of cells being neutrophils at 6 hours, 
macrophages at 24 hours, and T cells 48 hours and beyond128. The peak of the 
T cell response was shown to occur at 7 days128. 
Preparations of injectable recall antigens exist for various pathogens. The first 
was the tuberculin skin test, first employed by Von Pirquet in 1909 to demonstrate 
past exposure to tuberculosis140. Our group has extensively studied the DTH 
response to VZV skin test antigen141 as an in vivo measure of cell-mediated 
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immunity to VZV135,142,143. Greater than 90% of the UK adult population are 
seropositive for VZV144, meaning the skin test is suitable as a recall antigen for 
the majority of research participants. The VZV skin test has been shown to be a 
reliable indicator of immunity to VZV145,146, and predicts the risk of developing 
shingles147 and post-herpetic neuralgia148.  
Previous work by our group has shown that after skin challenge with VZV antigen, 
VZV-specific CD4+ T cells, mainly of a central memory (CD27+CD45RA-) 
phenotype, accumulated at the challenge site and this was due in part to local 
proliferation142. The number of infiltrating CD4+ T cells at the peak of the cellular 
response (Day 7) correlated with the magnitude of the clinical response (Day 3), 
highlighting the importance of early inflammation in the subsequent recruitment 
of T cell numbers to the challenge site142. Accumulation of CD4+Foxp3+ Tregs 
occurred in parallel and in proportion to CD4+ T cell effectors after VZV142 and 
PPD149 skin challenge. The proportion of Tregs in perivascular immune cell 
infiltrates inversely correlated with the degree of clinical response, providing 
indirect evidence for their inhibitory effect on the cutaneous memory immune 
response in vivo142.  
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1.5 Age-related changes in the Skin Immune System 
Clinical evidence for the impairment of the skin immune system in old humans is 
provided by the increased frequency of skin infection150, skin cancer151, 
autoimmune skin disease152 and the attenuation of DTH responses135,153 in this 
age group. Skin infections that are more prevalent in the old are due to a range 
of bacterial (eg. Staphylococcus aureus and beta-haemolytic Streptococci), viral 
(eg. VZV) and fungal (eg. Candida albicans) pathogens150. 
Physiological changes in elderly skin, such as thinning of the epidermis, reduced 
water retention in the stratum corneum, and diminished blood flow to the skin lead 
to impaired barrier function and prolonged healing150, increasing the likelihood of 
invasion by pathogens. In addition to these structural changes, the skin immune 
system also appears susceptible to the effects of ageing. Evidence for age-
related changes in the skin immune system is discussed below.  
1.5.1 The innate immune system 
Toll-like receptors 
TLRs are expressed by multiple cell types in the skin, including keratinocytes, 
Langerhans cells, DDCs, macrophages, endothelial cells and fibroblasts154. 
Some evidence exists for the impairment of TLR function during ageing155. In 
monocytes, stimulation of the TLR1/2 heterodimer and TLR7 resulted in reduced 
cytokine production in the old; TLR1 but not TLR2 expression was reduced in 
these old individuals156. In DCs, stimulation via TLR4, TLR7 and TLR9 led to 
impaired cytokine production in the old157. Diminished activation of innate immune 
cells via TLRs may therefore lead to the insufficient priming of adaptive immune 
responses in the skin.  
Antigen-presenting cells 
Several studies have demonstrated age-related changes affecting the various 
populations of APCs in the body, but only limited data exists relating to the skin 
specifically. Langerhans cells were shown to be reduced in number in the 
epidermis of old compared to young individuals158,159. Furthermore, after 
exposure to TNF-α, their capacity to migrate out of the skin was impaired in old 
humans, and this was considered to be due to inadequate IL-1β signalling158,159. 
During inflammation or injury, the Langerhans cell population in the skin is 
thought to be replenished by circulating monocyte precursors. However, no age-
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related defect was demonstrated in the phenotype and function of monocyte-
derived Langerhans cells160. Thus, it appears that there is an age-related 
impairment in the Langerhans cell population derived from local precursors in 
normal human skin, but not in the monocyte-derived Langerhans cell population 
in inflamed skin. 
Data on DDCs is lacking, but studies have found that the number of circulating 
myeloid DCs does not change in the old161,162. The phenotype of DCs appears to 
be comparable between young and old, as measured by surface co-stimulatory 
and antigen-presenting molecules163. Furthermore, in vitro stimulation of DCs 
resulted in the expression of comparable levels of surface activation markers, 
indicating no age-related decline in the ability of these cells to undergo 
maturation161,164. However, there does seem to be an age-related impairment of 
DCs in their ability to perform phagocytosis and micropinocytosis of antigens, as 
well as in their migration capability163. Cytokine-secreting ability may also be 
dysregulated in the old. Secretion of pro-inflammatory cytokines by DCs was 
increased in the resting state in the old, but there was reduced secretion when 
DCs were activated by a variety of stimuli157,163,165,166. Finally, DCs from old 
individuals were significantly impaired in their abilities to activate CD8+ T cells, 
induce T cell proliferation, and stimulate secretion of IL-12 and IFN-γ by T cells166. 
Similarly, there is a lack of data on dermal macrophages, and also a lack of 
human immunosenescence studies on macrophages in general. Mice studies 
have pointed to age-related defects in TLR expression, signal transduction and 
downstream cytokine production by macrophages, as well as impaired 
phagocytic and antigen-presenting properties167,168.  
1.5.2 The adaptive immune system 
Skin resident memory T cells 
Data on the effects of ageing on the skin TRM population are lacking, and 
investigating this will be the focus of the work here. A previous study by the Akbar 
group demonstrated significant telomere shortening in antigen-specific CD4+ T 
cells during the DTH response to PPD, and this was associated with the inhibition 
of telomerase169. This may suggest that T cells in the skin are particularly prone 
to premature replicative senescence.  
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Regulatory T cells 
The frequency of Tregs is higher in old skin and blood compared to young135,170,171 
- possibly due to greater resistance to apoptosis in the old172. nTregs appear to 
increase with age, whereas iTregs seem to decline in number173. The proportion 
of circulating Tregs expressing the skin homing marker CCR4 is higher in the old, 
suggesting a mechanism for circulating Tregs in the old to preferentially home to 
and lodge in the skin174.  
The phenotype of Tregs from old and young humans is comparable, with similar 
levels of expression of Foxp3, CD25, CTLA-4 and GITR171. Studies have shown 
that Tregs from old and young humans are equivalent in their ability to suppress 
proliferation and production of IFN-γ by CD4+ T cells170. The expression of co-
stimulatory molecules on DCs was reduced in aged compared to young mice, 
and this was shown to be due to the greater suppressive effect of aged Tregs175. 
However, Tregs from old mice were less capable of inhibiting the production of 
IL-2 173 and IL-17 176 by T cells. Overall these data suggest that ageing is 
accompanied by an increase in Tregs, which appear to remain as suppressive in 
the old than the young.  
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1.5.3 Impaired DTH responses in ageing skin 
The DTH clinical response is diminished in old individuals in response to 
mycobacterial, fungal and viral antigens135,143,153 (Figure 1-2 and Figure 1-3) . The 
cellular response, assessed both by total as well as antigen-specific CD4+ T cells, 
is also diminished in the old compared to the young – this has been demonstrated 
for VZV, candida and PPD135,143.  
 
 
 
 
 
 
Figure 1-2 Typical clinical response to VZV antigen challenge in a young (left) and old 
(right) individual135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 The effect of age on clinical response to VZV skin antigen challenge143 
Graph showing Day 3 clinical score plotted against age. Linear regression analysis line, R2 value 
and significance value are shown (n=185).   
In experiments performed by the Akbar group, it was shown that following 
intradermal injection of VZV antigen, young individuals had a strong 
transcriptional response in the skin at 72 hours in comparison to unchallenged, 
normal skin. The top 30 overexpressed genes in the young were also 
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overexpressed in the old (compared to normal skin), but to a much lesser degree 
in the old than the young. Genes that were expressed in the young but not the 
old were associated with T cell and dendritic cell activation; immunological, 
inflammatory and antiviral signalling pathways; pathways induced by type I 
interferons and IFN-γ signalling143. These transcriptional data lend support to the 
histological findings of impaired T cell accumulation and proliferation at the site 
of the DTH response in the old143. 
The mechanisms underlying the impaired DTH responses in the old remain 
unclear. Conceivably, a defect in any one (or more) of the following processes 
would attenuate the DTH response: 
1. The taking up of recall antigen by skin-resident DCs, DC activation and 
induction of local inflammation, antigen presentation to antigen-specific 
skin TRM. 
2. Antigen-specific TRM activation and proliferation, execution of effector 
functions, recruitment of other immune cells to response site. 
3. Recruitment of circulating memory T cells via dermal endothelium into the 
skin, and differentiation into effector cells. 
Diminished DTH T cell responses to candida antigen in the old at the 24 and 72 
hour time points were associated with reduced endothelial activation and 
decreased TNF-α production by dermal macrophages135. TNF-α production by 
dermal macrophages ex vivo was not impaired in the old, suggesting 
environmental factors in the skin may impair innate immune responses135. Our 
study of DTH responses to VZV showed impaired endothelial activation and 
reduced accumulation of DCs at the challenge site in the old, at 24 hours and 
beyond143. These studies indicate impaired cellular recruitment via the 
endothelium is central to impaired DTH responses in the old. 
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1.6 Varicella Zoster Virus Biology 
1.6.1 Varicella pathogenesis 
VZV is an exclusively human alpha-herpesvirus. Primary infection, which affects 
the vast majority of the population during childhood, causes chickenpox 
(varicella). Primary VZV is acquired via the respiratory mucosa, leading to 
invasion of the tonsillar epithelium, followed by viremia; next, infected 
lymphocytes transport virus to keratinocytes in the skin. Innate immunity 
temporarily inhibits VZV replication in the skin but is then overcome, leading to 
the development of a characteristic, generalised, vesicular rash. The incubation 
period is 10-21 days. Chickenpox (and shingles) skin lesions both contain high 
concentrations of infectious virus and are the source of transmission to 
susceptible individuals177,178.  
Primary VZV infection induces VZV-specific T cells and VZV-specific antibody. 
VZV-specific T cells are required to clear primary infection and also prevent viral 
reactivation. Cell-to-cell spread of VZV in the host, which avoids extracellular 
circulation of virions, may explain why T cell-mediated immunity is more critical 
for protection than specific antibody.  
During the course of primary infection, VZV particles reach cranial nerve ganglia 
and peripheral sensory nerve dorsal root ganglia, and this is thought to be either 
via retrograde axonal transport or via haematogenous spread inside T cells177. 
Latent infection is thus established and persists for life179. Human autopsy studies 
have shown that VZV genomes (~ 2-9 copies per cell) are present in 
approximately 4% of sensory neurons during latency180–183. 
1.6.2 Herpes zoster pathogenesis 
Occasionally, VZV reactivates from its latent state – the virus multiplies and 
spreads within the ganglion, infecting many additional neurons and supporting 
cells, which induces intense inflammation and neuronal necrosis184,185. Virions 
travel via anterograde axonal transport and access the area of skin (dermatome) 
innervated by the sensory nerve, leading to the symptoms of shingles infection 
(herpes zoster)177,184.  
The trigger for reactivation is unknown, but shingles is more frequent in the 
elderly, in whom there is an impairment in the degree of VZV-specific cell-
mediated immunity (CMI)184,186–189 but no decline in titres of VZV-specific 
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antibody186,190. Approximately 50,000 cases of shingles occur annually in those 
aged 70 and over in the UK; the estimated lifetime risk of developing shingles is 
1 in 4 191,192. Post-herpetic neuralgia (chronic nerve pain) is more likely to 
accompany shingles infection in the aged population and also more likely to be 
severe178,189,193. 
Similarly, immunocompromised patients with HIV infection, Hodgkin’s lymphoma, 
organ transplant recipients, and patients receiving immunosuppressant therapy, 
all of whom have impaired CMI to VZV but intact VZV-specific antibody levels, 
are at heightened risk of VZV reactivation184,187. Contrastingly, patients with X-
linked agammaglobulinaemia with intact CMI to VZV are not at greater risk of 
shingles184. These observations demonstrate that CMI is critical in host defence 
against VZV reactivation whereas humoral responses do not have a significant 
role.  
While VZV-CMI is correlated with immune protection against reactivation, the 
mechanisms of this protection have not been elucidated. The role of VZV-specific 
T cells and whether they can directly limit viral reactivation is unknown177. Ganglia 
latently infected with herpes simplex virus (HSV) have been shown to harbour 
HSV-specific resident T cells (predominantly CD8+)194, but in contrast, ganglia 
latently infected with VZV do not harbour VZV-specific resident T cells. This is 
despite the fact that neurons latently infected with VZV have been shown to 
express several VZV proteins (despite doubts about the specificity of the 
immunostaining), thereby presenting a theoretical opportunity for the immune 
system to recognise latent infection and contain it184,195,196. However, constitutive 
expression of MHC class I is low on neurons197,198 and furthermore, VZV has 
been shown in vitro to be responsible for the inhibition of MHC class I expression 
on fibroblasts (and T cells)199–201, pointing towards a potential mechanism of 
immune evasion during latency. In addition, VZV impairs IFN-γ-induced MHC 
class II expression on infected cells, suggesting a potential mechanism for 
evasion of CD4+ T cell-mediated immune surveillance202. This raises the 
possibility that virus latency is regulated by an innate immune response involving 
cytokines or chemokines203.  
Psychological stress around the time of space missions is associated with a 
depression in CMI to various antigens204, and CMV and EBV have been shown 
to reactivate in astronauts undergoing spaceflight205–207. Evidence for silent 
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reactivation of VZV, associated with a temporary depression in immunity, comes 
from a fascinating study in 3 astronauts, in 2 of whom VZV DNA was repeatedly 
detected in the saliva during a 13-day spaceflight as well as for the first 5 days 
after landing back on earth208. After landing, salivary samples were cultured and 
live virus was detected in the samples of these 2 astronauts from Day 2 only and 
no other days208. VZV DNA and infectious virus can be found in the saliva of 
patients suffering with acute shingles209. It is postulated that VZV reaches the 
saliva following reactivation in the geniculate ganglion and transaxonal transport 
to the nasopharynx208. Interestingly, VZV IgG levels were raised in these 2 
individuals at 10 days before the space mission compared to baseline (2-3 
months prior), and returned to baseline 2 weeks after landing208. The third 
astronaut had suffered with shingles 10 years previously and no changes were 
detected in his samples during the study, suggesting a boosting of his VZV-
specific immunity had occurred as a result of previous infection208.  
The lack of ganglion-resident T cells means it is unlikely that VZV reactivation is 
continually actively prevented by T cell interactions with neurons9. Innate immune 
mechanisms probably suppress viral reactivation under normal circumstances, 
and the silent reactivation of VZV during spaceflight suggests that these innate 
mechanisms are interrupted during psychological stress. Once reactivated, the 
virus was presumably contained by the astronauts’ functional T cell responses, 
preventing the full-blown clinical manifestation of shingles. Some astronauts have 
suffered with shingles207, however, likely reflecting global dampening of innate 
and adaptive immunity during spaceflight210.   
In the general population, it is considered likely that intermittent VZV reactivation 
occurs in the absence of overt shingles skin lesions, with active virus replication 
and spread within the ganglion presumably stimulating recruited VZV-specific T 
cell responses to terminate the propagation of virus9,189. This is likely to explain 
both episodes of silent reactivation detectable only by the resulting boost in VZV-
specific immunity211,212, as well as the clinical phenomenon zoster sine 
herpete184,213, where VZV-induced dermatomal pain occurs in the absence of a 
skin rash195. This capacity to contain, rather than prevent, viral reactivation is 
required for the lifespan of the individual and is the target of the shingles 
vaccine189.  
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Steain et al obtained ganglia from a 93-year-old male patient who had died from 
pneumonia and dementia, and who was suffering with acute shingles at the time 
of death196. Intense staining for the VZV protein IE63 was demonstrated in the 
ganglion in which VZV had reactivated196. This ganglion was densely infiltrated 
with CD4+ and CD8+ T cells, and many of the latter were positive for granzyme 
B196. A large number of CD3- granzyme B+ cells were present and these were 
proposed to be NK cells196. There was marked upregulation of MHC classes I and 
II on satellite glial cells (SGCs) but not on neurons (which typically do not express 
MHC molecules), suggesting that SGCs play an important role in the direction of 
the immune response during shingles196. SGCs completely encircle sensory 
neurons, providing protection214, barrier function215, nutritional support and 
displaying properties of APCs216. However, SGCs decline in number with 
increasing age215, thereby possibly contributing to the greater risk of uncontrolled 
VZV viral reactivation in the ganglion.    
VZV infection of ganglia in an explant ganglion model led to increased CXCL10 
production in vitro; this chemokine was also found to be elevated in a naturally 
infected ganglion during acute shingles infection. In the latter, this was associated 
with the presence of lymphocytes expressing CXCR3, the receptor for CXCL10, 
implicating this chemokine as a driver of T cell recruitment during shingles 
infection217.  
Combined, these findings demonstrate that during VZV reactivation in ganglia, 
intense expression of VZV protein may attract a robust T cell response, and in 
view of the lack of ganglion-resident T cells during latency, these infiltrating T 
cells are likely to be recruited from other sites, such as the circulation. In support 
of this, acute shingles infection was associated with an increase in circulating 
VZV-specific CD4+ T cells, with a striking shift in cytokine profile to IFN-γ single 
positive T cells compared to healthy controls218. The age-related decline in 
circulating VZV-specific CD4+ T cells would likely impair the circulating VZV-
specific T cell immune response and would be consistent with the greater 
propensity for VZV reactivation in older individuals.   
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1.7 Vaccination 
Unfortunately, few therapeutic interventions currently exist to boost immunity in 
old individuals. The principal current strategy is to vaccinate the elderly against 
the serious infections from which they are most likely to suffer, but this is limited 
by whether a vaccine exists for each specific disease. The current routine 
immunisation schedule for older adults in the UK recommends vaccinating 
against S. pneumoniae at 65 years old, influenza (annually) after 65 years of age, 
and shingles after the age of 70 219. Due to senescence of the immune system, 
however, vaccination responses are significantly diminished in old compared to 
young adults220–222 – and none of the three vaccines mentioned above confer 
satisfactory protection in the ageing population, although they do mitigate the 
effects of the disease223.  
The detailed mechanisms of action of vaccines are largely unknown. Most 
vaccines mediate their efficacy through the induction of specific antibodies, which 
must be present at the site of pathogen replication224. For the vaccines against 
shingles and tuberculosis, protection correlates with CD4+ T cell responses224,225. 
Protective mechanisms are likely to be complex and rely on multiple arms of the 
immune system. For example, CD4+ T cells are required for the generation of 
most antibody responses, by providing B cell help and cytokine production224,225. 
It is generally recognised that an ideal vaccine should induce a long-lasting, large 
and diverse antigen-specific T and B cell memory repertoire, as well as a robust 
specific antibody response221,226.  
The influenza vaccine provides poorer clinical protection in old compared to 
young individuals227,228. The standard correlate of protection for influenza 
vaccination is the specific antibody level (measured by haemagglutination 
inhibition), but immunological studies have shown that old individuals produce 
impaired antibody responses228,229 as well as CD8+ T cell-mediated 
responses229,230 to this vaccine.  
A number of changes in the ageing immune system may account for the 
impairment of vaccine responses in the old. The loss of naïve T cell numbers and 
diversity, and the accumulation of dominant clones of late-differentiated memory 
T cells, for example specific to CMV, restricts the expansion of pathogen-specific 
naïve cells in response to a vaccine223,226. With increased age there is an 
expansion of CD28- memory T cells, which manifest impaired activation and 
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proliferative capacity. Loss of CD28 in CD4+ T cells is also accompanied by a 
loss of CD40L, compromising B cell activation and antibody responses220,221,231. 
A higher proportion of CD8+ CD28- T cells in the old has been associated with 
impaired antibody responses to the influenza vaccine222,232. Additionally, 
telomere length was positively correlated with B cell and influenza M1-specific 
CD8+ T cell responses after influenza vaccination in older adults233, suggesting 
that reduced lymphocyte replicative capacity impairs vaccination responses in the 
old. Furthermore, the duration of T cell234 and antibody responses235 are impaired 
in the old.   
The B cell compartment is also adversely affected by ageing, impairing 
vaccination-induced specific antibody responses in the old. Similar to the T cell 
compartment, naïve B cell numbers decrease, and effector B cells with limited 
repertoire diversity accumulate in old age220,223,236. Age-related defects in isotype 
switching and somatic mutation lead to a reduced diversity of antibody responses, 
which are quantitatively decreased, less efficient and of lower avidity220,237.  
1.7.1 Zostavax® introduction 
The live attenuated shingles vaccine Zostavax® has been available since 2006 
and is currently offered to individuals in their 70s in the UK. The Shingles 
Prevention Study (SPS) showed this vaccine was 63.9% effective at reducing the 
incidence of shingles in the 60- to 69-year-old population, but this fell to 37.6% in 
the over 70s238. The increased incidence of shingles in older people is postulated 
to be due to an age-related decline in circulating VZV T-cell-mediated 
immunity186, and there is evidence that the vaccine stimulates VZV-specific CD4+ 
T cell responses in the circulation in old individuals189,239. The immunological 
effect of the vaccine on skin immunity is unknown. Given that shingles is a 
disease manifesting in the skin, it is of interest to consider how the vaccine 
modifies immune cell populations resident in the skin, and whether in vivo VZV-
specific immune responses in the skin can be enhanced by the vaccine.  
As of October 2017, a new non-live shingles vaccine Shingrix® has been licensed 
for use in the USA; preliminary studies have demonstrated a high efficacy which 
did not decline in older ages. This vaccine will be discussed in Chapter 4.  
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1.7.2 Review of the immune effects of Zostavax®  
The Shingles Prevention Study240 immunology substudy 
The substudy demonstrated a boost in CMI responses at 6 weeks after 
vaccination, as measured by responder cell frequency and IFN-γ ELISPOT239. A 
separate study investigating the early T cell response to Zostavax® 
demonstrated the frequency of IFN-γ-producing T cells increased approximately 
tenfold to peak between 8 and 14 days post-vaccination, but a decline was 
already observed by Day 28 (but still threefold higher than before vaccination)241. 
Importantly, the boost in VZV-specific T cell-mediated immunity was similar to 
that developing after naturally occurring shingles infection242. The boost in CMI 
was observed for the 3-year duration of the immunology substudy, but declined 
over time239. The largest drop was seen between 6 weeks and 1 year, during 
which period the vaccine-induced boost declined from 85% to 42% as measured 
by RCF and from 120% to 60% as measured by ELISPOT239. The VZV-CMI 
responses to Zostavax® correlated with the clinical efficacy observed in the 
SPS240, confirming the hypothesis that boosting VZV-CMI would result in clinical 
protection. Follow-up studies demonstrated that clinical efficacy of the vaccine 
declined with each additional year after vaccination, with no demonstrable clinical 
benefit after 8 years240,243,244.  
In addition, there was a boost in the antibody response at 6 weeks as measured 
by ELISA239. The boost in VZV antibody in vaccine recipients declined from 78% 
to 20% from week 6 to 1 year after vaccination, and fell 7%–15% per year 
thereafter239. There was a poor correlation between VZV-CMI and VZV antibody 
response, suggesting these classes of immune response are independent239. 
Despite this, fold-change in VZV antibody titres after vaccination of 50-59 year-
olds was an excellent correlate of clinical protection, perhaps suggesting that the 
antibody response is an indirect marker of a robust and multi-faceted immune 
response189,245.  
The measures of CMI at 6 weeks were lower in the ≥70s compared to participants 
aged 60-69239. When age was assessed as a continuous variable, measures of 
CMI at 6 weeks declined by 3.5% - 3.8% for every additional year of age239. In 
contrast, there was no significant difference in VZV antibody titre between the 60-
69 and ≥70 age groups at the 6-week time-point239. When age was assessed as 
50 
 
a continuous variable, antibody titres declined by 1% per additional year of age, 
at week 6239.  
Effect of Zostavax® on the quality of circulating T cell responses 
A limited number of recent studies have examined the effect of Zostavax® 
vaccination on the breadth and functionality of VZV-specific T cell responses in 
individuals aged over 50 246–248. Laing et al showed that CD4+ T cells responded 
to a median of 2.5 VZV proteins before vaccination, and the breadth of the 
response improved 4.2-fold at 1 month after vaccination to a median of 10.5 VZV 
proteins246. However, the breadth of responses returned to near baseline levels 
by 6 months246. The enhanced breadth of responses occurred in conjunction with 
an increase in magnitude of CD4+ T cell responses as discussed previously239,246. 
These results were consistent with findings by Qi et al, who identified a 
diversification of the T-cell receptor (TCR) repertoire following vaccination248. 
Interestingly, vaccination preferentially favoured expansion of infrequent VZV 
antigen-reactive TCRs, with a smaller effect on dominant, in-vivo-selected T cell 
clones248. Data from this study also suggested that VZV vaccination not only 
increased the frequencies of existing memory VZV-reactive CD4+ T cell clones 
but also activated naïve CD4+ T cell clones, thereby increasing the richness of 
the VZV-specific memory CD4+ T cell repertoire and potentially improving 
protective immunity to VZV248. 
Sei et al performed a comprehensive study into the functionality of ex vivo T cell 
responses following Zostavax® administration in 21 volunteers aged 55-65 
years247. After vaccination, IFN-γ and IL-2 production were boosted following 
whole blood stimulation with each of 17 separate VZV antigens or VZV lysate. 
Additionally, vaccination led to a boost in the frequency of VZV-specific CD4+ T 
cells producing IFN-γ by 8.6-fold, IL-2 5.5-fold, TNF-α 6.1-fold and CD154 (a T 
cell surface protein that regulates B cell responses by engaging CD40) 5.1-fold. 
Poly-functional T cells were defined as those expressing all four of these 
functions, and this subset constituted the highest frequency of memory VZV-
specific CD4+ T cells before and after vaccination. After vaccination, there was a 
boost in the frequency of poly-functional CD4+ T cells in response to all antigens 
tested. IE63 induced the strongest poly-functional CD4+ T cell responses247. 
On a per-cell basis, poly-functional CD4+ T cells expressed markedly higher 
levels of IFN-γ, IL-2, and TNF-α than mono-functional T cells, both before and 
51 
 
after vaccination. Vaccination led to a boost in IFN-γ production by poly-functional 
CD4+ T cells specific to IE63 and ORF-9 but not to other antigens247. Whereas 
CD4+ T cell responses were observed in response to multiple antigens, only ORF-
9 induced significant CD8+ T cell responses. Following vaccination, ORF-9-
specific poly-functional CD8+ T cells produced ~10-fold higher levels of IFN-γ, 
TNF-α and IL-2 compared to mono-functional CD8+ T cells247.  
This study suggests that poly-functional T cell responses contribute an important 
role in the boost in VZV-specific immunity due to Zostavax®. Poly-functional 
CD4+ and CD8+ T cells were predominantly found within the TCM and TEM 
compartments, indicating high proliferative potential. These cells have been 
shown to be important both in the control of infections such as Leishmania 
major249 and HIV250, as well as in vaccine responses to Vaccinia virus251 and 
others.  
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1.8 Aims & Objectives 
The aim of this project was to characterise skin TRM in young and old individuals 
with a view to identifying potential defects in the latter group, and exploring means 
to reverse the age-related impairment in cutaneous antigen-specific immune 
responses. 
The objectives were: 
• Characterise skin TRM in young and old individuals to identify defects in the 
latter group 
• Assess how the shingles vaccine modifies the skin TRM population in the 
old 
• Investigate whether the shingles vaccine boosts the in vivo VZV-specific T 
cell response in old skin, and the underlying mechanisms involved 
• Investigate whether modulating inflammatory pathways in old skin can 
lead to an enhanced VZV-specific cutaneous immune response 
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2 MATERIALS & METHODS 
2.1 Recruitment and ethics 
Healthy young (18−35 years) and old (>65 years) volunteers with a history of 
chickenpox infection were recruited to donate blood and skin biopsy samples. 
Young volunteers, predominantly personal contacts of our lab members, 
university students, and university staff, were recruited via word-of-mouth or via 
recruitment posters displayed around the university. Old volunteers were 
recruited from community organisations for older people, as well as from regularly 
held Divisional Public Engagement Days at the university open to older people 
from the local community.  
My specific roles in the recruitment of volunteers were: 
• Publicising our lab’s research studies among the above groups of people 
• Visiting and giving talks at community organisations for older people 
• Organisation of Public Engagement Days and speaking at these events to 
inform the public of our work 
• Designing recruitment posters 
• Making amendments to the Participant Information Sheet (PIS) 
• Seeking approval from the Research & Development Department at the 
university for amendments to posters and the PIS  
• Being the point of contact for interested volunteers 
• Consenting volunteers to participate in the study 
• Taking blood and skin samples from volunteers 
• Administering the intradermal VZV skin test and interpretation at 72 hours 
• Administering the Zostavax® vaccine and informing the participants’ 
General Practitioners 
• Training the Research Nurse to perform the above tasks independently 
  
54 
 
All volunteers provided written, informed consent, and the study was conducted 
in accordance with the Declaration of Helsinki. Ethical approval for the study was 
granted by the National Research Ethics Service London Queen Square. 
Exclusion criteria for recruitment were:  
• Active inflammatory skin disease 
• Acquired or inherited immunodeficiency 
• Immunosuppressant medication 
• Chronic inflammatory diseases 
• Diabetes mellitus 
• Infection or vaccination within preceding 1 month  
• Pregnancy or breastfeeding 
• Bleeding disorders 
• Cancer within the last 10 years (excluding nonmelanoma skin cancer) 
• History of radiotherapy or chemotherapy 
• History of keloid scarring 
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2.2 Clinical Procedures 
2.2.1 Skin biopsy 
The site used for skin biopsy was standardised as the sun-protected skin on the 
proximal, medial, volar forearm surface. The target site was cleaned with a swab 
impregnated with 70% isopropyl alcohol, and then locally infiltrated with 1% 
lidocaine for anaesthesia. Next the site was washed with Unisept 0.05% 
chlorhexidine gluconate solution (Medlock Medical, Oldham, UK). Once the 
volunteer had lost sensation of the target site, a Stiefel 5mm punch biopsy device 
(Schuco, Watford, UK) was used to produce the skin sample, and the wound was 
sutured. Aseptic technique was maintained throughout to reduce the risk of post-
operative skin infection. The skin biopsy was collected into saline-soaked gauze 
to avoid dehydration of the sample, and visible subcutaneous fat was removed 
with a surgical scalpel before further processing.  
2.2.2 DTH response  
Clinical response to VZV challenge was assessed by intradermal injection into 
the proximal, volar surface of the forearm of 0.02ml VZV skin test antigen. This 
was obtained from The Research Foundation for Microbial Diseases of Osaka 
University (BIKEN), and is composed of VZV viral glycoprotein. Production of 
VZV skin test antigen involves infecting human MRC-5 cells (derived from human 
embryonic lung cells) with VZV, followed by centrifugation of the culture fluid and 
then heat inactivation of the supernatant141,145. The injection site was ringed with 
marker pen, and the clinical response was then assessed after 72 hours.  
The response was graded according to 3 parameters: diameter of skin induration, 
palpability, and erythema. These parameters were assigned individual scores 
(Table 2-1), which were then summed to produce an overall clinical score. This 
method of assessing the clinical response has previously been published by our 
group252. 
The erythema index (EI) was measured using the DermaSpectrometer (Cortex 
Technology, Hadsund, Denmark), a portable narrowband reflectance 
spectrophotometer253. This is placed directly on the skin and generates an EI 
based on the intensity of absorbed and reflected light253. The mean of 3 repeated 
readings taken from the volunteer’s normal, uninjected skin was used to generate 
a background EI. Similarly, the mean of 3 readings taken from the injected site 
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was used to give a test site EI. Finally, the background EI was subtracted from 
the test site EI to produce a final EI result. This method takes into account the 
natural background variation in skin tone that exists between individuals.  
   
Clinical 
score 
0 1 2 3 4 5 Score 
Erythema 
index (EI) 
0 1-5 6-10 11-15 >16   
  
Size of 
induration 
(mm) 
0 1-5 6-10 11-15 16-20 >21 
  
Palpability 
Nil 
Just 
Palpable 
Easily 
Palpable 
Marked 
Very 
marked 
  
  
 TOTAL   
Table 2-1  Table for calculation of clinical score.  
Example: at Day 3 the test site has an erythema index of 4, induration size of 7mm, and is 
easily palpable. This adds up to an overall clinical score of 5. 
 
2.2.3 Shingles vaccination 
The shingles vaccine (trade name Zostavax®) was obtained from Sanofi-Pasteur 
MSD (Maidenhead, UK). This is a live, attenuated vaccine, each dose comprising 
at least 19,400 plaque-forming units of VZV (Oka/Merck strain). After 
reconstitution, the 0.65ml dose was administered subcutaneously into the deltoid 
region.  
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2.3 Sample acquisition and preparation 
2.3.1 Peripheral blood mononuclear cells (PBMCs) isolation 
PBMCs were isolated by density centrifugation. Venous blood was collected in 
Vacuette lithium heparin tubes (Greiner Bio-One, Stonehouse, UK) and diluted 
1:1 with Hanks’ Balanced Salt Solution (HBSS - Sigma-Aldrich, St. Louis, USA). 
15ml of Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) was added per 
50ml conical centrifuge tube, and 25ml of the blood/HBSS mix was layered slowly 
on top using a 25ml serological pipette, so as to produce 2 discrete layers. 
Centrifugation was performed at 800g for 20 minutes with no brake, leading to 
the formation of a thin layer of PBMCs above the layer of Ficoll-Paque Plus and 
below a layer of plasma. The PBMC layer was carefully removed using a Pasteur 
pipette, and transferred to a 50ml conical centrifuge tube. HBSS was added to 
make a total volume of 50ml, and the tube was centrifuged at 700g for 10 minutes. 
The supernatant was discarded, and the cell pellet was resuspended in a further 
50ml of HBSS. Centrifugation was performed at 300g for 10 minutes. The 
supernatant was discarded, and the pellet was re-suspended in complete 
medium – RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 
1% penicillin/streptomycin and 1% L-glutamine (all Sigma-Aldrich) – ready for 
counting and use in experiments.  
2.3.2 Cell counting 
To count cell numbers, 10μl of cell suspension was removed and mixed 
thoroughly with 10μl of trypan blue in a well of a 96-well round bottom plate. 10μl 
of the resulting suspension was transferred to each chamber of an improved 
Neubauer haemocytometer, and cells were then viewed using a microscope. 
Dead cells that stained blue were ignored, and live cells were counted using a 
tally counter. The average count for each of the 2 chambers was used to reduce 
error. The total cell number was calculated using the following formula: 
Total cells = Counted cells × 10000† × 2‡ × Total volume of cell suspension (ml)  
† 10000 is the scaling factor from the haemocytometer chamber volume to 1ml 
‡ 2 is the dilution factor to account for the addition of trypan blue 
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2.3.3 Freezing and thawing PBMCs 
PBMCs that were not required on the day of blood sampling were frozen for future 
use. The cell suspension was centrifuged at 700g for 5 minutes, the supernatant 
discarded, and the pellet resuspended in FBS. 20% dimethyl sulfoxide (DMSO) 
in FBS was added in a 1:1 ratio. The final concentration of cells ranged from 5 to 
10 million per ml, and 1ml of cell suspension was added per Nunc cryogenic vial 
(Thermo Scientific, Waltham, USA). Cryogenic vials were placed into a Nalgene 
Mr Frosty (Thermo Scientific) containing isopropyl alcohol, and then transferred 
to a -80°C freezer for slow freezing.  
When needed, frozen PBMCs were thawed by briefly warming in a 37°C water 
bath, followed by rapid and repeated addition of pre-warmed (37°C) complete 
medium to the cryogenic vial and transfer of all thawed contents to a 15ml conical 
tube. The cell suspension was centrifuged at 700g for 5 minutes and then 
resuspended in fresh complete medium before counting and use in experiments.  
2.3.4 Skin biopsies - frozen sectioning for immunofluorescence  
Excess moisture was removed from the skin biopsy by drying in paper towel. 
Each sample was then placed in a 12x12x20mm Shandon Peel-A-Way 
Disposable Embedding Mold (Thermo Scientific, Runcorn, UK) half-filled with 
Cryo-M-Bed optimal cutting temperature compound (Bright Instruments, 
Huntingdon, UK). The sample was oriented so that the epidermis lay vertical, and 
then immediately snap-frozen in a Dewar flask of liquid nitrogen, followed by 
storage at -80°C.  
Subsequently, frozen tissue blocks were cut into 6μm sections on polylysine-
coated slides, using a microtome-cryostat (Thermo Shandon, Runcorn, UK). 
Sections were left to dry overnight at room temperature. The following day, 
sections were fixed in acetone for 10 minutes, followed by ethanol for 10 minutes, 
and then left to dry for 10 minutes. Slides were wrapped individually in polyvinyl 
chloride cling film and then stored at -80°C.  
2.3.5 Skin biopsies - enzymatic extraction of leukocytes   
2 x 5mm fresh skin biopsies per volunteer were obtained to achieve adequate 
cell numbers for flow cytometry experiments. The samples were washed by 
transferring between 4ml Bijou tubes containing phosphate-buffered saline (PBS) 
and shaking, to reduce blood contamination. The biopsies were then manually 
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dissected into fragments up to 1mm in size (all dimensions), using a surgical 
scalpel on a plastic Petri dish. A small volume of PBS was added during the 
dissection process to prevent dehydration of the sample. Tissue fragments from 
each separate biopsy were added to 1ml of RPMI containing 0.8 mg/ml 
collagenase IV (Life Technologies, Paisley, UK) and 20% FBS in a well of a 24-
well plate, and left overnight in a humidified 5% CO2 incubator at 37°C.  
The following day, 5ml FBS was added to a 50ml conical centrifugation tube. A 
100μm cell strainer (Corning, Corning, USA) was placed onto the tube, and the 
strainer moistened with PBS. The tissue fragments from the well plate were 
transferred with a Pasteur pipette onto the strainer, and a 5ml syringe plunger 
was used to pulverise the tissue. PBS was added regularly to keep the strainer 
moist and wash cells through. This was continued until there only remained a 
small clump of residual, agglutinated tissue on the strainer that could not be 
broken down further. The well plate was washed out with PBS and the contents 
added onto the strainer. Finally, the 50ml tube was centrifuged at 300g for 10 
minutes, and the pellet was resuspended in complete medium, ready for counting 
and use in experiments. The number of skin-derived cells obtained from 2 
biopsies was typically in the range of 1-3 x105.   
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2.4 Shingles vaccine study protocol 
Volunteers participating in the shingles vaccine study were required to be aged 
70 and over, in accordance with the target age range of the national immunisation 
programme for this vaccine. Potential participants who had already received the 
shingles vaccine (at their GP surgery) were excluded. The timeline of the study 
protocol is shown in Figure 2-1. Volunteers donated a 20ml blood sample, 
received the VZV skin test challenge, and had a skin biopsy taken from normal 
skin on the contralateral arm. PBMCs were isolated from the blood sample and 
frozen for further use. The clinical score at 72 hours was recorded, and those with 
a score of 4 or more were excluded from further participation, as they were 
deemed to have robust baseline VZV-specific skin immunity. Skin biopsies of the 
DTH test site were collected from volunteers at 3 days and 7 days after injection; 
each individual was used for only 1 time-point. Samples were frozen for use in 
immunofluorescence experiments.  
After a minimum of 4 weeks, volunteers went on to receive the shingles vaccine. 
Following vaccination, volunteers proceeded to undergo repeat blood sampling, 
normal skin biopsy sampling, VZV skin challenge and clinical scoring, and skin 
biopsy sampling at the DTH test site. The time interval between vaccination and 
repeat VZV challenge ranged from 2 to 8 months.  
 
Figure 2-1 Timeline of shingles study protocol 
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2.5 Losmapimod study protocol 
Additional exclusion criteria for this study were: 
• History of liver disease 
• Elevated alanine transaminase or bilirubin level >1.5 times upper limit of normal 
• Prolonged QTc interval (abnormality on electrocardiogram) 
The timeline for this study protocol is shown in Figure 2-2. Old volunteers 
received the VZV antigen skin test and 48 hours later the clinical score was 
graded, as in Table 2-1. Volunteers with a score of 4 or above were excluded 
from further participation. A 5mm skin biopsy was taken from the site of antigen 
challenge at 7 days after skin test injection, and frozen for subsequent 
immunohistological analysis.  
Approximately 2 to 3 months later, volunteers received 15 mg of losmapimod 
twice daily for 4 days (provided by GlaxoSmithKline under a Medical Research 
Council Industrial Collaboration Agreement). The dose used in this study was 
chosen on the basis of the pharmacokinetic, pharmacodynamic, and safety 
profiles of losmapimod observed in GlaxoSmithKline phase I and II studies143. On 
day 4 of losmapimod treatment, VZV skin testing was repeated and clinical scores 
were recorded 48 hours later, as before. A 5mm skin biopsy at 7 days after 
injection was again taken and frozen for immunohistological analysis.  
Figure 2-2 Timeline of losmapimod study protocol 
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2.6 Experimental Techniques 
2.6.1 Immunofluorescence microscopy 
Indirect immunofluorescence was used to enumerate cells and study their 
phenotypic markers in normal and VZV-injected skin biopsies. A maximum of 4 
markers (including the nuclear stain DAPI) could be included per stain.  
2.6.1.1 Staining protocol 
Slides frozen at -80°C were thawed at room temperature for 5 minutes. The cling 
film was removed, and tissue sections were circled using a hydrophobic Dako 
pen (Dako, Ely, UK). The sections were rehydrated by submerging the slides in 
a PBS bath for 5 minutes. After this time, the slides were removed and excess 
PBS around the tissue sections was absorbed with paper towel. The hydrophobic 
rings were checked to be intact and dry. Incomplete rings were reinforced with 
hydrophobic pen once more. The slides were placed flat in a humid, dark 
chamber, and 2-3 drops of Protein Block, Serum-Free (Dako) were added for 20 
minutes at room temperature. After this time, excess blocking solution was 
removed and the primary antibodies were added (having been diluted in PBS at 
the appropriate concentration - see Table 2-2) at a sufficient volume to ensure 
coverage of the entire section, typically approximately 100µl. This was followed 
by overnight incubation in the staining chamber at 4°C.  
The following day, slides were washed twice in a PBS bath for 10 minutes each. 
Slides were removed individually and excess PBS was removed. Next, secondary 
antibody (diluted in PBS as below) was added at room temperature for 45 
minutes. After this time, excess antibody was removed, and slides were washed 
twice in a PBS bath in the dark for 10 minutes each. Slides were then removed 
individually, excess PBS removed, and a drop of Vectashield Antifade Mounting 
Medium with DAPI (Vector Laboratories, Burlingame, USA) was applied before 
mounting a coverslip, which was secured in place using nail varnish. Slides were 
subsequently stored at -20°C. 
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Primary 
Antibody 
Source Concen
tration 
Secondary Antibody Source Concen
tration 
NORMAL SKIN 
Rat (IgG1) anti-CD4 AbD Serotec 1:100 Goat anti-rat IgG AF488 Life 1:250 
Mouse (IgG1) anti-
CD4 
Santa Cruz 1:50 Goat anti-mouse IgG1 
AF488 
Life  1:400 
Rabbit (IgG) anti-
CD4 
Abcam 1:200 Goat anti-rabbit IgG 
AF488  
Invitrogen 1:800 
Rat (IgG2b) anti-
CD8 
AbD Serotec 1:100 Goat anti-rat IgG AF488 Life 1:250 
Mouse (IgG1) anti-
CD69 
BioLegend 1:50 
Goat anti-mouse IgG1 
AF568 
Life 1:250 
Goat anti-mouse IgG1 
AF647  
Life 1:400 
Mouse (IgG2a) anti-
CD103 
Thermo 
Fisher 
1:400 Goat anti-mouse IgG2a 
AF647 
Life 1:400 
Rat (IgG2a) anti-
Foxp3 biotin 
Ebioscience  1:100 Streptavidin Cy3 Invitrogen 1:400 
Mouse (IgG1) anti-
PD1 
Abcam 1:400 Goat anti-mouse IgG1 
AF568 
Life 1:400 
VZV-INJECTED SKIN 
Mouse (IgG1) anti-
CD4 biotin 
Immunotech 1:50 Streptavidin Cy3 Invitrogen 1:400 
Mouse (IgG1) anti-
CD8 biotin  
BD 1:50 Streptavidin Cy3 Invitrogen 1:400 
 
Mouse (IgG1) anti-
Ki67 FITC 
BD 1:50 No secondary   
Mouse (IgG1) anti-
CD4 
Santa Cruz  1:200 Goat anti-mouse IgG1 
AF488  
Life 1:200 
Rat (IgG2a) anti- 
Foxp3 biotin 
Ebioscience 1:100 Streptavidin Cy3  Invitrogen 1:400 
Table 2-2  Antibodies used for immunofluorescence microscopy 
AbD Serotec (Kidlington, UK) 
Life Technologies (Paisley, UK) 
Santa Cruz Biotechnology (Dallas, USA) 
Biolegend (San Diego, USA) 
Ebioscience (Hatfield, UK) 
Invitrogen (Paisley, UK) 
BD (San Jose, USA) 
Immunotech (Marseille, France)  
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2.6.1.2 Antibody titration 
Primary antibodies were titrated before use, using frozen sections of redundant 
skin from plastic surgery procedures. The initial concentrations used for titration 
were 1:50, 1:100 and 1:200, depending on the manufacturer’s recommendations. 
A control, using PBS instead of the primary antibody, was included. Slides were 
viewed using an Axioskop 2 Plus microscope (Carl Zeiss Ltd.).  
2.6.1.3 Image acquisition & analysis 
Normal skin 
Sections were marked and slides were loaded into a Zeiss Axio Scan.Z1 slide 
scanner (Carl Zeiss Ltd., Cambridge, UK). Settings were checked and adjusted 
for focusing and exposure times for each fluorescent channel, and then the entire 
stained sections were scanned at x200 magnification. Slide scans were analysed 
using Zen lite software (Carl Zeiss Ltd.).  
The cells of interest in this study were the T cells in the upper and mid-dermis, as 
described in previous publications by this group. T cells were identified using 
surface stains for CD4 or CD8, in combination with the nuclear stain DAPI. 
Counting of cells was performed manually using the marker function within Zen 
lite; a T cell was only counted if an immunofluorescent ring (representing the cell 
surface) was seen to envelop a DAPI-stained central nucleus. Once the total 
number of CD4 or CD8 cells was counted per section, additional fluorescent 
stains (for example for the surface marker CD69) were visualised on Zen lite; the 
number of previously counted T cells expressing this additional marker was then 
counted. This enabled a percentage of T cells expressing a certain marker to be 
calculated. Two sections per slide were analysed, and the average was taken to 
generate a data value.  
VZV-injected skin 
Slides were imaged using an Axioskop 2 Plus microscope (Carl Zeiss Ltd.). To 
assess the degree of cellular infiltration, the 5 largest perivascular infiltrates in the 
upper dermis were visually selected. These were photographed at x40 
magnification using Axiovision software (Carl Zeiss Ltd.). Images were viewed in 
ImageJ (National Institute of Health, Bethesda, USA), and the total number of T 
cells (either CD4 or CD8) was counted per perivascular infiltrate (for method of 
identifying T cells, see above). T cells staining positive for a particular marker (eg. 
Foxp3 or Ki67) were then counted, to generate a percentage of total T cells 
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expressing this marker. The mean value for the 5 perivascular infiltrates was then 
generated. Two sections per slide were analysed, and the average was taken to 
generate a data value. This method of cell counting for antigen-challenged skin 
has previously been published by our group149.  
2.6.1.4 Autofluorescence  
Immunofluorescence microscopy of skin sections was complicated by the fact 
that in many of the skin samples, the dermal fibres (collagen and elastin) 
fluoresced bright green254. This was particularly noticeable in the old compared 
to the young, presumably due to the alteration/degradation in the properties of 
skin collagen/elastin during the ageing process. Fibre fluorescence was much 
brighter in the fully stained sections compared to the controls, suggesting that the 
fibres were taking up primary antibody in a non-specific manner. 
Autofluorescence was also visible in the blood vessels of the skin, perhaps due 
to their collagen/elastin content. To negate autofluorescence, concentrations of 
secondary antibodies were kept as low as possible, and two washing steps of 10 
minutes each (after secondary antibody staining) were used as part of the 
staining protocol.     
2.6.2 In vitro functional assays 
PBMCs or skin-derived cells were suspended in 1ml complete medium, and 
placed in 5ml polypropylene round-bottom sterile culture tubes (Greiner Bio-
One). 106 PBMCs were used per sample; skin cell numbers ranged from 105 – 
106. Cells were incubated at 37°C with humidified 5% CO2. At the end of the 
incubation period, sample tubes were centrifuged at 700g for 5 minutes, 
supernatant tipped off, and tube tops were blotted on paper towel. The cell pellets 
were vortexed, prior to commencing antibody staining. 
2.6.2.1 PMA/ionomycin stimulation 
Cells were stimulated with 25ng/ml PMA and 500ng/ml ionomycin for 1 hour, 
followed by addition of 5 μg/ml brefeldin A (Sigma-Aldrich) and incubation for a 
further 5 hours. Unstimulated cells were used as the negative control. This was 
followed by intracellular cytokine staining for IL-2, IFN-γ, TNF-α and IL-22.  
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2.6.2.2 VZV stimulation  
Cells were stimulated with 40 μl/ml VZV lysate (Virusys, Taneytown, USA) for 2 
hours before addition of 5 μg/ml brefeldin A (Sigma-Aldrich). Unstimulated cells 
were used as the negative control, and cells stimulated with 1μl/ml staphylococcal 
enterotoxin B (SEB) were used as the positive control. Ventilation caps were left 
loose, and samples were incubated for 15 hours, before intracellular cytokine 
staining for IL-2, IFN-γ and TNF-α.  
2.6.3 Flow cytometry 
Multicolour flow cytometry was used for the investigation of single cells for 
multiple surface phenotypic markers and intracellular cytokines.  
2.6.3.1 Cell surface & intracellular staining 
Staining was performed in 100µl volume. A master mix of surface antibodies was 
made up (see Table 2-3), including 1μl Live/Dead UV stain (Invitrogen) per 
sample. The appropriate antibody mix volume was added to each sample tube, 
before vortexing and incubation in the dark for 30 minutes on ice. 
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Surface 
Antibody 
Fluorochrome Source Volume (μl) 
CD3 PE-CF594 BD 0.3 
CD4 A700 BD 2 
CD8 PerCP BD 15 
CD27 APC-H7 BD 5 
CD45RA BV605 BioLegend 2 
CLA FITC BD 10 
Table 2-3  Surface antibodies for flow cytometry 
Following the surface staining stage, 100μl Fix and Perm Cell Permeabilization 
Medium A (Invitrogen) was added for 15 minutes at room temperature. 
Approximately 1ml PBSA (PBS with 0.2% BSA and 0.1% azide) was added to 
each tube before centrifuging at 700g for 5 minutes. The supernatant was tipped 
off and tube tops were dried by briefly placing on paper towel. 100 μl Fix and 
Perm Cell Permeabilization Medium B (Invitrogen) was next added to each tube 
along with the intracellular antibodies from a master mix (Table 2-4). Samples 
were vortexed and incubated for 30 minutes at room temperature.  
Intracellular Antibody Fluorochrome Source Volume (μl) 
IFN-γ V450 BD 0.8 
TNF-α APC BD 5 
IL-2 (VZV stim experiment) PE BD 10 
IL-2 (PMA experiment) FITC BD 10 
IL-22 PE Biolegend 5 
Table 2-4  Intracellular antibodies for flow cytometry 
After the staining stages, PBSA was added to each tube before centrifuging at 
700g for 5 minutes, tipping off the supernatant, and adding 100μl 2% 
paraformaldehyde to fix the cells. PBMC samples were transferred to standard 
flow cytometry tubes; skin cell samples were transferred to Falcon flow cytometry 
tubes with a 35µm cell strainer cap (BD) to filter out debris.   
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Single colour compensation controls were prepared using CompBeads Set (BD). 
The following were added sequentially to a flow cytometry tube: 1µl of antibody; 
20µl of anti-mouse Ig, κ particles; 20µl negative control particles; 300µl 2% 
paraformaldehyde. This protocol was suitable for all antibodies used except CLA 
FITC, as this is a rat antibody. Therefore, a BD CD4 FITC antibody was 
substituted for the FITC compensation control.  
An unstained control comprising 106 fixed PBMCs was included. A live-dead 
control was prepared by heating 2.5 x 105 PBMCs in 50µl medium on a hot plate 
at 70°C for 4 minutes, allowing to cool, and adding to 2.5 x 105 live PBMCs in 
50µl medium. This control was stained with 1μl Live/Dead UV stain for 30 minutes 
and then fixed. Fluorescence minus one (FMO) controls, containing every 
fluorochrome in the panel except for the one being controlled for, were prepared 
and acquired.   
2.6.3.2 Flow cytometers 
An LSR II flow cytometer (BD, San Jose, USA), equipped with blue (488nm), red 
(640nm), yellow/green (561nm), violet (405nm) and ultraviolet (355nm) lasers, 
was used for flow cytometry experiments. Compensation control tubes were 
acquired and the flow cytometer used an automated compensation process to 
account for spectral overlap between fluorochromes. Next, the sample tubes 
were acquired, with up to 10 fluorochromes detected simultaneously. Data was 
processed by FACSDiva software (BD).  
2.6.3.3 Flow cytometry data analysis 
Data files were analysed using FlowJo version 10 software (FlowJo LLC, 
Ashland, USA). Initial gating strategy selected lymphocytes (based on forward 
and side scatter properties), live cells (that were negative for the live/dead UV 
stain), and singlet cells (based on side scatter pulse height and width). FMO 
controls were used to assist with gating strategy. 
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2.7 Statistical analysis 
Graphpad Prism version 5 (Graphpad Software, Inc., La Jolla, USA) was used 
for statistical analysis. Tests were deemed to be statistically significant where the 
p value was less than 0.05. The Shapiro-Wilk test was applied to data sets to test 
whether these were normally distributed. Where data was non-parametric, the 
Mann-Whitney U test was used to compare whether the medians of 2 populations 
(i.e. young and old) were statistically different. The non-parametric Wilcoxon 
signed-rank test was used to test whether paired samples were different. 
Parametric data were compared with the unpaired t test for unpaired groups, or 
paired t test for paired groups. Linear regression was used to assess whether 2 
variables were correlated.   
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3 AGE-RELATED CHANGES IN T CELLS WITHIN THE 
SKIN 
3.1 Chapter Introduction 
Antigen-specific immunity declines with age, and a key contributing factor is the 
constellation of age-related changes occurring within the circulating memory T 
cell compartment41. Skin immunity also declines with ageing, and the reasons for 
this have not yet been determined. TRM are recognised to play a key role in the 
immune protection of the skin against pathogens255, but to date they have not 
been characterised in the context of ageing; it is unclear whether skin TRM in old 
individuals are susceptible to changes associated with immunosenescence. 
Here, CD4+ and CD8+ skin TRM were identified and characterised in young and 
old individuals, with regards to numbers, phenotype, state of differentiation, and 
effector function. As clinical VZV reactivation is more frequent in the old191, and 
this is associated with impaired DTH responses to VZV skin test antigen143, it was 
also of interest to investigate VZV-specific T cells in the skin for potential age-
related impairments.  
3.2 Aims & Objectives 
The aim of this chapter was to characterise skin resident memory T cells in young 
and old individuals, and to identify potential defects in the latter age group. 
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3.3 Results 
3.3.1 Skin TRM numbers 
3.3.1.1 The number of skin CD4+ TRM is equivalent between young and old 
Frozen sections of normal skin from young and old individuals were stained with 
anti-CD4 antibody and analysed by immunofluorescence microscopy. Cells in the 
upper dermis were counted, where the majority of skin TRM are located. The 
epidermis and the lower dermis were not incorporated into cell counts as a result 
of intense background staining and adnexal structure staining in these areas 
respectively; in any case, very few T cells were observed in these areas. 
A representative immunofluorescence micrograph of a skin section stained for 
CD4 is shown in Figure 3-1A, with a close-up of a perivascular cluster of CD4+ T 
cells in the upper dermis in Figure 3-1B. The majority of CD4+ T cells were 
observed to be in perivascular clusters, with additional occasional single cells 
also present in the dermis, consistent with previous findings256. The median CD4+ 
T cell number per section was 65 for young and 67 for old (range 16-128; Figure 
3-1C), with no significant difference between the age groups.  
To establish the proportion of CD4+ T cells that were resident memory cells (TRM), 
as opposed to recirculating, skin sections were co-stained for the tissue residency 
marker CD69 (Figure 3-1A&B). The majority of CD4+ T cells in the dermis were 
found to be CD69+ (median 77.5% for young and 78.9% for old; Figure 3-1D) and 
there was no significant difference between age groups. Together, these data 
indicate that the numbers of skin resident CD4+ T cells remain stable from early 
adulthood into old age.  
As CD69 is not solely a T cell tissue residency marker but also a T cell activation 
marker, the intensity and pattern of CD69 expression following T cell activation 
was examined by staining skin sections that had been obtained by biopsy at 7 
days after cutaneous antigen challenge (Figure 3-1E). CD69 expression was 
seen to be intensely expressed in large numbers of perivascular T cells infiltrating 
into the skin. These observations highlight the usefulness of CD69 as a residency 
marker in unchallenged skin, and as an activation marker in challenged skin.   
CD103 is a tissue residency marker, predominantly of CD8+ T cells, whose 
expression varies depending on the tissue site, with highest expression seen in 
the gut257. Expression of CD103 in mouse skin is significantly higher than in 
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human skin79,87. CD103+ TRM were shown to have more potent effector abilities 
than CD103- TRM 87, and it was of interest to determine whether the proportion of 
human skin TRM expressing this marker changes with age.  
Anti-CD103 co-staining was performed and the majority of CD4+CD69+ TRM were 
observed to be CD103- (Figure 3-1A, B, F). The median proportion of CD4+CD69+ 
TRM expressing CD103 was 22.2% in the young and 25.7% in the old, with no 
significant difference between the 2 age groups. 
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Figure 3-1 Effect of age on CD4+ TRM numbers 
A:  Immunofluorescence micrograph (x200 original magnification) of a skin section stained for 
DAPI (blue), CD4 (green), CD69 (red), CD103 (white). 
B:  Close up of a perivascular cluster of CD4+ T cells in the upper dermis, the majority of which 
are CD69+. In the merged image, CD4+CD69+ TRM are seen as orange/yellow. Few of these cells 
are CD103+. 
C:  Graph showing the number of dermal CD4+ T cells per section in young (n=13) and old 
individuals (n=16).  
D:  Graph showing the percentage of CD4+ T cells in the dermis expressing CD69 (n=13 young, 
16 old).  
E:  Top – immunofluorescence micrograph (x200 original magnification) of a section of antigen-
challenged skin stained for CD4 (green) and CD69 (red), with large numbers of activated 
perivascular T cells visible. Bottom – close-up view (x400 original magnification) of a perivascular 
cellular infiltrate, with activated CD4+CD69+ T cells seen as orange.    
F:  Graph showing the percentage of CD4+CD69+ T cells in the dermis expressing CD103 (n=10 
young, 10 old).  
Medians and interquartile ranges are displayed, and populations were compared using the Mann-
Whitney test.  
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3.3.1.2 The number of skin CD8+ TRM is equivalent between young and old 
Frozen skin sections were stained with anti-CD8 antibody and analysed by 
immunofluorescence microscopy. CD8+ T cells in the upper dermis were counted 
as described in Section 3.3.1.1 for CD4+ T cells. A representative image of a skin 
section stained for CD8 is shown in Figure 3-2A, with a close-up of CD8+ T cells 
within a perivascular cell cluster in the upper dermis in Figure 3-2B. In general, 
CD8+ T cells were observed as a minority component of perivascular clusters or 
as isolated cells in the upper dermis. 
CD8+ T cells in the skin were observed to be more sparsely distributed throughout 
the skin than CD4+ T cells. The median number of CD8+ T cells per section was 
26 for both young and old (Figure 3-2C), with no significant difference between 
the groups.  
The median percentage of CD8+ T cells in the dermis expressing CD69 was 
83.6% in the young and 85.1% in the old, with no significant difference between 
the groups (Figure 3-2D). Together, these data indicate that the numbers of skin 
CD8+ TRM remain stable and unaltered by the ageing process.  
Co-staining with CD103 demonstrated the median percentage of CD8+CD69+ TRM 
expressing this marker was 23.3% in the young and 12.1% in the old (Figure 
3-2E). There was a trend to a difference (p=0.21) between the two age groups.  
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Figure 3-2 Effect of age on CD8+ TRM numbers 
A:  Representative immunofluorescence micrograph (x200 original magnification) of a skin 
section stained for DAPI (blue), CD8 (green), CD69 (red) and CD103 (white). 
B:  Close-up of a perivascular cluster of CD8+ T cells in the upper dermis, the majority of which 
are positive for CD69 (red) and a minority of which are positive for CD103. 
C:  Graph showing the number of dermal CD8+ T cells per section in young (n=14) and old (n=21) 
individuals.  
D:  Graph showing the percentage of dermal CD8+ T cells expressing CD69 in young (n=14) and 
old (n=21) individuals.  
E:  Graph showing the percentage of CD8+CD69+ T cells in the dermis expressing CD103 (n=10 
young, 12 old).  
Medians and interquartile ranges are displayed, and the groups were compared using the Mann-
Whitney test. 
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3.3.1.3 Old skin has a higher proportion of Tregs compared to young 
A previous study by our group showed an increased percentage of Tregs in old 
skin compared to young135. To confirm and extend these findings, frozen skin 
sections were stained for CD4 and Foxp3 and analysed by immunofluorescence 
microscopy. The number of CD4+ Foxp3+ T cells in the dermis was expressed as 
a percentage of the total number of CD4+ T cells.   
A representative image of a skin section stained for CD4 and Foxp3 is shown in 
Figure 3-3A, with a close-up image of a perivascular cell cluster containing a 
number of CD4+Foxp3+ T cells shown in Figure 3-3B. The median proportion of 
Tregs was significantly higher in the old (9.0%) than the young (3.3%), shown in 
Figure 3-3C (p=0.001).  
The proportion of Tregs that are resident in the skin is unknown, and this was 
investigated by co-staining with CD69. Figure 3-3D shows the median percentage 
of Tregs expressing CD69 in the young was 74.0%, significantly higher than the 
50.0% observed in the old (p=0.029). Interestingly, in the old the percentage of 
Tregs expressing CD69 was lower than the percentage of total CD4+ and CD8+ 
T cells expressing CD69, regardless of age (see Sections 3.3.1.1 and 3.3.1.2). 
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Figure 3-3 Effect of age on Tregs in the skin 
A:  Representative immunofluorescence micrograph (x200 original magnification) of a skin 
section stained for DAPI (blue), CD4 (green) and Foxp3 (red).  
B:  Close-up view of a perivascular cluster of CD4+ Foxp3- T cells and CD4+ Foxp3+ Tregs (green 
surface with red nuclear stain) in the dermis. 
C:  Graph showing the percentage of CD4+ T cells in the dermis expressing Foxp3, in young (n=9) 
and old (n=8) individuals.  
D:  Graph showing the percentage of Tregs in the dermis expressing CD69 in young (n=8) and 
old (n=5) individuals.  
Medians and interquartile ranges are displayed. Both groups were compared using the Mann-
Whitney test and the significance level is displayed.  
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3.3.2 T cell differentiation profiles 
3.3.2.1 There is no increase in the proportion of terminally differentiated 
CD27-CD45RA+ CD4+ T cells in old skin 
The differentiation state, defined by the surface expression of CD27 and 
CD45RA, of CD4+ T cells isolated from collagenase-digested skin was 
investigated in young and old using flow cytometry. CD4+ T cells from peripheral 
blood were also analysed for comparison. A representative flow cytometry gating 
strategy is shown in Figure 3-4A. Representative CD27/CD45RA plots for CD4+ 
T cells derived from young and old skin and blood are shown in Figure 3-4B.  
Cumulative data for blood (Figure 3-4C, left graph) showed that the majority of 
CD4+ T cells in blood in both young and old were of the naïve (CD27+ CD45RA+) 
and central memory (CD27+ CD45RA-) subsets, as previously described258. 
There were significant differences in the proportion of CD4+ T cells represented 
by each of the 4 differentiation subsets between young and old, with old 
individuals having a smaller proportion of naïve CD4+ T cells (p<0.0001) and 
greater proportions in the central memory (p=0.0007), effector memory 
(p=0.0006) and TEMRA subsets (p=0.0063), consistent with published 
studies258,259.  
Cumulative equivalent data for skin (Figure 3-4C, right graph) demonstrated that 
the vast majority of CD4+ T cells were CD45RA-, corresponding to the central and 
effector memory subsets according to the standard classification used for T cells 
in circulation. Old individuals had a significantly smaller proportion of CD4+ T cells 
in the CD27+CD45RA- central memory subset (p=0.0067) and a significantly 
larger proportion in the CD27-CD45RA- effector memory subset (p=0.0143) 
compared to the young. Importantly, there was no significant difference in 
proportions in the terminally differentiated CD27-CD45RA+ TEMRA subset between 
young (median 1.7%) and old (median 1.4%).  
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Figure 3-4 Effect of age on the differentiation status of CD4+ T cells in the skin 
A:  Representative flow cytometry dot plots of PBMCs showing the sequential gating strategy to 
identify CD4+ T cells, and division into the 4 differentiation subsets defined by CD27 and CD45RA 
expression. 
B:  Representative dot plots of the CD27/CD45RA expression profile of blood- and skin-derived 
CD4+ T cells from a young and old donor. 
C:  Bar graphs showing cumulative data for the proportion of CD4+ T cells represented by each 
of the 4 subsets defined by CD27 and CD45RA expression, in young and old individuals (n=23 
each). Blood data is shown in the left graph and skin data in the right. Medians and interquartile 
ranges are shown. Subsets were compared using the Mann-Whitney test and significance levels 
are displayed. 
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3.3.2.2 There is no increase in the proportion of terminally differentiated 
CD27-CD45RA+ CD8+ T cells in old skin 
The differentiation state of CD8+ T cells from collagenase-digested skin and blood 
samples was assessed by flow cytometry. Representative CD27/CD45RA plots 
for CD8+ T cells derived from young and old blood and skin are shown in Figure 
3-5A. 
Cumulative data for blood (Figure 3-5B, left graph) showed that in young 
individuals, the vast majority of CD8+ T cells were naïve CD27+ CD45RA+ cells, 
whereas in the old there was a more even distribution between the 4 subsets 
defined by CD27/CD45RA expression. There was a significant loss of naïve CD8+ 
T cells in the old compared to the young (p<0.0001) and a gain in the effector 
memory (p=0.0009) and TEMRA subsets (p<0.0001), consistent with published 
studies258.  
Cumulative data for skin (Figure 3-5B, right graph) demonstrated that the majority 
of CD8+ T cells were CD45RA-. Old individuals had a significantly smaller 
proportion of CD8+ T cells in the CD27+ CD45RA+ naïve subset (p=0.0002) and a 
significantly larger proportion in the CD27-CD45RA- effector memory subset 
(p=0.0003) compared to the young. Importantly, there was no significant 
difference in proportion in the terminally differentiated TEMRA subset between 
young (median 7.7%) and old (median 4.5%).  
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Figure 3-5 Effect of age on the differentiation status of CD8+ T cells in the skin 
A:  Representative dot plots of the CD27/CD45RA expression profile of blood- and skin-derived 
CD8+ T cells from a young and old donor. 
B:  Bar graphs showing cumulative data for the proportion of CD8+ T cells represented by each 
of the 4 subsets defined by CD27 and CD45RA expression, in young (n=16) and old (n=10) 
individuals. Blood data is shown in the left graph and skin data in the right. Medians and 
interquartile ranges are shown. Subsets were compared using the Mann-Whitney test and 
significance levels are displayed. 
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3.3.3 Programmed cell death 1 (PD-1) 
3.3.3.1 PD-1 expression on CD4+ T cells in the skin increases with age 
Frozen skin sections from healthy young and old donors were co-stained for CD4 
and PD-1 and analysed by immunofluorescence microscopy. A representative 
immunofluorescence micrograph of a skin section stained for CD4 and PD-1 is 
shown in Figure 3-6A, with a close-up image of a cluster of dermal CD4+ T cells 
in Figure 3-6B. The median percentage of CD4+ T cells expressing PD-1 was 
significantly higher in the old (57.1%) than the young (27.2%), as shown in Figure 
3-6C (p=0.03).  
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Figure 3-6 The effect of age on PD-1 expression in skin CD4+ T cells 
A:  Representative immunofluorescence micrograph (x200 original magnification) of a skin 
section stained for DAPI (blue), CD4 (green) and PD-1 (red). 
B:  Close-up image of a perivascular cluster of T cells; CD4+ PD-1+ T cells are seen as 
orange/yellow in the merged image.  
C:  Graph showing the percentage of dermal CD4+ T cells expressing PD-1 in young (n=9) and 
old (n=9). Medians and interquartile ranges are shown. Young and old were compared using the 
Mann-Whitney test, and the significance level is shown.  
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3.3.3.2 PD-1 expression on CD8+ T cells in the skin increases with age 
Frozen skin sections from healthy young and old donors were co-stained for CD8 
and PD-1 and analysed by immunofluorescence microscopy. A representative 
immunofluorescence micrograph of a skin section stained for CD8 and PD-1 is 
shown in Figure 3-7A, with a close-up image of a cluster of dermal CD8+ T cells 
expressing PD-1 in Figure 3-7B. The median percentage of CD8+ T cells 
expressing PD-1 was significantly higher in the old (70.7%) compared to the 
young (23.6%) as shown in Figure 3-7C (p=0.001).  
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Figure 3-7 The effect of age on PD-1 expression in skin CD8+ T cells 
A:  Representative immunofluorescence micrograph (x200 magnification) of a skin section 
stained for CD8 (green) and PD-1 (red).  
B:  Close-up image of dermal T cells, with CD8+ PD-1+ T cells seen as orange/yellow in the 
merged image.  
C:  Graph showing the percentage of dermal CD8+ T cells expressing PD-1 in young (n=8) and 
old (n=7). Medians and interquartile ranges are shown. Young and old were compared using the 
Mann-Whitney test, and the significance level is shown.  
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3.3.4 T cell effector function 
3.3.4.1 Skin-derived CD4+ T cells from old individuals are functionally 
competent in vitro 
To assess whether CD4+ T cells isolated from old skin were functionally 
competent in vitro, leukocytes derived from collagenase-digested skin were 
stimulated with PMA/ionomycin for 6 hours, and intracellular cytokine production 
by these cells was measured by flow cytometry, specifically IFN-γ, TNF-α, IL-2 
and IL-22. Unstimulated cells were used as negative controls. 
Representative dot plots showing the proportion of skin-derived CD4+ T cells 
producing IFN-γ and TNF-α in a young and an old individual are shown in Figure 
3-8A. Cumulative data are shown in Figure 3-8B. Although there was no 
significant difference in the percentage of cytokine-producing CD4+ T cells 
between young and old for any of the 4 cytokines measured, there was a trend 
towards an increase for IFN-γ, TNF-α and IL-2 in the old. IL-22 production was 
minimal.  
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Figure 3-8 Effect of age on cytokine production by skin CD4+ T cells 
A:  Representative dot plots showing the proportion of PMA/ionomycin-stimulated and 
unstimulated skin-derived CD4+ T cells producing IFN-γ and TNF-α in a young and old donor.  
B:  Graph showing cumulative data for the percentages of CD4+ T cells producing cytokines in 
the skin of young (n=8) and old (n=5) individuals after stimulation. Medians and interquartile 
ranges are shown. Young and old were compared using the Mann-Whitney test; significance 
levels are shown. 
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3.3.4.2 Skin-derived CD8+ T cells from old individuals are functionally 
competent in vitro 
Activated CD8+ T cells produce a variety of effector molecules in response to 
recognised pathogens, including the pro-inflammatory cytokines IFN-γ and TNF-
α 260. To investigate whether there was any age-related loss of cytokine-
producing ability by skin CD8+ T cells, skin-derived leukocytes from young and 
old were stimulated with PMA/ionomycin for 6 hours, and intracellular cytokine 
production (IFN-γ, TNF-α, IL-2 and IL-22) by CD8+ T cells was measured. 
Unstimulated cells were used as negative controls.  
Representative dot plots showing the proportion of stimulated skin-derived CD8+ 
T cells producing IFN-γ and TNF-α in young and old individuals are shown in 
Figure 3-9A. Cumulative data (Figure 3-9B) showed a significant increase in the 
proportion of IL-2-producing CD8+ T cells in the old compared to the young 
(p=0.045). There was no significant difference in the proportion of CD8+ T cells 
producing IFN-γ, TNF-α or IL-22 between young and old, although there was a 
trend to an increase in the old for each of these 3 cytokines. As with skin-derived 
CD4+ T cells, only a minority of CD8+ T cells produced IL-22.  
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Figure 3-9 Effect of age on cytokine production by skin CD8+ T cells 
A:  Representative dot plots showing the proportion of PMA/ionomycin-stimulated and 
unstimulated skin CD8+ T cells producing TNF-α and IFN-γ in a young and an old individual.  
B:  Graph showing cumulative data for the percentages of CD8+ T cells producing cytokines in 
the skin of young (n=8) and old (n=5) individuals after stimulation. Medians and interquartile 
ranges are shown. Young and old were compared using the Mann-Whitney test; significance 
levels are shown. 
 
  
A 
B 
TNF-α 
IF
N
-γ
 
Unstimulated PMA/ionomycin 
Young 
Old 
0
20
40
60
%
 C
y
to
k
in
e
-p
ro
d
u
c
in
g
 C
D
8
+
 T
 c
e
ll
s
Young
IFN- TNF-IL-2 IL-22
Old
p=0.28 p=0.045 p=0.15
p=0.18
96 
 
3.3.5 VZV-specific CD4+ T cells  
3.3.5.1 Skin-derived VZV-specific CD4+ T cells do not decline with 
increased age 
To identify VZV-specific CD4+ T cells, leukocytes from blood and skin biopsies 
from young and old individuals were stimulated overnight with VZV lysate, in the 
presence of brefeldin A. The following day, intracellular cytokine production (IFN-
γ, TNF-α, IL-2) was measured by flow cytometry.  
Representative dot plots of the percentage of IFN-γ-producing (i.e. VZV-specific) 
CD4+ T cells present in the blood and skin are shown in Figure 3-10A. Cumulative 
data demonstrated no significant difference in the percentage of cytokine-
producing CD4+ T cells between young and old, whether for IFN-γ, IL-2 or TNF-
α (Figure 3-10B). Individuals in whom IFN-γ- or TNF-α-producing CD4+ T cells 
could be detected in the skin were pooled together (young and old) for an analysis 
of paired blood and skin samples (Figure 3-10C). This revealed that as a group, 
the proportion of VZV-specific CD4+ T cells was significantly greater in the skin 
than the blood (p<0.0001).  
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Figure 3-10 Effect of age on the frequency of VZV-specific CD4+ T cells in the skin 
A:  Representative dot plots showing the percentage of IFN-γ-producing CD4+ T cells in the blood 
and skin in a young and old donor. SEB-stimulated PBMC control is shown on the right. 
B:  Graph showing cumulative data for the percentages of cytokine-producing CD4+ T cells in the 
skin of young and old individuals (n=11 young, 10 old). Medians and interquartile ranges are 
shown. Young and old were compared using the Mann-Whitney test.  
C:  Graph showing the percentage of cytokine-producing CD4+ T cells in blood and skin samples 
for pooled young and old individuals (n=21). The difference between blood and skin percentages 
was analysed by the Wilcoxon matched-pairs signed rank test and the significance level is shown.  
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3.3.5.2 There is an increase in the proportion of terminally differentiated 
CD27-CD45RA+ VZV-specific CD4+ T cells in old skin  
The differentiation state of VZV-specific CD4+ T cells in the skin was investigated 
by performing CD27 and CD45RA surface staining, in conjunction with VZV-
specific CD4+ T cell detection as described in 3.3.5.1. Cumulative data of the 
percentages of circulating and skin-derived VZV-specific CD4+ T cells within each 
of the four CD27/CD45RA differentiation subsets are shown (Figure 3-11). The 
majority of circulating and skin-derived VZV-specific CD4+ T cells were CD45RA 
negative, consistent with a memory phenotype.  
In the circulating compartment, there were no differences between young and old 
in the proportions of VZV-specific CD4+ T cells within each subset of 
differentiation (Figure 3-11, left graph). In the skin compartment, the percentage 
of VZV-specific CD4+ TEMRA cells was greater in the old compared to the young 
(p=0.029), while there were no differences within the other subsets (Figure 3-11, 
right graph). 
 
 
 
 
 
 
Figure 3-11 Effect of age on the differentiation state of VZV-specific CD4+ T cells in the 
skin and blood 
Bar graphs showing the percentage of VZV-specific CD4+ T cells within each subset of 
differentiation, defined by CD27/CD45RA expression. Cumulative data is shown for blood (left) 
and skin (right). Medians and interquartile ranges are shown. Young and old were compared by 
Mann-Whitney test (n=15 young, 9 old) and significance levels are shown. 
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3.4 Discussion 
The results showed that the total numbers of CD4+ and CD8+ T cells in the dermis 
(including both resident and recirculating T cells) were maintained in the older 
age group. Thus, impaired cutaneous immune responses in the old cannot be 
explained by a fall in the absolute CD4+ and CD8+ T cell numbers in the skin. In 
comparison, Martinet et al found that in ageing mice, there was no change in 
CD4+ T cell numbers in lung or liver, and there was an increase in these cells in 
gut mucosa-associated lymphoid tissue (GALT), accompanied by a decrease in 
SLOs, compared to young mice261. These age-related changes were speculated 
to be due to redistribution of CD4+ T cells from the SLOs to the periphery as there 
was no increased proliferation seen in the GALT-based CD4+ T cell population261. 
In the same study, analysis of ageing mice showed that numbers of CD8+ T cells 
were maintained in the liver, SLOs and Peyer’s patches, and increased in the 
lungs as well as small and large bowel lamina propria261. T cells in the skin were 
not considered, but the study demonstrated that other peripheral tissues (albeit 
in mice) also preserve their numbers of CD4+ and CD8+ T cells during the ageing 
process.  
Various studies have shown that in the circulation, total T cells, total CD4+ T cells 
and total CD8+ T cells all decline with increasing age258,262,263. This decline is 
primarily due to a fall in the number of naïve T cells in circulation258,263 as a 
consequence of thymic involution. The decline in naïve T cell numbers is only 
partially offset by an increase in numbers of circulating memory CD4+ T cells263 
and memory CD8+ T cells258. Skin TRM numbers are negligible at birth87 and 
accumulate during life after every cutaneous pathogen exposure98,105. The age-
related decline in circulating naïve T cell numbers might have meant that old 
individuals were less able to generate adequate numbers of skin-homing memory 
T cells following primary immune responses to newly encountered pathogens in 
the skin. However, by the age of 65, it is expected that most commonly occurring 
skin pathogens would have already been encountered earlier in life, such that a 
plateau in numbers of memory T cells found in the skin may be reached earlier 
on in adulthood. Therefore, the age-related decline in circulating naïve T cells 
does not appear to have an impact on the total numbers of T cells in the skin. 
The majority of T cells found in the skin are permanently resident (CD69+ TRM) 
and a minority are recirculating (CD69- TCM and TMM)87. The results in this work 
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demonstrated that there was no difference in the proportion of CD4+ T cells in the 
dermis expressing CD69 between young (77.5%) and old (78.9%). This is 
consistent with a study by Watanabe et al, who found that 77.6% of CD4+ T cells 
in human dermis (5 donors, age not mentioned) expressed CD69 87. Similarly, 
there was no significant difference in the percentage of dermal CD8+ T cells 
expressing CD69 between the young (83.6%) and the old (85.1%). The 
equivalent figure from the aforementioned study was 86.7% 87. Therefore, for both 
CD4+ and CD8+ T cells in the skin, the proportion expressing CD69 did not decline 
with increasing age. 
A subset of CD69+ TRM cells also express CD103. This work showed that the 
proportion of CD4+ CD69+ cells expressing CD103 was 22.2% in the young and 
25.7% in the old, with no difference between the groups. For CD8+ CD69+ cells 
the proportion was 23.3% in the young and 12.1% in the old. There was a trend 
to a decrease in the old group but this did not reach statistical significance. The 
equivalent proportions from the study by Watanabe et al87 using flow cytometric 
analysis were 37.9% (extrapolated) for CD4+ T cells and 38.5% (extrapolated) for 
CD8+ T cells87. One possible reason for the lower values in this work compared 
with the published study is that flow cytometry may be more effective at identifying 
dimly positive cells.  
While skin TRM are generally defined in the scientific literature by their expression 
of CD69 and CD103 87,264,265, expression of the latter marker is significantly higher 
in mouse than in human skin79,87,113. CD103 expression is therefore not a defining 
characteristic of skin TRM in humans. In this work, there is only one data set (CD69 
expression on each of the CD4+ and CD8+ T cell populations; Figure 3-1C and 
Figure 3-2C) referring to a human skin TRM phenotype. As only one marker has 
been used to detect the skin resident T cell population in this work, caution is 
needed in making definitive conclusions about the identity and function of this 
specific cell type. Other works have suggested the absence of the surface 
markers CD62L and CCR7 also denote a skin TRM phenotype85,97, as well as 
expression of the transcription factors Hobit and Blimp1 84, and the use of these 
additional markers should be considered in future work. 
The skin data presented here on VZV-specific T cells, T cell differentiation profiles 
(based on CD27 and CD45RA expression), and T cell cytokine-producing ability 
all relied on enzymatic extraction of leukocytes from skin biopsies, using 
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collagenase type IV. During our lab’s development of the protocol for overnight 
collagenase digestion of skin, lymphocytes extracted in this way demonstrated a 
reduction in the intensity of expression of certain surface markers, such as CD4. 
To verify whether this observation was specific to lymphocytes isolated from skin, 
PBMCs were incubated in collagenase type IV overnight – and also manifested 
reduced surface marker expression. Mulder et al found that this effect was due 
to protease contamination of commercially available collagenase266, and 
demonstrated that addition of serum abolished the effect. We found that 
increasing the serum concentration in the digestion medium from 10% to 20% 
prevented the loss of surface marker expression, and so 20% FBS was used in 
all experiments using the collagenase digestion technique. 
The frequency of VZV-specific T cells in the skin has not been investigated 
previously in the context of ageing. This work showed that the proportion of VZV-
specific CD4+ T cells in the skin did not decline with age, when identified by 
overnight VZV stimulation in vitro and measurement of intracellular cytokine 
production. These findings were confirmed by other group members, who 
identified VZV-specific T cells by binding to an HLA-DRB1*1501-restricted IE63 
tetramer267. Thus, an age-related change in the frequency of VZV-specific T cells 
in the skin is not responsible for the increased susceptibility of old individuals to 
cutaneous reactivation of VZV. An additional finding was that the frequency of 
VZV-specific CD4+ T cells in the skin was significantly greater than in the blood, 
for both the young and the old. This may reflect the fact that the range of antigens 
encountered by skin TRM is likely to be less diverse than those encountered by T 
cells in circulation, so cutaneous VZV-specific T cells represent a greater overall 
proportion of the skin TRM population. Additionally, VZV-specific T cells may be 
more highly concentrated in the skin so as to be strategically positioned to 
counteract any potential VZV invasion of the skin from local sensory nerves. 
Terminally differentiated memory T cells, particularly CD8+ T cells, accumulate in 
the circulation of old humans50. This work confirmed the proportions of circulating 
CD4+ TEMRA and CD8+ TEMRA cells were significantly increased in the old 
compared to the young. However, there was no corresponding increase in the 
proportion of CD4+ TEMRA or CD8+ TEMRA cells in the skin. These findings suggest 
that impaired cutaneous immune responses in the old are not due to a functional 
impairment arising from accumulation of terminally differentiated memory T cells 
103 
 
in the skin. The disparate findings for T cells in the blood and skin suggest that 
the T cell population in the skin is relatively protected from the circulatory 
environment that predisposes T cells to terminal differentiation in the old. 
Repeated cycles of proliferation drive the increased differentiation of circulating 
T cells in the old28. It is possible that low homeostatic proliferation by skin TRM 
accounts for their relatively less differentiated state.   
We have commented on the differentiation state of skin-derived VZV-specific T 
cells in Section 3.3.5.2, by analysing CD27 and CD45RA expression on gated 
CD4+ IFN-γ+ T cells267. A caveat to the findings presented here is that the number 
of VZV-specific T cells identified in the skin for each donor was small (generally 
represented by only a few dots in the CD4+ IFN-γ + quadrant). We are therefore 
aware that strong conclusions should not be drawn when the cell yield of the 
population of interest is so low in number.   
In this work, a greater percentage of CD4+ and CD8+ T cells in old skin expressed 
PD-1 compared to young skin. Due to limitations in staining for multiple antigens 
together using immunofluorescence microscopy, it was not possible to analyse 
PD-1 expression by memory subset here. PD-1 expression increases with 
chronic antigen exposure28. TRM in old skin can be presumed to have encountered 
more antigen throughout their lifespan than those in young skin, so this may 
explain the increased PD-1 expression in the old. Increased T cell PD-1 
expression is likely to contribute to impaired cutaneous immune responses in 
ageing skin. Melanoma-infiltrating CD8+ T cells demonstrate increased PD-1 
expression; evidence for the inhibitory role of PD-1 in the skin comes from the 
use of the anti-PD-1 immunotherapy drugs nivolumab and pembrolizumab as 
treatment options for patients with metastatic melanoma268. These drugs 
powerfully stimulate the T cell anti-tumour response and lead to tumour 
regression and prolonged survival.  
In this work, skin-derived CD4+ and CD8+ T cells were just as able to produce 
cytokines in vitro in the old compared to the young. Therefore, despite increased 
PD-1 expression, T cells did not appear to be functionally exhausted in the old. It 
has been mentioned that a plateau in the number of skin TRM may be reached in 
early adulthood. In an aged individual, the pool of skin TRM specific to a given 
pathogen would likely have first been generated from a relatively ‘young’ naïve T 
cell at the time of initial pathogen exposure. The pool of TRM cells is likely to be 
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long-lived, with maintenance of its numbers from low-level cell division in steady 
state, as well as rapid pool expansion during episodes of subsequent exposure 
to the same pathogen24. A study in mice has shown that memory T cells 
generated from aged naïve T cells demonstrated impaired responses to their 
cognate antigen, with less proliferation, reduced levels of cytokines, and reduced 
cognate helper function, compared with memory T cells generated from young 
naïve cells45. This suggests that it is the age of the naïve T cell that first gives rise 
to memory T cells, as opposed to the age of the memory T cell, that determines 
the strength of the immune response to re-encountered antigen. If this concept 
can be transferred to humans, then the robust ability of stimulated skin TRM to 
produce cytokines in the old may be due to the fact that these memory T cells 
were first generated not from aged naïve T cells but from naïve T cells during 
earlier stages of life.  
The percentage of CD4+ Foxp3+ Tregs in relation to total CD4+ T cells in old skin 
was more than double that compared to young skin, which is consistent with 
previous work135. This age-related increase is mirrored by studies on human 
blood that have shown the proportion of Tregs in relation to total CD4+ T cells 
increases with age170,171. Increased skin Tregs in the old may contribute to 
impaired skin immunity in this age group. Reasons for the increased frequency 
include a compensatory response to chronic inflammation64 or to chronic lifelong 
antigen exposure124.  
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4 THE EFFECT OF SHINGLES VACCINATION ON T 
CELL POPULATIONS AND VZV-SPECIFIC IMMUNE 
RESPONSES IN THE SKIN  
4.1 Chapter Introduction 
The mechanisms by which the live attenuated shingles vaccine Zostavax® 
prevents shingles are not fully understood. The vaccine is observed to boost 
circulating VZV-specific CD4+ T cell responses and VZV-specific antibody239, but 
its effects on immune cell populations within the skin are unknown. As the skin is 
the first site to which virus particles migrate from the affected sensory nerve 
during VZV reactivation, we would assume skin TRM play a role in immune 
protection against shingles infection. Therefore, the effects of Zostavax on skin 
TRM were investigated here.  
It was shown in Chapter 3 that there was no reduction in numbers or function (in 
vitro) of total or VZV-specific TRM in old compared to young skin. However, ageing 
skin was shown to be a more inhibitory environment than young skin, with higher 
Treg frequency and PD-1 expression on T cells in the old. A potential mechanism 
of action of Zostavax® might therefore be a remodelling or reversal of the 
inhibitory influences that exist in ageing skin.  
Individuals over the age of 70 years (the age group for which the vaccine is 
recommended) were recruited to our shingles vaccine study. TRM populations in 
normal skin were enumerated before and after vaccination. The extent to which 
vaccination altered the level of immune inhibition in the skin was quantified by 
analysis of T cell PD-1 expression and Treg frequency in the skin before and after 
vaccination.   
The effect of vaccination on an in vivo cutaneous VZV-specific immune response 
was studied by inducing a DTH response to VZV skin test antigen before and 
after vaccination; the DTH site was sampled at various time-points to investigate 
the kinetics of the cellular response. It was hypothesised that Zostavax® confers 
enhanced protection against shingles by boosting VZV-specific T cell responses 
in the skin, thereby overcoming the greater inhibitory environment in ageing skin. 
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4.2 Aims & Objectives 
The aim of this section was to identify whether the shingles vaccine induces in 
ageing skin: 
1. A change in the numbers of TRM present 
2. A less inhibitory skin microenvironment 
3. An enhancement of in vivo VZV-specific immune responses (and to 
investigate the cellular kinetics involved) 
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4.3 Results 
4.3.1 Shingles vaccination does not alter the number of CD4+ TRM in 
normal skin 
Frozen sections of normal skin from vaccinated individuals were stained with anti-
CD4 antibody and analysed by immunofluorescence microscopy. As previously, 
cell counts were performed for cells in the dermis, and the data are shown in 
Figure 4-1A. The median number of CD4+ T cells per section was not significantly 
different between vaccinated (59) and unvaccinated individuals (75).  
The proportion of CD4+ T cells resident in the skin was analysed by co-staining 
with CD69 (Figure 4-1B). 80.2% of CD4+ T cells in the dermis were CD69+ in 
vaccinated individuals, with no significant difference when compared with the 
unvaccinated old (median 80.4%). These data suggest that the shingles vaccine 
does not lead to the generation of additional skin CD4+ TRM distant to the 
vaccination site.  
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Figure 4-1 Effect of vaccination on numbers of skin CD4+ TRM  
A:  Graph showing the number of dermal CD4+ T cells per section in vaccinated individuals (n=8). 
Data for unvaccinated old are shown for comparison.  
B:  Graph showing the percentage of CD4+ T cells in the dermis expressing CD69 (vaccinated 
individuals n=8).  
Medians and interquartile ranges are displayed, and the populations were compared using the 
Mann-Whitney test. 
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4.3.2 Vaccination boosts the frequency of VZV-specific CD4+ T cells 
in circulation but not skin 
The effect of vaccination on the frequency of VZV-specific CD4+ T cells in the 
skin and blood was studied. Leukocytes were isolated from paired skin biopsies 
and blood samples, before and after vaccination. As previously, VZV-specific 
CD4+ T cells were identified by IFN-γ production following in vitro overnight 
stimulation with VZV lysate.    
As shown in Figure 4-2, there was a significant increase in the proportion of VZV-
specific CD4+ T cells in the blood after vaccination (median 0.046%) compared 
to before (median 0.032%; p=0.027). Surprisingly, there was no associated 
increase in the proportion of VZV-specific CD4+ T cells in skin (median 0.065% 
both before and after vaccination). These results indicate that the vaccine induces 
a boost in circulating VZV-specific T cell immunity, but not necessarily in the skin.  
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Figure 4-2 Effect of vaccination on the frequency of VZV-specific CD4+ T cells in the blood 
and skin 
Graph showing cumulative data for the percentages of IFN-γ-producing CD4+ T cells in the blood 
and skin, before and after vaccination (blood n=10, skin n=6). Medians and significance levels 
are shown. Data were compared using the Wilcoxon matched-pairs signed rank test.  
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4.3.3 Shingles vaccination does not alter the number of skin CD8+ 
TRM in normal skin 
Immunofluorescence microscopy experiments demonstrated no significant 
difference in the median number of CD8+ T cells per section between vaccinated 
(21.3) and unvaccinated old individuals (26.5), as shown in Figure 4-3A. There 
was also no significant difference in CD69 expression on CD8+ T cells between 
the vaccinated (median 84.3%) and the unvaccinated (median 85.2%) – shown 
in Figure 4-3B. Thus, as was the case with CD4+ T cells, the shingles vaccine did 
not appear to generate increased CD8+ TRM distant to the site of vaccine 
administration.  
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Figure 4-3 Effect of vaccination on numbers of skin CD8+ TRM 
A:  Graph showing the number of dermal CD8+ T cells per section in vaccinated individuals (n=8). 
Data for unvaccinated old are shown for comparison.  
B:  Graph showing the percentage of CD8+ T cells in the dermis expressing CD69 (vaccinated 
individuals n=8).  
Medians and interquartile ranges are displayed, and the populations were compared using the 
Mann-Whitney test.  
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4.3.4 Shingles vaccination does not alter the proportion of Tregs in 
normal skin  
The effect of the vaccine on the proportion of CD4+ T cells in the skin displaying 
a regulatory phenotype was analysed by immunofluorescence microscopy. As 
shown in Figure 4-4A, the median percentage of Tregs in vaccinated individuals 
(12%) was not significantly different to the percentage seen in the unvaccinated 
(8.7%). Figure 4-4B demonstrates the median percentage of Tregs expressing 
CD69 in the vaccinated (54.3%) was not significantly different compared to the 
unvaccinated (48.8%). Therefore, the Treg frequency in the skin appeared 
unaltered after vaccination.  
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Figure 4-4 Effect of vaccination on the proportion of Tregs in the skin 
A:  Graph showing the percentage of CD4+ T cells in the dermis expressing Foxp3 in vaccinated 
old individuals (n=8). Data for unvaccinated old are shown for comparison. 
B:  Graph showing the percentage of CD4+Foxp3+ Tregs in the dermis expressing CD69 in 
vaccinated old individuals (n=8). Data for unvaccinated old are shown for comparison.  
Medians and interquartile ranges are displayed. Populations were compared using the Mann-
Whitney test and significance levels are shown.  
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4.3.5 Shingles vaccination increases PD-1 expression on skin CD4+ 
T cells 
In Section 3.3.3, PD-1 expression was shown to be increased in CD4+ and CD8+ 
T cells in ageing skin. As vaccination boosts immunity, it was of interest to 
investigate whether PD-1 expression in the skin was reduced following vaccine 
administration.  
Interestingly, the median percentage of CD4+ T cells expressing PD-1 was higher 
in the vaccinated individuals (75.2%) compared to the unvaccinated (58.7%) as 
seen in Figure 4-5A (p=0.031). In contrast, the median percentage of CD8+ T 
cells expressing PD-1 was not significantly different between the vaccinated 
(63.9%) and unvaccinated (68.7%) individuals.  
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Figure 4-5 Effect of vaccination on PD-1 expression by skin CD4+ and CD8+ T cells 
Graph showing the percentage of CD4+ T cells (A) and CD8+ T cells (B) in the dermis expressing 
PD-1 in vaccinated old individuals (n=8). Data for unvaccinated old individuals are shown for 
comparison. Medians and interquartile ranges are displayed. Groups were compared using the 
Mann-Whitney test and significance levels are shown. 
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4.3.6 The shingles vaccine boosts the clinical response to VZV 
antigen challenge 
Ageing volunteers were challenged with the VZV skin test antigen before and 
after vaccination, and the clinical response at Day 3 was measured. Participant 
and clinical score data are listed in Table 4-1. Out of a total of 42 volunteers who 
consented to the study, 4 dropped out (3 for medical reasons, 1 declined further 
participation). A further 8 volunteers were excluded from the study due to a highly 
robust clinical score ≥ 5. Of the remaining 30 volunteers, 5 had a starting score 
of 4, reflecting a moderately robust response; none of these 5 experienced a 
boost in clinical response after vaccination. The age range was 70-93; median 
age 75.5; 10 male and 20 female. 
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Donor Age Gender 
Clinical Score 
Before vaccine After Vaccine 
1 82 M 0 3 
2 80 F 0 3 
3 82 M 0 Dropped out (medical reasons) 
4 70 F 0 0 
5 74 F 1 4 
6 84 M 4 4 
7 81 F 1 3 
8 82 F 1 Dropped out 
9 77 M 1 1 
10 74 F 3 4 
11 79 F 1 7 
12 82 F 0 0 
13 72 M 6 Excluded (high score) 
14 80 F 1 1 
15 71 F 3 6 
16 71 F 0 3 
17 70 M 6 Excluded (high score) 
18 72 F 1 6 
19 70 F 1 4 
20 75 M 0 0 
21 73 F 0 Dropped out (medical reasons) 
22 84 M 0 Dropped out (medical reasons) 
23 76 F 0 0 
24 75 F 4 4 
25 83 M 0 3 
26 93 M 0 3 
27 85 M 1 3 
28 71 F 5 Excluded (high score) 
29 70 F 4 3 
30 70 F 6 Excluded (high score) 
31 72 M 4 4 
32 75 F 3 4 
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33 76 F 3 4 
34 71 F 1 2 
35 73 F 3 5 
36 73 M 5 Excluded (high score) 
37 78 M 0 4 
38 77 F 6 Excluded (high score) 
39 74 F 9 Excluded (high score) 
40 74 F 4 4 
41 76 F 5 Excluded (high score) 
42 74 M 1 4 
 
Table 4-1 Table showing participant age, gender, and clinical score before and after 
vaccination 
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Before and after analysis was performed for the remaining 25 volunteers who had 
a starting clinical score ≤3. As shown in Figure 4-6A, 19 out of 25 (76%) had an 
enhanced clinical response after vaccination, with the others showing no 
improvement. There was a significant increase in clinical score after vaccination 
(mean score 3.1) compared to before (mean score 1) – as shown in Figure 4-6B 
& C (p<0.0001). 
To demonstrate whether repeated VZV skin testing per se enhances the clinical 
score, we re-challenged 14 volunteers with the VZV skin test without any 
attendant intervention, and found no significant enhancement on the second test 
(Figure 4-6D; p>0.99).  
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Figure 4-6 Effect of vaccination on clinical score following VZV skin challenge 
A: Graph showing the number of individuals whose clinical score improved (responders) and did 
not improve (non-responders) after vaccination (n=25).  
B&C: Graphs showing clinical scores of volunteers before and after vaccination (n=25). Means 
with standard deviations are shown in B. Values were compared using the paired t test and the 
significance level is shown. 
D: Clinical scores of 14 volunteers who underwent VZV skin test re-challenge. Data were 
analysed using the Wilcoxon matched-pairs signed ranked test and the significance level is 
shown. 
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4.3.7 The kinetics of the DTH response to VZV skin challenge 
The numbers of CD4+ and CD8+ T cells, as well as Tregs, within perivascular 
infiltrates at the site of VZV antigen challenge were quantified by 
immunofluorescence microscopy in old individuals before and after vaccination. 
The 5 largest perivascular infiltrates in the upper dermis were used to generate a 
mean value per infiltrate. By sampling the test site at various time points in 
different individuals, a time course was plotted to trace the kinetics of the T cell 
response. These data were compared with young donor data that had already 
previously been acquired by our research group142. Young data are shown in the 
graphs for comparison. 
4.3.7.1 Vaccination induced an enhanced CD4+ T cell skin response to 
VZV challenge 
Representative immunofluorescence micrographs showing perivascular CD4+ T 
cells in an old donor, before and after vaccination, are displayed in Figure 4-7A. 
The mean numbers of CD4+ T cells per perivascular infiltrate at the various time-
points are shown in Figure 4-7B. Over the 7-day time-course, the young mounted 
a robust cellular response, with large numbers of CD4+ T cells accumulating 
within perivascular infiltrates by Day 7 (p=0.0016). In contrast, the unvaccinated 
old generate a weak response, with significantly fewer CD4+ T cells than the 
young at Days 3 (p=0.014) and Day 7 (p=0.0025). Vaccinated individuals had 
enhanced cellular infiltration, with significantly more CD4+ T cells at Days 3 
(p=0.019) and Day 7 (p=0.030) than the unvaccinated.   
Cellular proliferation was analysed by staining with Ki67 (Figure 4-7A). The 
percentage of CD4+ T cells expressing Ki67 within perivascular infiltrates was 
calculated and the time-course is shown in Figure 4-7C. T cell proliferation was 
not detectable in unchallenged skin. Over the 7-day time-course, CD4+ T cell 
proliferation increased significantly in the young (p=0.036). Contrastingly, 
proliferation remained low in the unvaccinated old, with a significant difference 
from the young at Days 3 (p=0.0020) and 7 (p=0.030). In the vaccinated group 
there was a trend to increased proliferation compared to the unvaccinated group 
at Day 7 (p=0.082).    
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Figure 4-7 Time-course of infiltrating CD4+ T cells at the site of VZV challenge, and the 
effect of vaccination 
A: Representative immunofluorescence micrographs (x400 original magnification) of perivascular 
CD4+ T cells (red) co-stained with Ki67 (green), in an old donor before vaccination (middle) and 
after (right image). An image from a young donor (left) is shown for comparison. 
B:  Graph showing the mean number of perivascular CD4+ T cells at various time-points in young, 
unvaccinated and vaccinated old donors. Different donors were used for each time-point.  
C:  Graph showing the percentage of proliferating CD4+ T cells during the 7-day time-course in 
the different volunteer groups.  
Medians and interquartile ranges are shown. Groups were compared using the Mann-Whitney 
test and significance levels are shown. 
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4.3.7.2 Vaccination induced an enhanced CD8+ T cell skin response to 
VZV challenge 
Representative immunofluorescence micrographs showing perivascular CD8+ T 
cells in an old donor, before and after vaccination, are shown in Figure 4-8A. The 
mean numbers of CD8+ T cells per perivascular infiltrate at the different time-
points are shown in Figure 4-8B. In the young, a robust CD8+ T cell response was 
seen over the 7-day time-course (p=0.0043). In contrast, the unvaccinated old 
generated a poor response, with significantly fewer CD8+ T cells than the young 
at Days 3 (p=0.0080) and Day 7 (p=0.0043). Vaccinated individuals had 
significantly more CD8+ T cells at Days 3 (p=0.0080) and Day 7 (p=0.030) than 
the unvaccinated.   
The percentage of CD8+ T cells expressing Ki67 within perivascular infiltrates 
(Figure 4-8A) was calculated and the time-course is shown in Figure 4-8C. CD8+ 
T cell proliferation increased significantly in the young over the 7-day time-course 
(p=0.0079). Proliferation remained low at all time-points in the unvaccinated old, 
with a significant difference from the young at Days 3 (p=0.0014) and 7 (p=0.025). 
Among old individuals, proliferation was significantly increased in the vaccinated 
compared to the unvaccinated at Day 3 (p=0.0030) and Day 7 (p=0.0163).   
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Figure 4-8 Time-course of infiltrating CD8+ T cells at the site of VZV challenge, and the 
effect of vaccination  
A: Representative immunofluorescence micrographs (x400 original magnification) of perivascular 
CD8+ T cells (red) co-stained with Ki67 (green), in an old donor before vaccination (left) and after 
(right). 
B:  Graph showing the mean number of perivascular CD8+ T cells at various time-points in young, 
unvaccinated and vaccinated old donors. Different donors were used for each time-point.  
C:  Graph showing the percentage of proliferating CD8+ T cells during the 7-day time-course in 
the different groups.  
Medians and interquartile ranges are shown. Groups were compared using the Mann-Whitney 
test and significance levels are shown. 
A 
B 
Old Vaccinated old 
C 
***
**
nsns
Day 7Day 3
0
20
40
60
80
100
M
e
a
n
 N
o
. 
o
f 
C
D
8
+
T
 c
e
ll
s
 /
p
e
ri
v
a
s
c
u
la
r 
in
fi
lt
ra
te
Day 0
Young
Old
Vaccinated
old
Day 1
**
**
*
**
0
5
10
15
20
M
e
a
n
 %
 o
f 
C
D
8
+
 T
 c
e
ll
s
e
x
p
re
s
s
in
g
 K
i6
7
Day 1 Day 3 Day 7
*
Young
Old
Vaccinate
d old
**
ns **
127 
 
4.3.7.3 Vaccination led to a reduced proportion of perivascular Tregs at 
the site of VZV challenge 
Representative immunofluorescence micrographs showing perivascular CD4+ T 
cells co-stained with Foxp3 in an old donor, before and after vaccination, are 
shown in Figure 4-9A. The mean number of Tregs per perivascular infiltrate at 
the various time-points is shown in Figure 4-9B. Over the 7-day time-course, the 
number of Tregs per perivascular infiltrate increased progressively in the young 
(p=0.0016) but not in the old. By Day 7 there were significantly more Tregs in the 
young than the old (p=0.030). When the vaccinated old were compared with the 
unvaccinated old, there was no significant difference in Treg numbers at either 
Day 3 or Day 7.  
The mean percentage of perivascular CD4+ T cells displaying a regulatory 
phenotype was calculated (Figure 4-9C). Old individuals had a greater 
percentage of Tregs than the young in perivascular clusters in unchallenged skin 
(median 30.1% in the old and 11.9% in the young; p=0.0062). After antigen 
challenge, the percentage values fell in both young and old, but the old 
maintained a higher percentage than the young at all time-points (Day 1 p=0.032; 
Day 3 p=0.11; Day 7 p=0.030). Interestingly, vaccinated individuals had a lower 
percentage of Tregs than the unvaccinated at both Days 3 (p=0.0070) and Day 7 
(p=0.019). 
Treg proliferation was analysed by co-staining with Ki67 (Figure 4-9D). There was 
a trend to an increase in Treg proliferation in the young at Day 7 compared to 
Day 1 (p=0.071), but no change in the old. At Day 1 there was no significant 
difference in Treg proliferation between the young and the old, but at Days 3 and 
7, there was a trend to an increase in the young (Day 3 p=0.11; Day 7 p=0.15). 
In the vaccinated individuals there was a trend to an increase in Treg proliferation 
at both Day 3 and Day 7 compared to the unvaccinated (Day 3 p= 0.095; Day 7 
p=0.11).  
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Figure 4-9 Time-course of infiltrating regulatory T cells at the site of VZV challenge, and 
the effect of vaccination  
A: Representative immunofluorescence micrographs (x400 original magnification) of perivascular 
CD4+ T cells (green) co-stained with Foxp3 (red), in an old donor before vaccination (left) and 
after (right image). Cells with a red nuclear stain surrounded by a green surface membrane stain 
are Tregs.  
B: Graph showing the mean number of Tregs within perivascular infiltrates at various time-points 
in young, unvaccinated and vaccinated old donors.  
C: Graph showing the percentage of perivascular CD4+ T cells displaying a regulatory phenotype 
at the various time-points.  
D: Graph showing the percentage of Tregs that were proliferating during the 7-day time-course. 
The median and interquartile range for each group is displayed. Significance levels are shown, 
and groups were compared using the Mann-Whitney test. 
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4.4 Discussion 
4.4.1 Vaccination and skin TRM numbers 
The shingles vaccine did not lead to an increase in the number of skin CD4+ or 
CD8+ TRM at the site of sampling (forearm). There was also no increase in the 
frequency of VZV-specific CD4+ T cells in the skin, although a boost in the 
frequency of these cells was seen in the peripheral blood. Therefore, the 
mechanism of enhanced protection against shingles is not via an increase in the 
number of skin TRM. This is perhaps surprising, as the skin is the first tissue to 
which the virus migrates following reactivation in the dorsal root ganglion, and is 
the site where shingles infection becomes clinically apparent.  
As with many vaccines, the mechanisms by which the body processes the 
contents of Zostavax® and how this initiates an immune response are not fully 
understood. Following injection of a vaccine, particles less than 200nm can 
directly access lymphatic capillaries, with the optimal size for efficient passage 
being ~40nm, while particles larger than 200nm must be transported into the 
lymphatic system by DCs269. VZV virions are 150-200nm in diameter270 and 
therefore likely to be able to access the lymphatic system directly. Additionally, 
after vaccination with a live vaccine, live virions rapidly disseminate via the 
vascular route, as occurs in natural infection, and activate DCs at multiple sites225.  
Live viral vaccines are considered to be effective in activating DCs via their 
PRRs225. These DCs migrate to the corresponding draining LNs and initiate 
multiple foci of T and B cell activation225. This is one explanation for the greater 
immunogenicity of live versus non-live vaccines225. Furthermore, this method of 
lymphocyte activation means that the subcutaneous and intramuscular routes of 
vaccine administration are similarly immunogenic for live vaccines271.        
Following the activation and proliferation of antigen-specific T cells in the lymph 
node, a proportion persists as long-lived memory T cells in the circulation25, 
where they are detectable by peripheral blood sampling. Thus, the detection of 
an increased frequency of VZV-specific CD4+ T cells in the blood following 
vaccination in this study is not surprising. Similar findings were demonstrated in 
an immunology substudy accompanying the original clinical trial of Zostavax®, in 
which vaccination of older individuals led to an increase in T cell-mediated 
immunity (CMI) in peripheral blood at all time points between 6 weeks and 3 
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years, as measured by CD4+ responder cell frequency (RCF) and IFN-γ ELISPOT 
assays239.  
There may be several explanations for the lack of an increase in the number of 
TRM or frequency of VZV-specific T cells in the skin following vaccination. As live 
vaccine virus particles are able to migrate from the vaccine site to the draining 
LN without relying on uptake by DCs, imprinting of virus-specific lymphocytes in 
the LN with information relating to the site of inoculation may not occur, meaning 
that these lymphocytes may not acquire homing markers to that site100,272. 
Conversely, when DCs encounter antigen in the skin and present this to 
lymphocytes in the draining LN, skin-related signals are imprinted onto these 
lymphocytes, inducing their expression of skin homing receptors and facilitating 
their recruitment to the skin272.   
Zostavax® is injected into the subcutaneous layer in the shoulder/upper arm 
region. The subcutaneous layer is made up of adipose tissue, predominantly 
consisting of adipocytes and fibroblasts. Even if the majority of Zostavax® virus 
particles end up migrating through the vascular network to reach the LNs, it is still 
possible that some particles are taken up by DCs at the site of vaccination, 
processed and transported via lymphatic capillaries to the regional lymph node. 
The lymphatic system is intimately related to adipose tissue, and dermal 
lymphatic capillaries are located in close proximity to subcutaneous fat273. 
However, in contrast to the skin, the subcutaneous layer is relatively devoid of 
resident immune cells274. Despite this paucity of immune cell numbers, a variety 
of immune cell types have been identified in healthy, non-obese adipose tissue. 
The most numerous are Tregs, iNKT cells, macrophages and eosinophils, while 
B cells, Th1 CD4+ T cells, CD8+ T cells and mast cells are more sparsely 
present275. DCs in adipose tissue in healthy humans have not been well-
characterised but are considered to be scant in number, particularly in 
comparison to the neighbouring tissues of skin and muscle225, which represent 
alternative options for vaccination sites. DCs within adipose tissue have been 
better characterised in obese individuals, in whom they are proposed to have a 
pro-inflammatory role276. In summary, DC activation by Zostavax® vaccine 
antigen within the adipose tissue is unlikely to play a major role in the induction 
of immune memory and formation of VZV-specific TRM.  
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If Zostavax® does lead to the generation of VZV-specific effector T cells in the 
draining LN that home to the site of injection, then this may well lead to the 
formation of adipose tissue TRM275, but not skin TRM. To demonstrate whether 
adipose tissue TRM are generated by subcutaneous vaccination, samples of 
subcutaneous adipose tissue would need to be analysed, which was beyond the 
scope of the project detailed here. In any case, even if there was an expansion 
of VZV-specific T cells resident within adipose tissue, these would be unlikely to 
play an important contributory role in the defence against VZV reactivation, as 
virus particles are shed from the sensory nerve into the dermis and not into the 
subcutis.   
Leishmania major-specific CD4+ TRM were shown to be generated throughout the 
skin surface of mice following localised infection with L. major. These cells 
persisted at least 1 year and were protective against further infection107. Another 
study involving mice showed that acute epicutaneous infection (via skin 
scarification) with vaccinia virus led to the generation of antigen-specific CD8+ 
TRM at the site of infection, and these cells were long-lived and highly protective 
against vaccinia re-infection105. Importantly, antigen-specific CD8+ TRM were also 
generated throughout the entire skin surface, albeit at lower numbers than at the 
original site of infection. These cells were also long-lived, protective against 
vaccinia infection, and further increased in number with every subsequent 
episode of vaccinia infection105. Local inflammation and antigen recognition 
encourage lodgement and retention of TRM 277, which may explain the greater 
numbers of TRM at the original site of infection. 
The subcutaneous adipose tissue layer is directly underneath and in contact with 
the dermis. It is thus conceivable that vaccine contents injected into the 
subcutaneous layer may come into contact with the overlying dermis and the 
dermal dendritic cells (DDCs) within. It is therefore possible that Zostavax® 
antigens are taken up by DDCs, which present antigen to and activate VZV-
specific T cells in the skin or in the draining LN, ultimately leading to an expanded 
population of VZV-specific T cells in the skin. If this is indeed the case, then the 
technology used in this study for identifying VZV-specific T cells in the skin is not 
sensitive enough to detect an increase following vaccination.  
The number of live T cells identified by flow cytometry following overnight 
collagenase digestion of 2 x 5mm punch biopsies, a subsequent 15-hour in vitro 
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stimulation with VZV lysate in the presence of brefeldin, and then a surface and 
intracellular flow cytometry staining protocol – is low, perhaps a few thousand 
cells on average. T cells from the skin are prone to death in culture in the absence 
of homeostatic cytokines, and the above experimental protocol from the time of 
biopsy to the cell fixing stage is prolonged (may be up to 48 hours depending on 
time of biopsy) and testing. If the frequency of VZV-specific CD4+ T cells is, for 
example, 0.2% for a given donor, and the total number of skin-derived CD4+ T 
cells obtained from 2 biopsies is, say 1000 (both of which are plausible figures), 
then the number of VZV-specific CD4+ T cells identified on the flow cytometer will 
be 2. Such a low absolute number of antigen-specific cells calls into question the 
reliability of this technique. For example, if 1 more or 1 fewer VZV-specific T cell 
is detected, this would increase or decrease the calculated frequency by 50%, 
giving rise to a wide confidence interval.  
Furthermore, it must be noted that in the study volunteers, the site of vaccination 
(upper arm/shoulder) was different to the site sampled by skin biopsy (forearm). 
As the highest concentration of skin TRM occurs at the site of original infection, 
perhaps if the skin overlying the vaccination site was sampled, an increase in 
VZV-specific CD4+ T cells may have been seen.  
Additionally, in this study the time interval between vaccination and skin biopsy 
sampling was 2-8 months. A uniform time point of 2 months was aimed for but for 
a variety of reasons, including volunteer availability, this could not be adhered to. 
Once antigen-specific TRM in the skin have been generated after skin infection, 
they remain long-term but their frequency may decline gradually over time in the 
absence of further antigenic stimulation105. Peak Zostavax®-induced VZV-
specific T cell responses in the circulation were observed at 6 weeks, and the 
sharpest decline was seen between 6 weeks and 1 year239. Therefore, it is 
possible that if all skin samples in our study were consistently taken at an early 
time-point, such as 6 or 8 weeks after vaccination, then a boost in VZV-specific 
T cells in the skin may have been seen. 
4.4.2 Alternative routes of vaccination 
For reasons explained above, the intradermal route of vaccination may be more 
effective at generating skin TRM than the hypodermic route. The skin has a dense, 
well-characterised network of DCs278, meaning that antigen uptake, initiation of 
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inflammation, and antigen presentation to T cells are more likely to lead to the 
efficient generation of antigen-specific TRM.  
Several studies have compared the immunogenicity of reduced dose intradermal 
vaccines versus full dose hypodermic vaccines, with the former superior or 
equivalent to the latter. Rabies vaccine, which contains killed rabies virus, is given 
intradermally at one tenth of the dose as intramuscularly and generates similar 
antibody responses279, demonstrating the highly immunogenic nature of 
vaccination into the dermis. Consequently, reduced-dose intradermal rabies 
vaccine has been adopted by a number of developing countries to reduce the 
economic burden of mass vaccination with a vaccine that is expensive to 
produce279. Kenney el al. showed that when influenza vaccine, containing purified 
surface antigen from the influenza virus, was administered intradermally at one 
fifth of the standard dose, it generated equivalent or superior antibody responses 
as when administered at full dose via the intramuscular route280. Hepatitis B 
vaccine (containing hepatitis B surface antigen), when administered intradermally 
at one sixth the dose of the intramuscular route, led to similar seropositivity rates 
over 2 years (protective levels), although antibody titres were higher in the 
intramuscular group281. 
The mechanism of immune memory generation for these non-live vaccines is 
distinct from live vaccination, however. Activation of DCs at the site of vaccination 
is less critical for live viral vaccines than it is for non-live vaccines, as free virus 
particles can make their own way to LNs via the lymphovascular system225. Beals 
et al. compared the immune responses generated by subcutaneous and 
intradermal routes of administration of Zostavax®; the intradermal route led to a 
more pronounced increase in VZV IgG at 6 weeks (3.25-fold increase) compared 
to the subcutaneous route (1.74-fold increase)282. Importantly, fold-change in 
VZV IgG at 6 weeks post-vaccination has been shown to be an excellent correlate 
of protection against shingles245. At 18 months the fold increase in antibody titre 
remained higher in intradermally vaccinated compared to subcutaneously 
vaccinated participants282. However, there was no difference in the cell-mediated 
immune response, as measured by IFN-γ ELISPOT, between both routes of 
administration. There is no licence in place for Zostavax® to be administered to 
individuals via the intradermal route, and this is unlikely to change given the 
increased pain associated with this route.  
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Another route of vaccination that is yet more immunogenic than intradermal is the 
epicutaneous route, using skin scarification. Variola major infection (smallpox) 
killed 300-500 million people in the 20th century, yet was eradicated by mass 
vaccination with the related live vaccinia virus via skin scarification.  
Studies in mice have demonstrated the usefulness of vaccination by scarification 
to generate antigen-specific immunity in the skin. Scarification of mice with 
vaccinia virus led to upregulation of skin-homing molecules on CD8+ T cells in the 
draining lymph nodes, with subsequent migration of a proportion of these cells 
back to the skin283. Liu et al showed that mice vaccinated with live vaccinia virus 
via skin scarification generated more IFN-γ-producing CD8+ T cells, a superior 
recall IFN-γ response and superior humoral responses, compared to the 
intradermal, subcutaneous or intramuscular routes284. The skin scarification route 
led to prominently higher viral gene expression at the inoculation site than the 
other vaccination routes284, suggesting enhanced viral activation and presumably 
also heightened stimulation of the immune system via this route. Mice previously 
immunised by skin scarification were shown to be better protected against 
secondary vaccinia skin challenge than mice which had been immunised via the 
intradermal, subcutaneous, intramuscular or intraperitoneal routes; this 
enhanced protection was shown to be due to a boost in T cell memory283,284. 
Furthermore, it was particularly the skin TRM generated by the original skin 
scarification procedure that mediated the enhanced protection284. Importantly, 
increased numbers of CD3+ T cells were observed in the skin of mice previously 
vaccinated by scarification but not via any of the other routes284. This 
demonstrates that scarification is a more effective method of generating skin TRM 
than other routes of vaccination.  
In humans, skin scarification with vaccinia virus protects against natural smallpox 
infection, which is acquired via the respiratory route. Interestingly, mice 
vaccinated by scarification were completely protected against intranasal vaccinia 
infection, in contrast to the mice vaccinated by all the other routes which 
developed clinical signs of infection284. This suggests that scarification is far 
superior to all other routes of vaccination at generating immunity at distant 
peripheral tissue sites. A combination of T cells resident within the upper 
respiratory mucosa and TCM in the lymph nodes draining respiratory mucosa was 
needed to provide full protection against intranasal vaccinia infection284.  
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Thus, in general it appears that skin scarification is superior to intradermal 
vaccination, which itself is superior to the hypodermic route. It is recognised that 
a successful vaccine must be capable of inducing a robust innate immune 
response, which then translates into vigorous stimulation of the adaptive immune 
system and generation of long-lived and potent immune memory. The differences 
in efficacy between the various routes of vaccination are likely to be due to the 
varying ability to initiate activation of the innate immune system. Hypodermic 
vaccination bypasses the dense network of APCs in the skin and targets 
anatomical areas that are relatively devoid of APCs274, a clear disadvantage for 
the induction of immune memory. The hypodermic route is effective at generating 
antibody responses285,286, useful for preventing systemic infection, but where the 
aim is prevention of infection at an epithelial site such as the skin, then the 
generation of TRM at that site may be more desirable286 – an aim that is more likely 
to be achieved by introducing the vaccine directly into the skin.  
The usefulness of administering a vaccine at the same anatomical site as the 
entry point for the pathogen is demonstrated by the efficacy of the oral polio 
vaccine, oral rotavirus vaccine and intranasal influenza vaccine. Mucosal 
vaccination has been shown to mediate humoral and cell-mediated immune 
protection both at mucosal surfaces and systemically287. This route of vaccination 
also strongly induces long-term T and B cell memory287. 
In summary, future strategy for vaccination against pathogens that invade the 
body through the skin should take into consideration the option for administering 
vaccines via skin scarification or intradermally. Such skin-tropic pathogens 
include Staphylococcus aureus, Streptococcus pyogenes, herpes simplex, 
human papillomavirus, Candida albicans and dermatophyte fungi. The problem 
with the skin scarification route is that, in the context of smallpox vaccination, it 
led to morbidity and mortality in people with compromised immune systems or 
atopic dermatitis288. Intradermal vaccination is more painful than the 
subcutaneous or the intramuscular routes, and the injected volume is restricted 
to a maximum of 200µl, whereas large volumes can be injected via the 
hypodermic route274.   
Using skin scarification to vaccinate against pathogens that do not typically 
invade the body via the skin (such as smallpox) should also be considered as a 
future strategy, given that this method of immunisation appears effective in 
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generating cell-mediated immunity at other epithelial barriers (eg. lung) as well 
as in circulation.  
4.4.3 Vaccination and PD-1 expression in the skin 
PD-1 expression was increased on dermal CD4+ but not CD8+ T cells in the 
vaccinated compared to the unvaccinated group. There may be several 
explanations for this finding. Firstly, it is possible that the increased PD-1 
expression was transient and due to CD4+ T cell activation following viral antigen 
encounter. This could be investigated further with serial biopsies at various time 
points, and a reduction in PD-1 expression back to baseline over time would 
support this possibility. 
Another explanation is that the vaccine induced a relative state of T cell 
exhaustion, due to its high antigenic load. Previous work showed that T cells in 
the skin experienced accelerated telomere erosion as early as 19 days after 
induction of a cutaneous secondary immune response to PPD169. It is conceivable 
therefore that skin resident T cells have a heightened propensity to exhaustion 
and senescence following secondary immune responses.  
4.4.4 Improved clinical response to VZV skin challenge following 
vaccination 
Vaccination of old volunteers with Zostavax® led to a significant improvement in 
the clinical score (a visible marker of inflammation) at the site of VZV antigen 
challenge. The mechanism for this restoration of inflammation is unclear. In this 
chapter it was shown that skin TRM numbers remained the same following 
vaccination, so a boost in TRM numbers prior to DTH induction cannot account for 
the enhanced inflammation. Khan et al showed antigen-specific CD8+ TRM in 
mouse skin were potent stimulators of localised inflammatory responses after 
cognate antigen challenge112. Therefore, it is possible that after vaccination, VZV-
specific TRM have a lower threshold for activation, and undergo more rapid 
proliferation and produce more pro-inflammatory cytokines, thereby driving the 
inflammatory process early on during the response. Another possibility is that the 
increased frequency of VZV-specific T cells in circulation after vaccination leads 
to enhanced recruitment of these cells to the skin after VZV challenge. With both 
these possibilities, greater amounts of T-cell-derived IFN-γ would lead to 
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enhanced activation of skin resident macrophages and increased macrophage-
derived TNF-α production, perpetuating the inflammatory response.  
Endothelial expression of E-selectin and VCAM-1 was equivalent between young 
and old at 6 hours after induction of the DTH response to VZV antigen, and was 
significantly elevated compared to unchallenged skin in both age groups143. This 
suggests that endothelial cells in the old are functional at the early stages of the 
DTH response. However, from 24 hours onwards, there was a significant 
increase in endothelial E-selectin expression in the young compared to the old, 
implicating active inhibition in the later stages of the immune response or a failure 
of immune response amplification in the old, or both143. It would be interesting to 
measure endothelial expression of E-selectin from 6 hours onwards in the 
vaccinated old, to investigate whether vaccination restores the expression of this 
molecule to levels seen in the young. If confirmed, this would highlight endothelial 
expression of cell adhesion molecules as a critical mechanism for the generation 
of robust antigen-specific immune responses, and would be a candidate for 
therapeutic manipulation to boost immunity in the old.  
76% of volunteers in our study had an improved clinical score after vaccination. 
Several other studies have investigated the effect of VZV vaccination on the 
clinical response to VZV skin test antigen in older adults and the results are 
summarised in Table 4-2. 
Study Participant 
age 
Time after 
vaccine 
Skin test response 
measure 
Response 
rate 
Takahashi et 
al. 2003289 
70-79 4-6 weeks 
Negative/weak 
positive to positive 
76.2% (16/21) 
Takahashi et 
al. 2001290 
>50 5-7 weeks 
Negative/weak 
positive to positive 
76.9% (10/13) 
Takahashi et 
al. 1992291 
60-82 2 weeks Negative to positive 56.3% (9/16) 
 
Table 4-2 Previous studies examining the effect of VZV vaccination on clinical response 
to VZV skin test 
These studies first confirmed the loss of clinical response to VZV skin test antigen 
in older adults, and then demonstrated the boost provided by VZV vaccination in 
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a proportion of volunteers. The response rates from the two more recent 
studies289,290 are similar to the percentage of responders in our study. These two 
studies used a higher vaccine dose of 3.0 x 104 PFU per vaccine, compared with 
1.94 x104 PFU in our study. The vaccine dose in the 1992 study was not stated 
but if a lower dose was used then this may explain the lower response rate in that 
study.  
In our study, volunteers with a pre-vaccination score of 4 or above, indicating at 
least moderately robust VZV-specific immunity in the skin, were excluded from 
further participation. The reason for this is that the aim of our work is to 
understand how the immune system declines in old age, and to investigate 
strategies to boost failing immunity in this age group. The scope for enhancing 
immunity in an ageing individual with good baseline immune function is therefore 
limited. A similar strategy for excluding ageing volunteers with good baseline 
immunity (as indicated by the robustness of the VZV clinical score) before 
investigating the immune effects of the VZV vaccine was also adopted in two of 
the studies listed in the table above289,291. A caveat in our work is that the 
volunteers who did complete the study may not be wholly representative of the 
ageing population, as undoubtedly the ageing population contains a minority of 
individuals who demonstrate vigorous immune responses akin to those in early 
adulthood.     
The clinical response to VZV skin test antigen has been shown to be an excellent 
correlate of clinical protection against shingles147. Additionally, the clinical 
response is inversely correlated with the severity of shingles skin lesions and 
associated pain292. Oxman et al showed that in the over 70s Zostavax® reduced 
shingles incidence by only 37.6%, and burden of illness (taking into account 
duration and severity of pain) by 55.4%238. This suggests that an improvement in 
cell-mediated VZV-specific immunity in the skin following vaccination does not 
necessarily equate to protection against VZV reactivation. 
Interestingly, our figure of 76% is not dissimilar to the percentage reduction in the 
incidence of post-herpetic neuralgia (PHN) in the >70-year-old population, found 
to be 66.8% in the study by Oxman et al238. Imoto et al demonstrated that a lack 
of clinical response to the VZV skin test is an important predictive factor for 
PHN148. It is possible that the boost in clinical response to VZV skin test after 
vaccination may be correlated with a reduction in incidence of PHN. It is believed 
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that PHN results from viral and inflammatory damage to sensory nerves, so it is 
possible that enhanced cell-mediated immunity to VZV after vaccination protects 
the nerves from viral attack.  
The possibility that the first VZV skin test leads to a boosting of the response 
induced by the second skin test was considered. Ideally this study would have 
involved a control group that did not receive a vaccine, but there were an 
inadequate number of volunteers to achieve this. In parallel studies we showed 
that re-challenge of old volunteers with VZV skin test antigen did not significantly 
boost their original clinical scores. 
To consider the immunogenicity of the VZV skin test in comparison to live 
attenuated VZV vaccine, Takahashi et al measured the glycoprotein content of 
both preparations289. Their standard 100µl dose of VZV skin test contained 
0.37µg of glycoproteins, whereas the VZV vaccine (3.0 x 104 PFU per dose) 
contained 9.18µg of glycoproteins per dose. We used the same skin test but at a 
dose of 20µl, and Zostavax® consists of 1.94 x 104 PFU per dose and may be a 
different preparation to the vaccine used in the referenced study from 2003. 
Nevertheless, adjusting their calculated glycoprotein content to match the doses 
used in our study, the VZV skin test contains 0.07µg per dose, and Zostavax may 
contain approximately 5.94µg per dose – meaning that the vaccine contains 
approximately 80 times more glycoprotein than the skin test at the doses used in 
our study. This would suggest that the immunogenicity of the skin test is negligible 
in comparison to the vaccine. Furthermore, skin test antigen is soluble, a less 
immunogenic form than particulate antigen as contained in live VZV 
vaccine289,293.  
Several studies have investigated whether repeated injection of the VZV skin test 
leads to an enhancement of the VZV-specific cell-mediated and antibody immune 
response146,289,291,294–298. Guinea pigs immunised with live VZV vaccine 
developed VZV-specific humoral and skin test responses291,294. Heat-inactivated 
vaccine induced only a humoral response but no skin response291. Unimmunised 
guinea pigs were injected with 1ml of VZV skin test antigen subcutaneously 2-3 
times, and this led to a VZV-specific antibody response but no visible skin 
reaction291,294. Injection of 0.1ml VZV skin test via the intradermal route 5 times 
did not lead to an antibody or visible skin response291,294. These results 
141 
 
demonstrated an absence of boosting with repeated intradermal skin test 
injections.  
In a study of 60 humans Berger et al found the VZV skin test was unable to induce 
an antibody response in seronegative individuals or an antibody booster 
response in seropositive individuals298. Furthermore, volunteers who had a 
negative VZV-specific lymphocyte transformation test (a measure of CMI) 
remained negative 2 weeks after administration of the VZV skin test298.  
In a study by Somekh et al, none out of 4 VZV seronegative participants 
seroconverted 1 month after having a negative VZV skin test146. An antibody 
booster effect was observed in 6 out of 12 (50%) seropositive and skin test-
positive participants146. LaRussa et al performed VZV serology 2 to 3 weeks after 
initial screening with the VZV skin test, VZV serology and lymphocyte proliferation 
assay (LPA)296. They found that out of 7 individuals with no evidence of past VZV 
infection, none of them seroconverted after receiving the VZV skin test296. In 
contrast, 6 out of 17 (35%) individuals with evidence of immunity to VZV 
demonstrated an antibody booster effect after the VZV skin test296.  
In another study of 4 VZV-immune volunteers, the VZV skin test antigen boosted 
the level of VZV-specific antibody after 2 weeks, with minimal further increase 
after vaccination with Oka VZV vaccine295. In this study, the VZV skin test was 
injected 5 times over 7 months, but the VZV vaccine was administered after the 
first skin test, complicating the interpretation of the effect of the skin test only. In 
any case, the clinical response fluctuated between the 4 tests administered 
during the 6-month post-vaccine period in an apparently sporadic manner. In total 
there were 7 sequential decreases and 5 sequential increases among the 4 
volunteers. No consistent boosting effect was seen.  
There is one study by Duchateau et al, involving 30 individuals over the age of 
70, which concluded that repeated VZV skin tests led to a boosting of the skin 
immune response after 4 weeks297.   
These studies investigating the immunogenicity of the VZV skin test are limited 
in number, making interpretation of the results difficult. Additionally, they 
predominantly focus on the humoral response to the VZV skin test while our study 
focused on the skin test response. Bearing in mind the limitations regarding the 
available published data, it appears that in individuals with no history of VZV 
infection, the skin test does not induce detectable VZV-specific humoral or cell-
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mediated responses. In VZV-immune volunteers however, the VZV skin test 
appears to boost the humoral response, but the effect on further skin test 
responses remains unclear289. With the exception of the one study by Duchateau 
et al297, it is of the opinion of the authors of the studies investigating this question 
that the VZV skin test has low immunogenic potential and unlikely to lead to a 
boosting of the cell-mediated response291,294–296. All but one of these studies are 
authored by researchers who were involved in the original development of the 
VZV skin test in Japan in the late 1970s and early 1980s291,294,295.  
The effect of vaccination on DTH responses to other pathogens has been 
investigated in ageing individuals previously. Tetanus toxoid has been shown to 
be an effective recall antigen for evaluating CMI in the skin, with response rates 
in young healthy individuals ranging from 79% to 90% 299–301. However, in an 
older population (mean age 54) the response rate was only 45.5% 302, reflecting 
the diminishment of CMI with increased age. French et al identified 27 individuals 
with an approximate mean age of 60 years who failed to respond to intradermal 
challenge with a 1:10 dilution of tetanus toxoid302. These volunteers were 
randomised to either receive 0.5ml tetanus toxoid vaccine (n=14) or no 
intervention (n=13). 10 weeks later the volunteers were retested with intradermal 
tetanus toxoid, and surprisingly none of the vaccinated group, or unvaccinated 
group, responded.  
A reason for the variance of this study’s findings with our work may be the 
different formulations of the vaccines used. Tetanus toxoid contains an inactive 
form of Clostridium tetani-derived toxin and its primary aim is to stimulate an 
antigen-specific antibody response, whereas Zostavax® contains live attenuated 
virus designed to boost CMI. It therefore appears that the latter vaccine is more 
potent at enhancing a DTH response than the tetanus vaccine. The difference in 
response between both vaccines highlights the problems regarding the efficacy 
of vaccination in the older population.  
4.4.5 Enhanced cellular responses to VZV skin challenge after 
vaccination 
There was a boost in the CD4+ and CD8+ T cell responses (greater numbers and 
proliferation) to VZV skin challenge after vaccination. The enhanced responses 
were detectable at both time-points measured in the vaccinated – Days 3 and 7. 
As discussed in the previous section, the clinical response to VZV antigen 
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challenge, measured at Day 3, was also boosted in the vaccinated group. 
Previous work by our group has shown that the Day 3 clinical score is positively 
correlated with the mean number of CD4+ T cells per perivascular infiltrate142. 
Young individuals have more robust clinical and cellular responses to VZV 
challenge than the old135,252, so vaccination of the old appeared to partially restore 
impaired VZV-specific cutaneous immune responses to the more robust 
responses associated with the young.  
Previous work using skin suction blisters in robust responders to VZV skin 
challenge showed that approximately 5% of infiltrating CD4+ T cells at the site of 
VZV challenge at Day 7 were antigen-specific, measured both by IFN-γ 
production after in vitro VZV-restimulation and also by tetramer staining142. In a 
study of skin immune responses to the Mantoux test, the proportion of IFN-γ-
producing antigen-specific CD4+ T cells accumulating at the challenge site was 
significantly greater in the young than the old135. Presumably therefore, the 
proportion of VZV-specific CD4+ T cells accumulating at the site of VZV challenge 
would be higher in the vaccinated than the unvaccinated old, and further 
experiments should be performed to verify this is the case.  
In Section 4.3.2 it was shown that the frequency of VZV-specific CD4+ T cells 
after vaccination remained the same in unchallenged skin but was boosted in the 
blood. Therefore, if indeed a greater proportion of VZV-specific CD4+ T cells at 
the site of VZV challenge were confirmed in the vaccinated, the origin of these 
cells should be considered. After pathogen re-encounter, tissue resident DCs can 
directly present antigen to antigen-specific TRM in the skin, leading to proliferation 
and effector function by these latter cells in situ111,303. Therefore, it is conceivable 
that after vaccination, activation and proliferation of VZV-specific CD4+ skin TRM 
occurs more rapidly than before vaccination.  
Another explanation, consistent with the data generated in this project, is that the 
higher frequency of VZV-specific CD4+ T cells in the circulation after vaccination 
leads to enhanced recruitment of these cells into the skin. As the predominant 
memory phenotype of circulating VZV-specific CD4+ T cells is the TCM (CD27+ 
CD45RA-) subset267, these cells have access to the LNs, where they could 
encounter cognate antigen transported from the skin, become activated, and 
generate effector T cells that home to the skin to participate in the immune 
response. A greater initial frequency of VZV-specific CD4+ T cells in the 
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circulation would presumably lead to a larger pool of expanded effector T cells 
after antigen challenge, which would then home to the challenged skin site.  
It has also been shown that circulating memory T cells can be recalled to infected 
tissue in a lymph-node-independent manner119,304. After recall antigen challenge, 
successful initiation of inflammation and activation of the local endothelium leads 
to significant recruitment of T cells from the circulation to the skin111. This 
predominantly occurs in a non-specific manner, but some antigen-specific T cells 
are also recruited in this way without encountering antigen in the lymph 
nodes111,304. Furthermore, these antigen-specific T cells proliferate in infected 
tissue preferentially to non-specific T cells, leading to a pool of expanded specific 
T cells at the site of infection142,304.  
The association of reduced endothelial expression of E-selectin with diminished 
T cell infiltration in old humans during a DTH response to VZV antigen suggests 
that lymphocyte recruitment from the circulation is essential for amplification of 
the cutaneous immune response143. Studies in rodents have shown that inhibition 
of leukocyte trafficking to the skin by separate blockade of E-selectin305, E-
selectin ligands306, LFA-1 and VLA-4307, and CCR4308 respectively led to impaired 
T cell accumulation in cutaneous hypersensitivity models. This provides further 
evidence for the importance of lymphocyte recruitment from the circulation to 
participate in the DTH response. Therefore, the association between the 
Zostavax®-induced boost in frequency of circulating VZV-specific CD4+ T cells 
and boost in clinical response to VZV antigen appears to be a highly important 
one.   
Proposed mechanism of action for Zostavax®  
Combining the findings of Zostavax®-induced enhanced clinical and cellular 
responses after VZV antigen challenge in the old, a proposed mechanism of 
action for the vaccine is proposed. In the old, there was an excessive and 
dysregulated non-specific inflammatory response at 6 hours in VZV-challenged 
(and saline-challenged) skin, and this was associated with reduced clinical DTH 
responses to VZV143. At 24 hours and beyond, there was impaired endothelial 
activation and DC accumulation143, suggesting that early (6h) excessive 
inflammation prevents subsequent leukocyte recruitment via the endothelium. To 
correct for these defects in the old, it is now proposed that the vaccine leads to 
an early enhancement of the cytokine response from skin resident VZV-specific 
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T cells. IFN-γ secreted by these T cells activates local macrophages, which 
produce TNF-α in a regulated manner, in turn activating local endothelium. 
Memory T cells are thus recruited from the circulation in a non-specific manner, 
but some of these will include VZV-specific T cells, which are more numerous in 
circulation due to the boosting effect of the vaccine. VZV-specific T cells 
infiltrating the site of antigen challenge proliferate and produce cytokines, further 
amplifying the response. Within days, VZV-specific T cells are also recruited from 
the draining lymph node and generate larger clones of effector T cells due to 
increased baseline numbers following vaccination. These effector T cells home 
to the site of antigen challenge and magnify the immune response yet further.   
The role of Tregs in the DTH response after vaccination 
Interestingly, the percentage of Tregs in the vaccinated was significantly lower 
than for the unvaccinated at both Days 3 and 7. This may be explained by the 
significant accumulation of effector CD4+ T cells and the lack of an increase in 
absolute Treg numbers in the vaccinated (although there was a trend to increased 
Treg proliferation in the vaccinated). 
It may be that the absolute number of Tregs within perivascular infiltrates is a 
reflection of the need to terminate the immune response once foreign antigen has 
been eliminated. In the young, as the skin immune response is more robust with 
more effector T cells present, more Tregs are required to subdue the response 
once it has peaked. Conversely, in the old, fewer absolute numbers of Tregs are 
needed to terminate the more attenuated immune response. With regards to the 
vaccinated individuals, the median Treg number did lie between the medians for 
the young and for the unvaccinated, and so this hypothesis may still hold true; 
however, the differences observed were not large enough to be significant. 
Perhaps more n numbers would elucidate this further.  
Tregs are thought to exert their suppressive function at least in part via cell-cell 
contact13, and for this reason the proportion of Tregs out of the total CD4+ T cell 
population should be considered when analysing the inhibitory influence of this 
cell type on the immune response. The lower percentage of Tregs in the 
vaccinated compared to the unvaccinated may be due to one of two separate 
mechanisms. Firstly, and more likely, the vaccine directly leads to a marked 
accumulation of effector T cells but not Tregs, thereby lowering the observed Treg 
percentage within perivascular infiltrates. Secondly, after vaccination it is possible 
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that via an unknown mechanism perivascular Tregs are prevented from exerting 
their inhibitory effects, thereby allowing larger numbers of effector T cells to 
accumulate, which secondarily leads to a drop in the Treg percentage.  
4.4.6 The transcriptional response to vaccination 
In work performed by Akbar group members, global gene expression analyses 
were performed to identify genes that may be associated with the improved 
response to VZV antigen challenge following vaccination. In each donor, 3mm 
skin biopsies were taken from the site of VZV antigen challenge (at 6h and 72h 
post-injection), both pre- and post-vaccination. The gene expression was 
compared to biopsies taken from normal, un-injected skin. In a previous study we 
showed that in normal steady state skin, there was little difference in gene 
expression in young or old age groups267. At 6 hours post-VZV antigen challenge 
there was a relatively minor difference in the numbers of differentially expressed 
genes (DEG) before and after vaccination (Figure 4-10A & B). Genes associated 
with migration (e.g. SELL, CXCL10, SELE, ICAM1, IL-8) were amongst the most 
upregulated genes in both groups (pre- and post-vaccine) as compared to normal 
skin although the expression was relatively higher post-vaccination. 
At 72h after VZV antigen challenge, vaccination led to a strong transcriptional 
response that was considerably stronger than the response prior to vaccination 
(>5000 DEG post-vaccine (false discovery rate, FDR<0.05 and fold-change>2); 
1711 DEG pre-vaccine, Figure 4-10A & B). The top 30 significantly DEG following 
vaccination are shown in Figure 4-11, indicating that the same genes were 
upregulated after intradermal VZV challenge but to a significantly higher extent 
following vaccination. Genes associated with migration (CXCL10, CXCL9, SELL, 
CCL5, ITGAL), T cell and DC activation including ITGAX (which encodes CD11c), 
CD2, CD28, CD69, EOMES, ICOS and STAT1 were more highly expressed in 
the skin at 72h after VZV antigen challenge in vaccinated compared to 
unvaccinated individuals (Figure 4-11). This supports the histological 
observations showing an increase in T cell accumulation in the skin after 
vaccination (Figure 4-7B and Figure 4-8B).  
These data also showed marked upregulation of genes involved in signaling 
pathways associated with innate immune responses, inflammation, immune 
response to viruses and inflammatory cytokine signaling (type I IFN, TNFα and 
IFN-γ) in vaccinated old individuals. Interestingly, many genes associated with 
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the activity of CD8+ cytotoxic T cells including GZMB, GNLY, GZMA and CD8A 
were highly induced in vaccinated individuals, coinciding with the significantly 
increased CD8+ T cell proliferation at the site of intradermal VZV challenge at 72 
hours (Figure 4-8C). This indicates that Zostavax vaccination enhances the 
activity of VZV-specific CD8+ T cells in the skin. 
In a previous study, whereas circulating CD4+ T cell responses were observed in 
response to multiple VZV antigens, only ORF-9 induced significant CD8+ T cell 
responses247. Zostavax® vaccination led to an increase in the frequency of ORF-
9-specific CD8+ T cells producing IFN-γ by 2.8-fold and TNF-α by 4.9-fold247. 
Additionally, a 20-fold increase in the frequency of IFN-γ+ perforin+ CD8+ T cells 
was observed following vaccination in the study247. VZV vaccination therefore 
appears to induce a robust CD8+ T cell response in the circulation, and ORF-9 
appears to be the key VZV antigen that mediates this response. The enhanced 
CD8+ T cell signature in the skin after VZV challenge in vaccine recipients in our 
study indicates that it will be important to determine the specificity of these cells 
and their role in the protection against shingles. 
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Figure 4-10 Transcriptomic analysis of VZV-challenged skin before and after vaccination 
Skin biopsies were taken at the site of VZV challenge (n=9 pre-vaccine, 7 post-vaccine) and from 
normal skin in an additional group of volunteers (n=6). Total skin RNA was isolated, amplified and 
hybridized to Affymetrix Human Genome U133 plus 2.0 arrays 
A:  Heatmap showing the relative expression of differentially expressed genes between normal 
skin (left panel) and VZV-injected skin pre-vaccination (middle panel) and post-vaccination (right 
panel) at Fold change>2 and FDR>0.05.   
B:  Venn diagrams showing numbers of DEG at 6h (top) and 72h (bottom) following VZV antigen 
challenge, compared to normal skin. Up-regulated genes are shown in red, down-regulated genes 
in blue. 
Akbar group data 
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Figure 4-11 Genes upregulated in the skin after vaccination 
Table showing the top 30 genes upregulated at 72 hours post-VZV challenge pre- and post-
vaccination. 
Akbar group data 
 
 
 
 
  
150 
 
4.4.7 Zostavax® mechanisms and VZV-specific TRM 
If VZV reactivates and is not contained within the ganglion, virus is able to migrate 
to the skin, where it will encounter a dense network of resident immune cells, 
including virus-specific T cells. In an Israeli population-based study, the incidence 
of shingles in 25-34 year-olds (n=291,314) was 2.35 per 1000 person-years, 
compared to 10.23 per 100 person-years in 65-74 year-olds (n=83,511)309. This 
suggests that, although far more common in the old, shingles is not a rare disease 
even in healthy young individuals. Therefore, once in the skin, reactivated VZV 
appears at times to be able to overcome host defence by VZV-specific T cells.  
In the skin, VZV suppresses innate responses, including disruption of IFN-
mediated responses in infected cells, and activation of STAT3 which upregulates 
survivin, a protein that is necessary to support VZV infection177. Thus the 
inhibition of innate immune responses in the skin by VZV may lead to a failure to 
adequately activate skin resident VZV-specific T cells, and these combined 
events may impede VZV-specific T cell recruitment from the circulation, thereby 
permitting clinical disease to develop310. In the old, impairment of innate 
responses in the skin and of VZV-specific T cell immunity in the blood is therefore 
likely to increase the risk of shingles. 
Zostavax® may provide immune protection by:  
1. Enhancing the responsiveness of skin resident VZV-specific T cells, to 
compensate for their impaired activation by innate cells 
2. Boosting circulating VZV-specific T cells, enhancing recruitment to the skin 
and ganglia during VZV reactivation 
As argued by Kupper, robust immune protection against secondary infection in 
peripheral tissue relies on the successful integration of rapid responses by TRM 
that act against pathogens invading through epithelial surfaces, as well as a 
secondary wave of circulating TCM that can expand massively to provide 
reinforcements286. There is now evidence that Zostavax® boosts the latter; 
however, the extent to which it may boost skin TRM responsiveness remains 
uncertain and requires further investigation. Perhaps the lack of evidence for a 
boost in VZV-specific TRM frequency in this work may partially explain why the 
vaccine is only 37.6% effective in the over-70 population238. The accumulating 
evidence for enhanced immune protection against repeated infection by 
peripheral tissue TRM suggests that vaccines designed to boost this particular cell 
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population at the initial site of infection may well improve the likelihood of optimal 
immune protection31,286,311–314.   
As an example, Stary et al. found that mucosal vaccination of mice against genital 
Chlamydia trachomatis (Ct) infection led to rapid seeding of the uterine mucosa 
with TRM, and optimal clearance of subsequent infection with Ct required both 
local TRM as well as infection-recruited circulating memory T cells315. Similarly, 
Iijima and Iwasaki found that intravaginal immunisation of mice with HSV-2 virus 
protected the host against lethal genital HSV-2 challenge, and CD4+ TRM were 
shown to be responsible for this protection316.  
A potentially effective vaccination strategy against shingles might be to enhance 
VZV-specific TRM in the ganglia as well as the skin. In support of this, Khan et al 
showed in the context of mouse HSV-1 infection that vaccination boosted the 
number of trigeminal ganglion-resident CD8+ T cells (and effector memory CD8+ 
T cells) and reduced recurrent ocular infection317. A key difference between latent 
human VZV and HSV infections, however, is that ganglion-resident antigen-
specific T cells have been shown to exist for the latter but not the former. 
Therefore, introduction of VZV-specific TRM to a niche which is unaccustomed to 
hosting such cells may not be possible.   
4.4.8 Age-related immune defects that may impair the efficacy of 
Zostavax® 
Zostavax® led to a broadening of the TCR repertoire in healthy adults246,248, and 
recruitment of both naïve and memory VZV-specific CD4+ T cells were involved 
in this response. In ageing individuals there is an abrupt decline in the naïve CD4+ 
T cell population after the age of 75 318, suggesting a reduced potential for this T 
cell subset to contribute to Zostavax®-induced immune responses in the old. 
Furthermore, in ageing individuals there is a contraction of the TCR repertoire 
accompanied by oligoclonal expansion of memory CD4+ T cells, particularly in 
the context of chronic viral infection such as CMV318–320, as well as a baseline 
reduction in the frequency of VZV-specific T cells186,241,267,321, and these factors 
are likely to impair the capacity of memory CD4+ T cells to expand following 
stimulation with Zostavax®. In support of this, although not conclusive evidence, 
there was a trend to a positive correlation between fold-change in VZV-specific T 
cell frequencies from Day 0 to Day 28 after vaccination and initial VZV-specific T 
cell frequency (p=0.12) 241.  
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Interestingly, the proliferative capacity of PBMCs in response to stimulation with 
a range of concentrations of VZV lysate in vitro was equivalent between young 
and old, except at the lowest concentration used, where proliferation was higher 
in the young267. This is perhaps a surprising finding given that ageing in general 
is associated with impaired T cell proliferation. Using a systems biology approach, 
Qi et al showed that the initial expansion of VZV-specific T cells after vaccination 
was relatively independent of age. By contrast, there was a greater loss of VZV-
specific T cells following peak expansion in the old, and this accounted for the 
impaired generation of long-lived VZV-specific memory T cells in the old241.  
Gene expression arrays of whole blood before and after vaccination identified a 
change in the expression of a small number of monocyte-related, but very few 
lymphocyte-related, genes. Pathways involving TNF-α and STAT3 appeared to 
influence the expansion and apoptosis of short-lived effector T cells, suggesting 
a central role for monocyte activation in the generation of T cell responses 
following vaccination241. Overall, however, there was far less expression of innate 
immune system genes with Zostavax® as compared to other live vaccines322,323.  
The only inflammatory cytokine that increased in serum after vaccination was 
resistin, a member of the adipokine family241. The observed increase in resistin 
after vaccination was associated with reduced T cell expansion241. Resistin has 
been shown to induce other pro-inflammatory cytokines including TNF-α and IL-
6324,325, although in the context of adaptive immunity it may have an inhibitory 
influence by expanding Tregs through the inhibition of DCs326.  
In addition to environmental factors, investigation of CD4+ T cell-specific factors 
demonstrated that genes regulating cell division and DNA repair mechanisms 
were associated with long-term survival of VZV-specific T cells following 
vaccination. There was a suggestion that these processes were more likely to be 
dysregulated in the old. Interestingly, molecules involved in apoptosis or markers 
of cellular senescence were not found to correlate with the attrition of effector T 
cells241.  
Overall, the data from the study by Qi et al highlighted the critical importance of 
the T cell contraction phase after peak expansion in determining long-lived VZV-
specific T cell memory, and this was particularly true for older individuals. 
Contraction was largely regulated by cell-intrinsic gene expression patterns, with 
serum cytokine levels of lesser importance to this phase of the immune 
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response241. These findings suggest that therapeutic targeting of the contraction 
phase may be a useful strategy for improving shingles vaccine responses in the 
old.  
Weinberg et al performed a study comparing the cellular immune responses to 
Zostavax® in young and old individuals327. Dual-function (expressing any 2 out 
of IL-2, IFN-γ, CD107a) VZV-specific CD4+ and CD8+ T cells increased at Day 7 
after vaccination in the young but not the old. At baseline, VZV-specific CD8+ T 
cells had higher expression of PD-1 and CD57 in the old compared to the young. 
It is possible the increased expression of these two markers was driven by 
chronic stimulation by VZV antigens, maybe during episodes of silent reactivation 
or exogenous exposure to overtly infected individuals. After vaccination there was 
a marginal increase in VZV-specific CD8+ CD57+ senescent T cells in the old. An 
increase in VZV-stimulated CD4+ CD69+ CD57+ PD-1+ and CD8+ CD69+ CD57+ 
PD-1+ T cells from baseline to post-vaccination was associated with concurrent 
decreased CD4+ VZV-memory and CD8+ effector responses, respectively, in 
older adults. Blocking PD-1 during ex vivo re-stimulation increased CD4+ and 
CD8+ T cell proliferation but not effector cytokine production, while TIM-3 
blockade did increase IFN-γ production in CD8+ T cells. This study suggested 
that increased senescent (CD57+) and exhausted (PD-1+) VZV-specific T cells 
may contribute to poor vaccination-induced effector responses in the old327, and 
targeting exhaustion and senescence pathways may therefore be useful 
strategies to boost vaccination responses in this age group.  
Poly-functional CD4+ T cells make up the majority of VZV-specific T cells and 
these cells produce the largest amount of pro-inflammatory cytokines on a per-
cell basis, before and after vaccination247. Additionally, after vaccination ORF-9-
specific poly-functional CD8+ T cells produced ~10-fold higher levels of pro-
inflammatory cytokines compared to mono-functional CD8+ T cells247.  
Poly-functional VZV-specific CD4+ T cells (IL-2+, IFN-γ+, CD107a+) but not CD8+ 
T cells appeared to be increased in frequency in the old compared to the 
young327. Van Epps et al studied the poly-functionality of CD4+ and CD8+ T cells 
by differentiation subset, in response to stimulation with SEB, and found an 
increase in poly-functional effector memory CD8+ (but not CD4+) T cells in the 
old. This was accompanied by a decrease in poly-functional central memory 
CD4+ and CD8+ T cells in the old328. Other studies have shown that the poly-
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functionality of memory CD8+ T cells elicited by acute West Nile virus or chronic 
CMV or EBV infection was not impaired by old age329,330. Furthermore, Riddell et 
al demonstrated that poly-functional CMV-specific CD4+ T cells are not restricted 
by ageing331. Overall, therefore, it appears that T cell poly-functionality may 
remain preserved in old age, and loss of VZV-specific T cell poly-functionality 
does not appear to be responsible for impaired VZV vaccine responses in the old.  
4.4.9 Strategies to improve the efficacy of zoster vaccination in the 
old 
Evidence gathered from the studies mentioned in the previous section allows for 
the identification of possible specific targets for improving VZV vaccine 
responses. Starting with the loss of VZV-specific naïve cells during the ageing 
process, this is unlikely to be a reversible process in view of the permanent thymic 
atrophy that occurs in adolescence. Narrowing of the TCR repertoire occurs due 
to the combination of loss of naïve T cells and oligoclonal expansion of dominant 
clones, such as CMV-specific and EBV-specific T cells. Given that CMV and EBV 
are ubiquitous viruses in the environment, these chronic viral infections may not 
be preventable and TCR repertoire narrowing may therefore be unavoidable. 
There remains a theoretical potential to introduce widespread CMV and EBV 
vaccination, but this seems unrealistic and may not necessarily avoid the problem 
of oligoclonal expansion of memory T cells.  
It is unclear why the frequency of circulating VZV-specific T cells declines with 
age, but replenishing this population appears critical to the success of VZV 
vaccination. Currently Zostavax® is designed to be administered as a one-off 
dose to older adults and there are no recommendations in place for a booster 
programme – despite evidence that immune protection significantly declines and 
may not be protective by Year 8 post-vaccination244,332,333. Levin et al showed that 
>70-year-olds receiving a booster dose of Zostavax® 10 years after the first dose 
mounted a greater VZV-specific T cell response at 1 and 52 weeks, as compared 
with age-matched controls receiving their first dose only334. This demonstrates 
that a booster strategy would be a useful means of enhancing VZV vaccination 
efficacy.  
Another strategy might be to increase the dose of the vaccine from 19,400 
plaque-forming units (PFU). Doses up to 67,000 PFU have been given, and while 
there was no clear evidence of an immediate boost in T cell response189, some 
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evidence exists for larger doses giving rise to a delayed boost in VZV-specific T 
cell memory335.  
The contraction following peak expansion of VZV-specific effector T cells after 
Zostavax® appears to be a critical factor that impairs the induction of long-term 
immune memory in the older population241. Therefore, investigation into the 
factors that contribute to effector T cell contraction in the old may yield potential 
therapeutic targets to boost vaccination efficacy.  
Fang et al found that CD39, a cell membrane ATPase, was more frequently 
induced on activated CD4+ T cells in the old than the young. CD39+ CD4+ effector 
T cells were highly differentiated, with greater expression of Tbet, IFN-γ, IL-4 and 
IL-17. These cells were unlikely to be Tregs as Foxp3 expression was not raised 
and there was no association with suppressive activity. CD39+ T cells were 
metabolically stressed, with increased phosphorylation of AMPK, reduced 
cytoplasmic ATP, and dysfunctional mitochondria. Furthermore, CD39+ T cells 
were highly prone to apoptosis, and this was shown to be a consequence of the 
ATPase activity of the CD39 molecule336.     
Older individuals over 50 years of age with genetically determined low CD39 
expression had a trend to a greater fold increase in VZV-specific T cells 4 weeks 
after Zostavax® than those with a high CD39 genotype (p=0.097). Similar, but 
this time significant, findings were obtained with influenza-specific T cells after 
administration of 2 out of 3 strains of influenza vaccine in a group of over-60-year-
olds. This suggests that CD39 impairs the long-term survival of virus-specific T 
cells after vaccination in ageing individuals. Interestingly, in the context of chronic 
viral infection, high CD39 genotype was associated with a greater proportion of 
TEMRA cells in CMV-positive individuals over 60 years of age336. The findings from 
this study suggest that CD39 inhibitors may enhance vaccine responses to 
Zostavax®.  
Increased PD-1 expression on circulating CD4+ and CD8+ T cells after Zostavax® 
correlated with impaired VZV-specific CD4+ T cell memory and CD8+ effector T 
cell responses, and blocking PD-1 boosted T cell proliferation327. In this work, 
increased PD-1 expression was also seen on CD4+ TRM in the skin after 
Zostavax® (Section 4.4.3), and so anti-PD1 therapy may be a potential strategy 
for boosting immunity with the shingles vaccination.  
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Another pathway that could potentially be manipulated to enhance the survival of 
effector T cells in the old is the type I interferon signalling pathway. This pathway 
has been shown to be impaired in activated naïve CD4+ T cells during ageing, 
due to recruitment of SHP-1 to the IFN receptor signalling complex. This results 
in the loss of ability to produce IL-2, thereby impairing survival and the generation 
of antigen-specific memory CD4+ T cells226,337. Restoration of CD4+ T cell 
responsiveness to type I IFN in the old may therefore promote enhanced VZV-
specific memory CD4+ T cell formation following Zostavax® administration.  
Several gene modules expressed by activated CD4+ T cells on Days 8 and 14 
after Zostavax® correlated with increased frequency of VZV-specific T cells on 
Day 28. These modules were functionally related to cell cycle control or DNA 
repair241. Modulation of cell cycle pathways or DNA repair mechanisms may 
therefore facilitate the survival of VZV-specific T cells after vaccination, and such 
strategies should be investigated further.  
4.4.10 Shingrix®: A new recombinant subunit shingles vaccine 
A phase 3 clinical trial investigating the efficacy of a novel recombinant subunit 
shingles vaccine was recently completed338. The vaccine consists of VZV 
glycoprotein E (gE) and the AS01B adjuvant system, and is known as the HZ/su 
vaccine or Shingrix®. It is now licensed for use in the USA. VZV gE was selected 
as it is the most abundant glycoprotein on infected cells, is essential for viral 
replication and cell-cell spread, and is a primary target for VZV-specific antibody 
and T cell responses338–340. The AS01B adjuvant system was chosen as it 
promotes robust humoral and CD4+ T cell immune responses against 
recombinant proteins338,341–343. The vaccine is administered via the intramuscular 
route and 2 doses are given, 2 months apart.  
This landmark clinical trial recruited 15411 participants to receive Shingrix® or 
placebo, and had a remarkable overall efficacy of 97.6% in the over 60s during a 
3.2-year period338. This compared highly favourably with Zostavax®, which had 
a 51.3% efficacy in the over 60s over 3.1 years240. Critically, Shingrix® did not 
lose efficacy with increased participant age, with 96.6% efficacy in the 50-59 year-
old age group, 97.4% in the 60-69s and 97.9% in the over 70s338. In comparison, 
the efficacy of Zostavax® declined sharply with increased age, with efficacy rates 
of 69.8%, 63.9% and 37.6% for the same corresponding age groups238.      
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The 2-dose as opposed to 1-dose schedule was shown to be an important factor 
in the immunogenicity of Shingrix®, as there was a 3-fold increase in the 
generation of gE-specific CD4+ T cells after 2 doses compared with a single 
dose343. The adjuvanted vaccine induced substantially higher immune responses 
compared to the unadjuvanted formulation, highlighting the importance of AS01B 
343.  
Immunological investigation into the effects of Shingrix® demonstrated robust 
CD4+ but not CD8+ T cell responses in the over 60s 343. This supports previous 
data that CD4+ T cells dominate the immune response to VZV340,344–346. The peak 
frequency of gE-specific CD4+ T cells occurred at 3 months (i.e. 1 month after the 
second dose), and there was an approximately 50% decline from 3 to 12 
months343,347. The drop in this period was the largest seen over the 6-year follow-
up period. gE-specific CD4+ T cell frequency continued to decline until 4 years 
after which a plateau was reached347. At 6 years the gE-specific CD4+ T cell 
frequency was still 4-fold greater than pre-vaccination levels347.  
Similarly, peak anti-gE antibody levels were reached at 3 months, declining 
sharply by 12 months, and reaching a plateau by 24 months347. At month 72 the 
level of anti-gE antibody was 7.3 times higher than pre-vaccination levels347. The 
duration of immune responses to Shingrix® over at least several years 
corresponds to a clinical study demonstrating no significant loss of protection 
against shingles for 4 years post-vaccination348. A recent study that continued to 
follow up a subgroup of the original Shingrix® study participants demonstrated 
the frequency of gE-specific CD4+ T cells and concentration of gE-specific 
antibody remained higher at 9 years compared to pre-vaccine levels regardless 
of age group; statistical modelling predicted immune responses would remain 
above baseline for up to 15 years after vaccination349. This compares favourably 
with Zostavax®, where immune responses above baseline could only be 
demonstrated for 8 years after vaccination244.  
Importantly, the T cell and antibody responses to Shingrix® were comparable 
between 60-69 year-olds and over-70s at all time points studied over 6 years347. 
These remarkable findings suggest that this vaccine in particular is able to 
overcome mechanisms of immunosenescence that dampen VZV-specific T cell 
responses in older age. The maintenance of immunogenicity and efficacy of 
Shingrix® in older adults confers a vital advantage over Zostavax®, as it is the 
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oldest people in society who are most vulnerable to shingles and its 
complications. A study directly comparing the immunogenicity of both vaccines is 
currently underway (NCT02114333) and its results are keenly awaited. A 
secondary advantage of Shingrix® is its suitability in immunocompromised 
patients in whom live vaccines are contra-indicated, such as organ transplant 
recipients, HIV patients, and those taking immunosuppressant drugs for 
inflammatory conditions350. 
The formidable immunogenicity of Shingrix® raises interest in the properties of 
its adjuvant AS01B, which appears to activate both the innate and adaptive 
immune systems in a coordinated manner351. It is a liposome-based adjuvant that 
contains 2 immunostimulants: 3-O-desacyl–monophosphoryl lipid A (MPL) and 
QS-21. MPL is the detoxified derivative of lipopolysaccharide from Salmonella 
minnesota. It directly stimulates APCs via activation of TLR4, enhancing the 
production of cytokines and co-stimulatory molecules. QS-21 is a saponin 
molecule extracted from the bark of the South American tree Quillaja saponaria 
Molina. It promotes antigen-specific antibody responses but also stimulates 
cytotoxic CD8+ T cells, primarily in animal studies352,353.  
Animal studies showed that after intramuscular injection, AS01 rapidly induced 
local cytokine production and innate immune cell recruitment to the muscle site. 
AS01 and vaccine antigen were rapidly cleared from the muscle, ruling out a 
depot effect, and were detectable in the draining LN within 30 minutes. In the LN 
AS01 increased the recruitment of monocytes and DCs, and enhanced their 
expression of the co-stimulatory molecules CD86 and CD40. Activated DCs in 
the LN were efficient and necessary for the effective priming of CD4+ T cells. MSL 
and QS-21 acted synergistically to produce the highest antigen-specific 
response. Interestingly, AS01 induced production of IFN-γ by NK cells within 4 
hours, and this appeared to be essential for the activation of DCs and 
development of Th1-type immunity351–353. 
The unique features separating AS01 from other adjuvants is the lack of depot 
effect, the robust increase of a diverse population of activated APCs, and the 
effective synergy between the two active constituents. The consequences are a 
potent early induction of the innate immune system, leading to strong activation 
of antigen-specific Th1 CD4+ T cells and B cells capable of producing specific 
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antibodies351,353. Shingrix® serves as a model for highly effective vaccine design 
aimed at the ageing population.  
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5 BLOCKING P38 MAPK TO ENHANCE VZV-SPECIFIC 
IMMUNE RESPONSES IN AGEING SKIN 
5.1 Chapter Introduction 
We have seen that antigen-specific immunity declines in the skin of older people, 
and this may be due in part to an inhibitory microenvironment in this peripheral 
tissue in the old. We have also examined how the vaccine Zostavax® enhances 
the secondary immune response to VZV in the skin in a proportion of older 
people, although the clinical efficacy and immunological response to the vaccine 
decline significantly in the very old238,239. It is clear that vaccination strategies are 
currently suboptimal, highlighting the importance of investigating other 
approaches to boosting immunity in the old.  
In this chapter we investigate a novel strategy to boost cutaneous immunity in the 
old by the therapeutic manipulation of the p38 mitogen-activated protein kinase 
(p38 MAPK) signalling pathway. This pathway was chosen on the basis of 
observations that human senescent T cells demonstrate spontaneous, increased 
activity of p38 MAPK, and blockade of this pathway restored proliferative potential 
and telomerase activity in these cells55–57.  
Interestingly, injection of a physiological 0.9% saline solution led to an 
overexpression in the skin of multiple pro-inflammatory genes and genes 
associated with myeloid cell activation in the old at 6 hours (compared to normal 
skin) but not in the young (Figure 5-1A). Pathway analysis found a significant 
association between these genes and predicted p38 MAPK activation. 24 of the 
top 30 overexpressed genes are induced by, or regulators of, the p38 MAPK 
signalling pathway (Figure 5-1B, asterisks). Many of the overexpressed genes at 
6 hours after saline injection in the old were similar to the induced genes after 
VZV antigen challenge at the same time point, suggesting that the early 
transcriptional response to VZV in the old comprises a significant non-specific 
inflammatory component that may impair the antigen-specific immune 
response143. 
Additionally, the expression of 384 genes regarded as positive regulators of the 
immune response was evaluated in saline-injected skin at 6 hours in young and 
old individuals, and was used to generate an “inflammatory index” score for each 
person. When the inflammatory index was plotted against the clinical score in 
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response to VZV antigen (Figure 5-1C), a highly significant inverse correlation 
was found (p=0.0007)143.  
Skin biopsies taken from the site of saline-injected skin at 6 hours demonstrated 
an early transient influx of mononuclear phagocytes into old but not young skin, 
and these cells were no longer present at 24 hours. A similar transient increase 
was also observed in VZV-injected skin at 6 but not 24 hours143.  
In summary from these experiments it appears that excessive sterile inflammation 
at an early time point in the old, associated with heightened activation of the p38 
MAPK signalling pathway, is detrimental to generating a robust immune response 
to VZV antigen. This inflammatory response is likely to be driven by cells of the 
monocyte/macrophage lineage.  
We therefore hypothesised that inhibition of p38 MAPK in the old would boost the 
antigen-specific immune response in the skin. To test this hypothesis, we 
measured the clinical and cellular response to VZV antigen in old individuals 
before and after treatment with the oral p38 MAPK inhibitor losmapimod for 4 
days, in an experimental medicine trial. These individuals were selected for 
having a previously known poor clinical response to the VZV antigen.  
5.2 Aims & Objectives 
The aim of this chapter was to investigate whether pre-treatment of old individuals 
with losmapimod leads to an enhancement in the VZV-specific immune response 
in the skin. 
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Figure 5-1  Comparison of global gene expression between normal, saline-injected, and 
VZV-injected skin  
A: Heat map showing relative expression of DEGs (fold change > 2 and false discovery rate > 
0.05) between normal skin, saline-injected skin and VZV-injected skin at 6 hours, in young (left) 
and old (right) individuals.  
B: A table of the top 30 upregulated genes at 6 hours in saline-injected skin from old and young 
individuals compared with normal skin. Genes not reaching statistical significance are indicated 
in blue. Asterisks indicate genes related to p38 MAP kinase signalling. 
C: An inflammatory index was calculated for each individual and plotted against VZV clinical 
scores at 72 hours (young n=6; old n=10). Regression line, R value and significance level are 
shown. 
Akbar group data  
A B 
C 
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5.3 Results 
5.3.1 Losmapimod boosts the clinical response to VZV skin 
challenge 
18 old volunteers (8 male and 10 female subjects; age range 65-77 years; median 
age, 69 years) were challenged with VZV skin test antigen before and 
immediately after losmapimod treatment (data shown in Table 5-1).  
Donor Age Gender 
Clinical score 
Before losmapimod After losmapimod 
1 75 F 0 2 
2 76 F 1 3 
3 80 M 0 5 
4 76 F 1 4 
5 71 F 1 1 
6 68 M 1 0 
7 67 M 1 3 
8 79 M 0 1 
9 75 M 2 0 
10 70 F 3 4 
11 69 M 0 4 
12 77 F 1 1 
13 69 F 0 3 
14 67 M 0 0 
15 70 M 1 4 
16 70 F 2 3 
17 88 F 1 5 
18 67 M 3 3 
 
Table 5-1 Participant data for the losmapimod study 
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Overall there was a highly significant increase in the clinical score after treatment 
(mean score 2.6) compared to before treatment (mean score 1.0), as depicted in 
Figure 5-2 (p=0.0027).   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Effect of losmapimod on clinical response to VZV challenge 
A & B: Graphs showing clinical scores before and after losmapimod treatment (n=18). The paired 
t test was used for analysis and p value is shown.   
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5.3.2 The effect of losmapimod on the CD4+ T cell response to VZV 
skin challenge 
5.3.2.1 Losmapimod boosted the CD4+ T cell response in VZV-challenged 
skin  
In a subset of individuals (n=7) taking part in the study, the mean numbers of 
perivascular CD4+ T cells at Day 7 post-VZV skin challenge were enumerated by 
immunofluorescence microscopy, as described previously. Day 7 was chosen as 
this time point has previously been demonstrated to represent the peak in cellular 
response following VZV challenge. For analysis, individuals were grouped into 
those who had a good clinical response to VZV following treatment with 
losmapimod – defined by an increase in clinical score of at least 2 from baseline 
– and those who did not. These groups were termed “responders” and “non-
responders” respectively. Losmapimod treatment was associated with a trend to 
an increase in CD4+ T cell numbers in responders (Figure 5-3A; p=0.057), 
whereas there was no change in non-responders. 
As there was some variation in the numbers of CD4+ T cells pre-treatment 
between individuals, the mean increment in CD4+ T cells was calculated (Figure 
5-3B). The mean increment was significantly higher in responders (88.0) 
compared to non-responders (3.6); p=0.0067.   
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Figure 5-3 The effect of losmapimod on the CD4+ T cell response in VZV-challenged skin 
A: Before-after graph showing the effect of losmapimod on the mean number of CD4+ T cells per 
perivascular infiltrate, separated into individuals who had a clinical response to the drug 
(responders, n=3) and those who did not (non-responders, n=4). The paired t test was used to 
compare the groups. 
B: Graph showing the mean increment in CD4+ T cells per perivascular infiltrate, from before to 
after losmapimod treatment. Mean and standard deviations are shown; groups were compared 
using the unpaired t test.  
Significance levels are shown. 
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5.3.2.2 The effect of losmapimod on CD4+ T cell proliferation 
The percentage of CD4+ T cells staining positive for Ki67 was calculated to 
indicate the frequency of proliferating cells. There was a trend to increased 
proliferation after losmapimod in the responders (p=0.068), and there no change 
in the non-responders (Figure 5-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 Before-after graph showing the effect of losmapimod on CD4+ T cell 
proliferation 
Data were analysed using the paired t test; significance levels are shown.    
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5.3.2.3 The boost in the CD4+ T cell response in VZV-challenged skin is 
correlated with the increase in clinical score 
The mean increment of CD4+ T cells after losmapimod was plotted against the 
change in clinical score for the non-responders and responders combined (Figure 
5-5). Linear regression analysis demonstrated a significant positive correlation 
between the two variables (p=0.040).   
 
 
 
 
 
 
 
 
 
Figure 5-5 Change in clinical score plotted against mean increment in CD4+ T cells per 
infiltrate 
Linear regression analysis is displayed; significance value and R-squared value are shown. 
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5.3.3 The effect of losmapimod on the CD8+ T cell response to VZV 
skin challenge 
5.3.3.1 Losmapimod boosted the CD8+ T cell response in VZV-challenged 
skin  
The CD8+ T cell response at the site of VZV antigen challenge was examined 
before and after treatment with losmapimod. Losmapimod treatment was 
associated with an increase in mean CD8+ T cell numbers (Figure 5-6A; p=0.047) 
in the responder group and there was no change in the non-responders. The 
mean increment in CD8+ T cells after treatment was significantly higher in 
responders (mean 37.6) compared to non-responders (mean -0.7), shown in 
Figure 5-6B (p=0.0034).  
 
 
 
 
 
Figure 5-6 The effect of losmapimod on the CD8+ T cell response at the site of VZV 
antigen challenge 
A: Before-after graph showing the effect of losmapimod on the mean number of CD8+ T cells per 
perivascular infiltrate, separated into individuals who had a clinical response to the drug 
(responders, n=3) and those who did not (non-responders, n=4). The paired t test was used to 
compare the groups. 
B: Graph showing the mean increment in CD8+ T cells per perivascular infiltrate, from before to 
after losmapimod treatment. Mean and standard deviations are shown; groups were compared 
using the unpaired t test.  
Significance levels are shown.  
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5.3.3.2 Losmapimod boosted CD8+ T cell proliferation in VZV-challenged 
skin  
The percentage of CD8+ T cells that were proliferating was calculated (Figure 
5-7). There was significantly increased CD8+ T cell proliferation after losmapimod 
in the responders (p=0.0058), and there no change in the non-responders. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7 Before-after graph showing the effect of losmapimod on CD8+ T cell 
proliferation 
Data were analysed using the paired t test; significance levels are shown.  
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5.3.3.3 The boost in the CD8+ T cell response in VZV-challenged skin 
correlated with the increase in clinical score 
The mean increment of CD8+ T cells after losmapimod treatment was plotted 
against the change in clinical score for the non-responders and responders 
combined (Figure 5-8), and there was a significant positive correlation between 
the two (p=0.029). 
 
 
 
 
 
 
 
 
 
Figure 5-8 Change in clinical score plotted against mean increment in CD8+ T cells per 
infiltrate 
Linear regression analysis is displayed; significance value and R-squared value are shown.  
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5.4 Discussion 
Pre-treatment with losmapimod led to a significant increase in the clinical 
response to VZV antigen. Contemporaneous experiments performed by the 
Akbar group showed that losmapimod treatment led to a reduction in serum C-
reactive protein (CRP) levels and also decreased production of TNF-α, IL-6 and 
IL-8 by LPS-stimulated PBMCs. The increase in clinical score correlated with the 
reduction in CRP levels143. 
As shown in the Results section for this chapter, losmapimod treatment led to an 
enhanced CD4+ and CD8+ T cell response in the skin after VZV challenge, and 
these enhanced responses correlated with the boost in clinical score. There was 
also a significant increase in CD8+ T cell proliferation in VZV-challenged skin after 
losmapimod. Together, these experiments have confirmed that blocking p38 
MAPK-mediated inflammation in the old enabled the induction of a more robust 
VZV-specific immune response in the skin, at both the clinical and cellular level. 
The sample size presented here is small and will need to be extended to 
strengthen the findings. 
The findings in this study are supported by a previous study in ageing individuals 
that demonstrated higher levels of systemic inflammation as measured by serum 
CRP were associated with poorer clinical DTH responses to Candida antigen354. 
It is perhaps counterintuitive that excessive early inflammation in the old prevents 
amplification of the VZV-specific immune response. The conventional dogma is 
that a robust innate immune response is an essential precursor to a strong 
antigen-specific T cell response; this is particularly apparent in vaccinology where 
the development of potent adjuvants for inducing a profuse inflammatory reaction 
is considered desirable. It is now proposed that excessive and dysregulated 
inflammation prevents innate immune cells from efficiently activating local 
endothelium early in the immune response, thereby preventing recruitment of 
antigen-specific T cells to the VZV-challenged site. It is proposed that blocking 
p38 MAPK reduces this excessive skin inflammation, facilitating the amplification 
of innate immune signals into a coordinated antigen-specific response – although 
the underlying mechanism for the immunosuppressive effect of exaggerated 
inflammation in this setting remains unclear.  
Another previous study showed that pro-inflammatory macrophages from 
patients (mean age 69.9 years) with coronary artery disease, an ageing-related 
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disease, actively suppressed T cell activation and expansion, leading to impaired 
VZV-specific T cell immunity355. The mechanism involved was shown to be via 
the upregulation of PD-L1 on macrophages inhibiting PD-1+ T cells355. It is also 
notable that macrophage chemokines, including MCP-1, are prominent 
components of the SASP, providing further evidence that macrophages are key 
cells involved in the age-related dysregulation of inflammation64,356.  
Several studies of ageing individuals have demonstrated an association between 
higher baseline levels of inflammation and poorer vaccine responses, for the 
shingles357, influenza358,359, hepatitis B360 and yellow fever361 vaccines. One could 
hypothesise, therefore, that suppressing baseline inflammation in old individuals 
before administering a vaccine would heighten the immune response to that 
vaccine362.  
This hypothesis is supported by a study in which the concomitant administration 
of oral aspirin alongside influenza vaccination in ageing individuals led to 
increased specific antibody responses compared to placebo given with 
vaccination363. Aspirin inhibits prostaglandin and thromboxane production 
through its irreversible inactivation of cyclooxygenase (COX). It has the 
advantage of being cheap and easily available, but this early study from 1994 has 
not been followed up by further trials investigating the use of this drug as an oral 
adjuvant. The use of paracetamol (mechanism of action unknown but does have 
weak anti-COX activity) before influenza vaccination364,365, or indomethacin (COX 
inhibitor) before pneumococcal vaccination366, in ageing individuals was not 
found to confer any boost in vaccine response. Further studies investigating the 
use of oral non-steroidal anti-inflammatory drugs (NSAIDs) as adjuvants prior to 
vaccination of the elderly are warranted.  
In another study, inhibition of the mammalian target of rapamycin (mTOR) 
pathway using the mTOR inhibitor everolimus boosted the influenza vaccine 
response by 20% in elderly volunteers, and this was associated with a reduction 
in PD-1 expression by CD4+ and CD8+ T cells367. Aspirin363 and everolimus367 are 
therefore two potential anti-inflammatories that may boost vaccine responses in 
the ageing population, and it is possible that other drugs may also be used in this 
manner by targeting alternate inflammatory pathways.    
We have now seen that the p38 MAPK pathway is a key player in the 
dysregulated early inflammatory response in ageing skin, and this raises the 
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possibility of the same pathway being implicated in the inflammaging of other 
compartments including the circulation. Having demonstrated that blockade of 
this pathway using losmapimod can enhance an antigen-specific response in the 
skin, the question now remains whether the same p38 MAPK-blocking strategy 
can be used to stimulate vaccine responses in older people. It is likely this will be 
investigated in further work.   
Adjuvants are used in non-live vaccines to boost immune responses and can be 
highly effective in the right setting – an example includes the adjuvanted 
Shingrix® vaccine which was 91.3% effective in the over-70s338,348. Adjuvants 
modulate the innate immune response by providing danger signals to APCs and 
inducing a highly specialised inflammatory profile; this provides the conditions for 
generating a specific effector response that correlates with protection against the 
target disease362,368. In the context of inflammaging, it may be the case that 
inflammation induced by certain adjuvants may be counter-productive in some 
ageing individuals with a dysregulated early inflammatory response. A future 
strategy for vaccinating the elderly may be to establish a baseline inflammatory 
profile on an individual level, and tailor the adjuvant accordingly in a personalised 
approach.  
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6 GENERAL DISCUSSION 
A deeper understanding of the mechanisms of immunosenescence in peripheral 
tissues is required to facilitate the targeting of specific components of the immune 
system when designing immune therapies for older people. In this work, 
immunosenescence of human skin was investigated by focusing on the role of a 
central player in barrier and tissue immunity – the tissue resident memory T cell. 
Further to this, two distinct therapies targeting the immune system were 
administered separately to human volunteers – a vaccine and an anti-
inflammatory – to investigate whether they could enhance an in vivo antigen-
specific response in the skin, and to explore the immune mechanisms involved in 
their mode of action.  
6.1 Ageing and Cutaneous TRM 
Skin resident memory T cells, identified by their expression of CD69, did not 
diminish numerically in ageing skin. This is consistent with mice studies showing 
T cells in peripheral tissues remain numerically constant with increased age. TRM 
are known to be long-lived, and so in the skin it is presumed their numbers are 
maintained through low-level homeostatic proliferation and this is likely to be 
independent of antigen113. Mechanisms for survival of TRM are poorly understood, 
but some of the factors that have been suggested in promoting the long-term 
maintenance of TRM include local availability of the cytokines TGF-β, IL-15, TNF-
α and IL-33 83,102, as well as a metabolic switch to free fatty acid oxidation120 .  
There was no age-related accumulation of terminally differentiated TEMRA cells, 
and no loss in the ability to produce IL-2, providing some evidence that skin TRM 
in the old were not of a senescent phenotype. Despite the increased PD-1 
expression in skin CD4+ and CD8+ T cells in the old, these cells were fully 
functional in their ability to produce the pro-inflammatory cytokines IFN-γ and 
TNF-α, suggesting they were not functionally exhausted. Therefore, impaired skin 
immunity in the old does not appear to be due to defects occurring within the TRM 
population, and other immune cell types in human skin require characterisation 
and investigation for age-related defects.  
In addition to increased T cell PD-1 expression in the skin, the proportion of 
regulatory T cells in the skin was higher in the old, confirming the findings of 
previous work135, and contributes to the impression that the skin is a tolerogenic 
176 
 
environment in the old. With ageing there is a loss of lipids from the stratum 
corneum in the skin, leading to a deterioration in skin barrier function369. Healthy 
skin is exposed to a multitude of environmental, commensal and pathogenic 
antigens, and the loss of barrier function in the old may therefore increase the 
antigenic load encountered by the skin immune system. The age-related 
transition to a more tolerogenic environment may therefore be a necessary 
adaptation to prevent allergy, autoimmunity, and exaggerated immune responses 
to microbes – and/or a response to the excessive and dysregulated inflammation 
seen when challenging the skin with a sterile or pathogen-derived antigen 
challenge, as discussed below. PD-1 inhibition or Treg depletion may be 
strategies to consider for boosting ageing immunity in the skin; however, this 
approach may carry an unacceptable risk of inducing a hyper-inflammatory skin 
environment.  
6.2 Vaccination to boost cutaneous VZV-specific immunity – 
mechanisms  
Vaccination with the live attenuated shingles vaccine Zostavax® is known to 
boost circulating VZV-specific CD4+ T cells and VZV-specific antibody, but its 
immune effects on the skin – the site where shingles infection manifests – have 
not previously been studied. Here, a boost in VZV-specific CD4+ T cells in the 
blood was confirmed after vaccination, but no parallel increase in the skin was 
observed. On VZV skin antigen challenge, vaccinated individuals had an 
enhanced clinical response as well as improved local CD4+ and CD8+ T cell 
responses – demonstrating the vaccine’s ability to boost an in vivo VZV-specific 
immune response in the skin. Further work is required to confirm the vaccine’s 
mechanism of protection, but the findings here suggest that VZV-specific memory 
T cells in circulation are critical in mediating immune protection against VZV 
reactivation, perhaps more so than VZV-specific TRM in the skin. The absence of 
VZV-specific TRM from sensory nerve ganglia latently infected with VZV implies 
that TRM may not play an active role in suppressing VZV reactivation, and perhaps 
innate immune mechanisms take on this role. Dense CD4+ and CD8+ T cell 
infiltration of ganglia196 and elevated circulating VZV-specific CD4+ T cells218 
during acute shingles infection raises the possibility that VZV-specific T cells 
recruited from the blood are required for the control of already-reactivated VZV in 
the ganglia.  
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Zostavax® loses its ability to boost VZV-specific immunity in the very old, 
however, and the accumulation of defects in circulating VZV-specific memory T 
cells may account for this. These include the age-related reduction in the 
frequency of circulating VZV-specific CD4+ T cells186,321, narrowing of the TCR 
repertoire, increased PD-1 and CD57 expression on VZV-specific CD8+ T cells327, 
and loss of VZV-specific CD4+ T cells following peak expansion after vaccination 
with an impairment in long-lived memory responses241. Contrastingly, Shingrix® 
is highly effective in older adults, and must therefore have the ability to circumvent 
some of these defects.   
As there is now copious evidence for the protective role of TRM in barrier tissues, 
some investigators have focused on using vaccines to enhance TRM 
formation315,370. Mathematical modelling predicted that boosting CD8+ T cells in 
human vaginal mucosa by 50% would achieve better control of HSV shedding for 
at least a year314. A strategy termed “prime and pull” has been developed, 
whereby parenteral vaccination is administered in combination with topical 
chemokine application, aiming to recruit activated effector T cells into a desired 
site and persist as local TRM 313. In humans the aim is that this strategy could be 
applied in some form to the development of vaccines for HSV and HIV313. In this 
work Zostavax® did not boost the VZV-specific T cell frequency in the skin, and 
this may be partly due to the subcutaneous route of vaccination, which bypasses 
the dense network of APCs in the dermis. The intradermal or skin scarification 
routes may have boosted VZV-specific T cells in the skin and this should be 
explored further. It is interesting to speculate that if an alternate vaccine could 
achieve such a boost, then perhaps this would confer an increased level of 
protection against VZV reactivation. Investigating the effect of the new shingles 
vaccine Shingrix® on skin VZV-specific T cell frequency remains an appealing 
prospect.   
6.3 Dampening inflammation to enhance VZV-specific immunity 
in the skin 
Increased p38 MAPK-associated inflammation in old skin at 6 hours after sterile 
saline injection was inversely correlated with the robustness of clinical response 
to VZV recall antigen challenge143. Here it was shown that experimental blockade 
of this pathway using the p38 MAPK inhibitor losmapimod enhanced clinical and 
cellular responses to VZV skin challenge, confirming that excessive early non-
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specific inflammation impairs VZV-specific immune responses in the skin of old 
people. This novel finding adds to the existing evidence that inflammaging is 
detrimental to immunity in older adults. Transcriptional, flow cytometry and 
immunofluorescence data by lab colleagues implicated cells of myeloid lineage 
as the source of this excess inflammation in challenged skin, and further work is 
needed in characterising macrophages and dendritic cells in old compared to 
young human skin to further elucidate the mechanisms involved. Identifying the 
responsible cell type would facilitate more targeted therapies in boosting 
immunity in the old.  
Human senescent T cells in circulation demonstrate spontaneous, increased 
activity of p38 MAPK, and blockade of this pathway restored proliferative potential 
and telomerase activity in these cells55–57. To extend the findings from this work, 
it is planned to employ p38 MAPK inhibition before administering the influenza 
vaccine to old individuals, with the intention of boosting influenza-specific 
immunity in an age group that is characterised by its typically poor immune 
responses to this intervention. Unfortunately, the use of losmapimod has not 
demonstrated clinical benefit in the treatment of a variety of medical disorders 
where inflammation plays a central role, including chronic obstructive pulmonary 
disease (COPD)371, acute myocardial infarction372, neuropathic pain from 
lumbosacral radiculopathy373, and major depressive disorder374. These 
pathological disorders represent a distinct setting from vaccinating in order to 
reverse putatively physiological immunosenescence mechanisms, however, and 
so it is hoped that the use of this drug will be beneficial for the latter use.  
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7 FUTURE WORK 
7.1 Further characterisation of TRM and other skin resident 
immune cells during ageing 
As skin TRM represent a relatively newly discovered population, they remain 
incompletely characterised. Transcriptional analysis has been performed and 
phenotypic markers of differentiation and residency have been identified for skin 
TRM; further characterisation in the context of ageing would include senescence 
markers such as KLRG1, CD57, telomere length, telomerase expression, γH2AX, 
and exhaustion markers such as CTLA4, LAG3, TIM3, Blimp1 and BIM. The 
ability of CD4+ TRM to produce effector cytokines has been investigated, but the 
ability of CD8+ skin TRM to produce cytotoxic proteins requires clarification.  
As it has been shown that excessive early inflammation in challenged old skin is 
likely to be of myeloid cell origin, it would be interesting to investigate how 
macrophages and DCs in healthy skin change with regards to their phenotype, 
transcriptional analysis and function during the ageing process. This may yield 
clues as to why the change to a pro-inflammatory state occurs. 
7.2 Effects of Shingrix® on cutaneous immunity 
Shingrix® is clearly superior to Zostavax® at providing the elderly with long-
lasting protection against shingles, and it will therefore likely supersede the latter 
in UK clinical practice in the near future. The reasons for the superiority of this 
adjuvanted non-live vaccine are unclear. It has been shown to induce long-lasting 
VZV-specific CD4+ T cell memory in the circulation and this was reviewed in 
Section 4.4.10. It would be interesting to establish what effects this vaccine has 
on resident immune cell populations in the skin, the extent to which it can enhance 
the VZV-specific DTH response in the skin, and whether there is clear evidence 
of an advantage over Zostavax® in this regard. If there was evidence of an 
enhanced VZV-specific TRM population in the skin, then this would confirm the 
validity of attempting to boost local TRM in the barrier tissues to enhance immunity 
against pathogens invading via this route.   
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7.3 Implications for vaccination strategy in an ageing 
population 
The advent of the highly effective Shingrix® is a major advance for vaccination 
strategy in the elderly. However, the currently recommended influenza and 
pneumococcus vaccines for the old are sub-optimal in their efficacy, and 
improved preparations would be welcome. Investigating the effect of adding 
AS01B, or similar adjuvant systems, to these vaccines would be worthwhile. The 
following factors may be targeted in an attempt to achieve higher vaccine 
response rates: 
• Vaccine Factors223 
- Higher dose of vaccine antigens5 
- Booster doses375 
- Considered selection of vaccine route eg. intradermal vaccination375 
- Vaccination at an earlier age  
- Adjuvants5,351,375,376 
- Viral vectors5 
• Environmental factors375 
- Time of day of vaccine administration 
- Modifying psychological stress 
- Increased physical exercise 
The AS01B adjuvanted preparation of Shingrix® was shown to be significantly 
more immunogenic than the unadjuvanted vaccine343, and so it will be important 
to investigate the effects this adjuvant has on the ageing immune system, to 
explain its high efficacy in the old. ASO1B induces early (within hours) activation 
of the innate immune system353, and perhaps this is at odds with the observations 
in this work that blocking innate-derived inflammation led to an enhanced VZV-
specific response in old skin. It seems likely that multiple inflammatory pathways 
are involved in inducing a vaccine response; blocking excessive and 
dysregulated p38 MPAK-mediated inflammation may be as valid a strategy as 
stimulating detrimentally underactive inflammatory pathways with adjuvants. 
Thus, AS01B may mitigate dysregulated inflammation in the old and restore an 
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appropriate inflammatory response in these individuals. It would be of interest to 
investigate the efficacy of Shingrix® in a subset of individuals with high baseline 
inflammation, for example identified by biomarkers such as CRP, TNF-α and IL-
6, or in individuals affected by a specific chronic inflammatory disease such as 
rheumatoid arthritis. Reduced efficacy in such individuals would strengthen the 
case for employing anti-inflammatory therapy as a therapeutic strategy for certain 
groups.  
Increased baseline monocyte activation has been associated with poorer immune 
responses to the influenza vaccine359; the next challenge will be to investigate 
whether pre-treatment with losmapimod can boost influenza vaccination 
responses.  
Due to the limitless variability between individuals’ immune systems, future 
vaccination strategy may benefit from adopting an approach that is customised 
to the baseline immune profile of the individual. Employing a systems biology 
approach could identify biomarkers of vaccine efficacy and hyporesponsiveness, 
enabling targeted immune therapies at individuals who are prone to poor vaccine 
responses351. Examples of these may include: 
• Counteracting inhibitory pathways362 
- Inhibitory cytokine blockade eg. anti-IL-10 and anti-TGF-β   
- Inhibitory receptor blockade376 eg. anti-PD-1 and anti-CTLA-4 
- Inhibitory cell depletion376 eg. Treg, myeloid derived suppressor cells 
(MDSC) 
• Anti-inflammatory therapy362 
- Blockade of specific inflammatory pathways376 eg. p38 MAPK 
inhibitors, COX inhibitors, rapamycin (targeting mTOR)  
- Metabolic anti-inflammatories eg. metformin, statins 
- Microbiome modulation376 
More work is needed in characterising the ageing immune system and the 
detrimental role of inflammaging before the effectiveness of such targeted 
therapies can be demonstrated. Individualised strategies are likely to be 
expensive and time-consuming, however, and it may be some time before we 
see these methods reach clinical practice.  
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